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ABSTRACT 
 The development of orally bioavailable small molecule drugs targeting protein-
protein interactions (PPIs) has been challenging1. Unlike conventional targets, PPIs’ 
extended, open surface makes it difficult for small molecules to bind. In order to achieve 
strong binding, it is frequently necessary to use larger molecules, which traditionally is 
considered to disfavor druglikeness2. However, PPIs possess great therapeutic potential 
due to their abundance and regulatory roles in cells3. More extensive studies are needed 
to identify larger chemotypes that retain good druglike properties and therefore might 
have utility against PPI targets. 
NF-κB Essential Modulator (NEMO), interacting with IκB Kinase subunit β 
(IKKβ), is an important PPI target because of its regulatory role in NF-κB signaling4. 
Literature suggests that the N-terminal domain of NEMO is intrinsically disordered in the 
absence of bound ligand5. To test this hypothesis, I developed variants of the NEMO N-
terminal domain, and studied their secondary structure, stability, and affinity for IKKβ, 
showing that the N-terminal domain of NEMO is intrinsically structured (Chapter Two). I 
also characterized partially peptidic NEMO inhibitors from our collaborator, Carmot 
Therapeutics. We tested the binding of these compounds and their peptidic fragments to 
full-length NEMO using fluorescence anisotropy (FA)6 and surface plasmon resonance 
	 vii 
(SPR). The results provided information about hit validity, binding affinity and kinetics 
(Chapter Three). Macrocycles are of interest for inhibiting PPIs partly because of their 
proposed good membrane permeability7. To evaluate this hypothesis, I implemented a 
membrane permeability assay, tested the permeability of a set of macrocyclic 
compounds, and used the results to develop a multiple linear regression model to predict 
permeability from macrocycles’ physicochemical properties. The model suggests that 
hydrophobicity correlates positively with good permeability, while high polarity or high 
aromatic ring count renders macrocycles less permeable (Chapter Four). Finally, in a 
separate project, to elucidate the origins of protein-ligand binding energy between 
interleukin-2 (IL-2) and its known small molecule inhibitors8, I developed a SPR based 
binding assay, and validated it by showing that the KD value of known inhibitor Ro26-
45508 agrees with the literature value (Chapter Five). The assay will be useful in future 
studies of IL-2 inhibitors and their fragments. 
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CHAPTER 1. PROTEIN-PROTEIN INTERACTIONS AS DRUG TARGETS 
1.1. Protein-Protein Interactions 
 Protein-protein interactions (PPIs) are mediated by a combination of forces such 
as hydrogen bonds, hydrophobic forces, electrostatic interactions, and Van der Waals 
forces. Permanent PPIs usually exist between subunits of protein complexes. Transient 
PPIs control most cellular signaling functions. It is estimated that there are between 
130,000 and 650,000 distinct PPIs in human cells alone9. To identify PPIs 
experimentally, yeast two-hybrid screening, protein microarrays, and pull-down assays 
coupled with mass spectrometry are used10. Databases have been established over the 
years to store information about PPIs. For example, STRING, a functional protein 
association database, covers 9,643,763 proteins from 2031 organisms3b. Rognan has 
recently reviewed current databases for PPI associations and for small molecule 
inhibitors of PPIs11. 
 PPIs regulate the specificity of signal transduction3c, 12. External signals trigger 
cellular responses through different pathways. Along the pathways, specificity is 
imparted by PPIs on multiple levels, ranging from receptor-ligand recognition to 
signaling protein motif recognition inside the cells3c. Dysfunction of PPIs leads to many 
pathological phenotypes such as cancer, inflammation, and neurological diseases3d, 13. In 
summary, PPIs exist abundantly in cells and maintain important cellular functions, 
deregulation of which may lead to disease. 
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1.2. PPIs As Drug Targets 
 Compared with traditional drug targets, PPIs are considered to be challenging 
targets for small molecules1, 13a, 14. Traditional targets such as enzymes have deep binding 
pockets15 where small molecules can easily bind and generate enough interaction energy 
to achieve good binding affinity. PPIs, on the other hand, have quite different surface 
topology. In many cases PPI interfaces are relatively flat and extended. The contact area 
of PPIs ranges from 1000 to 2000 Å2, 16, which is much larger than ligand contacting area 
in traditional targets (300 to 500 Å2)15. It is difficult for a conventional druglike small 
molecule to bind to such flat and delocalized protein surfaces with good affinity because 
the small molecule cannot gain a sufficient number of noncovalent interactions given its 
limited molecular volume1 (Figure 1.1, upper panel). Also, PPI interfaces can undergo 
conformational changes upon ligand binding17, making rational inhibitor design rather 
difficult. For example, it has been shown that upon binding of an inhibitor by Roche, a 
hydrophobic binding pocket is induced to form on interleukin-218 (Figure 1.1, lower 
panels). In addition, unlike enzymes that usually have a small natural ligand as a 
medicinal chemistry starting point, PPIs usually do not14. In summary, their flat, large 
surfaces, conformationally adaptive structures, and lack of a medicinal chemistry starting 
point all make PPIs a difficult class of drug targets for small molecule drug discovery. 
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Figure 1.1. Challenges in targeting PPIs. The top panel shows traditional targets have a deep 
binding pocket for ligand while PPIs generally do not. The bottom two panels show the X-ray 
crystal structure of interleukin-2 with or without Ro26-4550. A hydrophobic binding pocked is 
induced to form upon inhibitor binding18. 
As competition in drug discovery against traditional targets such as G protein-
coupled receptors, kinases, and other enzymes becomes fiercer, PPIs offer a great number 
of biologically attractive new drug targets, in spite of the technical challenges involved19. 
Small molecule inhibitors targeting six different PPIs have been developed in recent 
years to the point of entering clinical trials14. These are leukocyte function-associated 
antigen-1 (LFA-1), inhibitor of apoptosis proteins (IAPs), bromodomains, HIV Integrase, 
B-cell lymphoma (Bcl) family proteins, and mouse double minute 2 homolog (MDM2)14.  
The furthest advanced of these programs is the potent and selective B-cell lymphoma 2 
(Bcl-2) small molecule inhibitor, GDC-0199/ABT-199, developed by AbbVie and 
Genentech. This orally bioavailable inhibitor binds the pro-apoptotic protein Bcl-2 to 
disrupt the Bcl-2/BH-3 interactions, thereby promoting apoptosis in cancer cells20. 
Compared with its precursor ABT-263, GDC-0199/ABT-199 has more than 5000 fold 
selectivity for Bcl-2 over Bcl-xL14, 20a. A PPI target that has been successfully targeted by 
Traditional PPIs 
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multiple small molecules is bromodomain/acetylated lysine (Kac). Disruption of this PPI 
has therapeutic potential in curing cancer and inflammatory diseases21.  There are 
currently five clinical candidates for bromodomains/Kacs14. These small molecule 
inhibitors were identified either by cell-based high throughput screening or by merging a 
previously identified potent inhibitor with newly identified fragments14.  
 Along with some initial successful discoveries of PPI inhibitors are some 
growing theoretical advancements. One useful concept for PPI inhibition is hot spots. 
Although the interface of PPIs is large, not all residues within the interface contribute to 
binding significantly. Clackson et al. showed for the extracellular domain of human 
growth hormone receptor (hGHbp) that, among the 30 side chains that make direct 
contact with human growth hormone (hGH), a subset of these residues that lie in a central 
region of the interface contribute most of the binding energy22. Regions that contain these 
energetically important residues are called hot spots (Figure 1.2). Since this original 
study, it has been shown to be generally the case that the interaction energy at PPI 
interfaces is provided primarily by localized binding energy hot spots surrounded by 
regions that contribute little or nothing to the binding energy23. 
 
Figure 1.2. Hot spots of hGHbp. Areas colored in red are residues contribute most binding 
energy against hGH. Areas colored in pink are residues that contribute moderate amount of 
binding energy against hGH. 
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Experimentally, hot spots are mapped by the technique of alanine-scanning 
mutagenesis22. In this method, each residue within the contact area is mutated into 
alanine individually and the binding activity of the alanine mutants is assessed. The 
change in binding free energy is calculated to reflect the energy contribution of each 
mutated residue. There also exist computational methods for finding hot spots and a 
recent review of these methods has been reported by Morrow et al.24. One such method is 
FTMap25, which uses dynamic simulations to study the binding of a set of small 
molecular probes analogous to the “fragments” used in fragment-based experimental 
screening26. Upon energy minimization, these fragment probes tend to bind at hot spots. 
Recently, our lab has mapped out hot spots on IκB kinase β (IKKβ) at the interaction site 
with NF-κB Essential Modulator (NEMO) both experimentally and computationally27. 
The results from the two methods agree with each other quite well27. The implication of 
hot spot theory is that there is no need to find a small molecule that interacts with the 
entire PPI interface. Just focusing on several hot spots can help molecules achieve high 
binding affinity. And if some of those hot spots are localized in a small molecular 
volume, such as those at the NEMO/IKKβ interface, it is likely that a high binding 
affinity molecule can be found that is within the size limitations of druglike molecules2a.  
Another theoretical advancement is our improved understanding regarding the 
druggability of PPIs, where druggability is defined as the likelihood of a protein that can 
be bound by small druglike molecules. By analyzing empirical data, Hopkins et al. 
concluded that PPIs as a class tend to have low druggability 28. A recent review reached a 
similar conclusion29. However, these empirical studies do not directly prove that PPIs 
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necessarily have poor druggability. Other factors such as compound library and industry 
priority also determine what drug targets are addressed and which ones succeed. Our 
current understanding is that PPIs represent a diverse range of interface geometries and 
druggabilities. Some interfaces have a relatively well-defined deep groove for small 
molecules to bind. For example, Bcl-2 has a relatively deep, if wide, groove where the 
Bcl-2 homology domain 3 (BH3) peptide binds30. Multiple small molecule inhibitors 
have already been developed to bind this groove20a, 31, as is shown in Figure 1.3 for the 
example of ABT-19931b. 
 
Figure 1.3. Crystal structure of GDC-0199/ABT-199 binds at the deep groove of Bcl-231b. 
 
Hajduk et al. has compiled a panel of protein targets that were extensively studied 
and screened in NMR with fragments. They found that the hit rate observed for fragment 
binding by NMR correlates with the likelihood of a high affinity binders being identified 
for that target32. This finding is significant because it allows researchers to assess the 
target’s druggability by NMR fragment screening before any extensive assay 
development or medicinal chemistry effort is made. Through multiple linear regression 
analysis, they proposed a model that is able to predict NMR hit rate, and thus predict 
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druggability, based on structural and physicochemical features of the binding sites. The 
parameters of this model provide insight in what properties are important in molecular 
recognition. However, because only 23 known targets were used to derive the model and 
none of the 23 targets is PPI, the model may not be suitable to predict the druggability for 
PPI targets. Since then, a number of PPI inhibitors have been identified and databases 
have been established to store the information33. A recent study on PPI inhibitors and PPI 
hot spots identified by FTMap25 reveals that certain PPIs, which have relatively 
delocalized hot spots, can nevertheless be druggable if larger but still pharmaceutically 
relevant compound chemotypes are used. For example, macrocycles offers larger 
scaffolds, which may be utilized to explore more distant hot spots while still maintaining 
good pharmaceutical properties7a. 
 
1.3. Current Approaches to Targeting PPI 
Natural products (NPs) have historically been one of the most fruitful sources for 
new drugs34. Their success in modulating difficult targets has been attributed to 
stereochemical complexity and good bioavailability35, even though NPs generally do not 
conform to the traditional conception of druglikeness2. For example, the P53-mouse 
double minute 2 homolog (P53-MDM2) PPI disruptor, chlorofusin, was identified from 
microbial extracts36. Chlorofusin, with a molecular weight (MW) of 1363 Da, is almost 
three times the size of a typically druglike molecule (< 500 Da)2a. Although natural 
products temporarily lost their attractiveness in the early 1990s, due to problems like 
HTS-screening platform incompatibility, difficulties in identifying and isolating the 
		
8 
active compounds, complex structure assignment, and difficult analog synthesis34, NPs 
have been an important source of new drugs since the earliest days and will continue to 
be important as we move to more difficult targets.  
Biology-orientated synthesis (BIOS) is natural product-inspired combinatorial 
chemistry applied to generate diverse compounds in a focused bioactive chemical space. 
The method starts by identifying a number of natural product scaffolds as synthesis 
starting points. A structural classification of natural products (SCONP) is used to analyze 
different scaffolds37. BIOS compounds are said to have better hit rates and better 
bioactivity than traditional compounds do38. Introduced by Waldmann et al. a decade ago, 
BIOS has been used to identify several tropanes and their analogs targeting hedgehog 
signaling39. Even though a drug has yet to be developed from a BIOS library, it is 
considered by some to have good potential in drug discovery38. 
Diversity-orientated synthesis (DOS), similar to BIOS, is combinatorial chemistry 
designed to achieve library functional diversity, which correlates with the likelihood of 
hit identification for a broad range of biological targets40. Contrary to BIOS, DOS does 
not assume any privileged scaffold for certain targets but emphasizes scaffold diversity40. 
Originally introduced by Schreiber et al. 41, DOS has become a popular way of generating 
a wide range of small molecules. For instance, an inhibitor of transcription factor 
homeobox protein Hox-A13 (HOXA13) and DNA was identified from a DOS library42. 
As our conception of the druggable genome evolves, a greater demand will be placed 
upon synthetic chemists to generate more diverse compounds for drug screening. DOS 
may provide an answer to this challenge.  
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Macrocycles, including macrocyclic peptides, represent one privileged class of 
scaffolds that holds great potential in tackling difficult targets, especially those with 
extended binding interfaces such as protein-protein interactions. Macrocyclization is 
considered to help reduce the conformational entropy cost of binding to the target. 
Sufficient flexibility of the macrocyclic ring is retained to enable the compound to 
maximize the enthalpy of interactions43. This balance between preorganization and 
flexibility is considered to lead to good binding affinity. In addition, macrocycles are also 
proposed to have good pharmaceutical properties such as degradation stability, solubility 
and permeability, compared to acyclic molecules of similar size7a. A number of 
macrocyclic drugs originating from natural products are currently on the market43. 
Synthesizing organic macrocycles with diverse stereochemical properties has been a 
challenge in medicinal chemistry. However, there is significant progress on this front44. A 
greater challenge lies in our insufficient knowledge of how macrocycles achieve good 
bioavailability. Fortunately, there are studies trying to address this gap7a, 43, 45. Villar et al. 
compared oral macrocycle drugs with non-oral ones. They identified a set of 
physicochemical properties as guidelines for designing orally bioavailable macrocycles7a. 
However, existing macrocycle drugs represent only a very narrow range of chemical 
space. Future attention should be continuously directed to study macrocycle properties by 
including more macrocycles from a wider chemical space. 
Peptide foldamers are compounds that are designed to mimic a secondary 
structural element of a protein structure, such as an alpha-helix or beta-turn, which can 
bind and inhibit a target. For example, a biologically active foldamer was identified to 
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bind the BH3 recognition cleft on Bcl-xL46. Current peptide foldamer design is restricted 
to imitate secondary structures. Few examples of peptide foldamers based on tertiary or 
quaternary structure have been reported. Even secondary structure mimicry, however, is 
not an easy task. The challenge mainly lies in poor bioavailability. So-called “stapled 
peptides”, pioneered by Verdine et al., have been shown to have good bioavailability and 
stability. This chemotype is a peptide foldamer stabilized by a hydrocarbon linker of two 
residues along the peptide. The all hydrocarbon stapling is considered to stabilize the 
desired folded, active conformation. ALRN-6924, a stapled peptide, the first foldamer 
clinical candidate, inhibits both MDM2 and mouse double minute X homolog (MDMX) 
equal potently47. 
Covalent inhibitors have traditionally been identified initially by chance. Off-
target safety has been the biggest concern for this chemotype. In recent years, a new 
approach called “targeted covalent inhibitors” (TCI) is gaining a more favorable 
reception48. For example, Ibrutinib is an orally bioavailable drug that covalently inhibits 
Bruton’s tyrosine kinase49. Compared with noncovalent inhibitors, carefully designed 
covalent inhibitors have advantages like sustained inhibition, lower dosing requirement, 
and possibly better drug resistance48. For PPI inhibition, TCI offers opportunities to 
develop high-potency inhibitors, which are difficult to achieve through noncovalent 
inhibition. A targeted covalent inhibitor first orients onto the target through noncovalent 
interactions, and then chemically links to a selected residue on the target through a fine-
tuned reactive group. Future efforts can be directed to develop novel chemistry allowing 
selective targeting of residues other than cysteine. 
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Stable transition metal co-ordination complexes organize protein-binding groups 
with a scaffold coordinated by inert metals. This chemotype provides additional building 
blocks for synthesizing compound with diverse 3-D structures. It therefore provides great 
potential for pursuing difficult targets50. Pioneered by Dwyer et al. more than sixty years 
ago51, this chemotype has recently begun to attract more attention as an approach to drug 
discovery. For example, Ma et al. discovered a cyclometalated iridium (III) complex as a 
tumor necrosis factor-α inhibitor52. However, compound synthesis and in-depth 
evaluation are needed for this chemotype in the future. 
 With our growing knowledge of PPIs and ever more successful discoveries, this 
class of targets that comprise what were once considered impossible targets are 
increasingly within reach today1, 9a, 11, 14, 17b, 19, 21, 25b, 30, 33b, 53. Silvian et al. has reviewed 
some current methods being applied to target PPI53c. Still, more studies and deeper 
understanding in this field are needed to fully capitalize on these therapeutic 
opportunities. We aim to address this gap by testing a number of approaches using as a 
test case PPI target NF-κB Essential Modulator (NEMO). Our choice of NEMO as a PPI 
target is based on two reasons: (a) NEMO and its natural ligands IKKα/β form the IKK 
complex, which regulates NF-κB signaling pathway54. Dysfunction of this pathway has 
been linked to multiple diseases such as inflammation55 and cancer56.  It has been shown 
that inhibiting NEMO provides a great opportunity for therapeutic intervention4, 57. (b) 
NEMO, as well as the NF-κB pathway as a whole, has been well studied and validated as 
a drug target. There are known structures for separate domains of NEMO in association 
with their natural ligands5, 58. In particular, NEMO44-111, in association with IKKβ701-746, 
		
12 
has been reported5. According to this structure, two NEMO44-111 monomers come together 
to form a coiled coil. Two IKKβ701-746 bind onto the deep groove on each side of NEMO. 
Compared with a complete flat surface, the groove on NEMO provides a good 
opportunity for small molecules binding.  
Although much has been learned about NEMO and its associated pathway, there 
are still questions to be answered. Rushe et al. have reported that the IKKβ binding 
region of NEMO is intrinsically disordered5. However, previous work from our 
laboratory suggests that this region is likely to be ordered if it is in a dimeric state6. In 
chapter two of this dissertation, I test whether the N-terminal domain of NEMO, which is 
the region that makes contact with IKKβ, is intrinsically disordered in the dimeric state, 
and develop a NEMO construct that is stable and active for use in hit identification and 
optimization. 
To develop small-molecule inhibitors of NEMO, we collaborated with Carmot 
Therapeutics. Applying their patented screening method, called “Chemotype 
Evolution”53f, using a fluorescence anisotropy assay developed in our lab, we identified a 
several hits. In chapter three, I characterize two of these hits using a fluorescence 
anisotropy inhibition assay and surface plasmon resonance (SPR).  
In chapter four, I test whether natural product-inspired macrocycles have good 
membrane permeability. PAMPA assays and mass spectrometry detection are 
implemented in this study. I also correlate macrocycles’ physicochemical properties with 
their permeability by multiple linear regression analysis, to develop a model to 
		
13 
understand and predict MC permeability based on the chemical structure of the 
compound. 
Finally, known IL-2 inhibitors and their fragments are studied in chapter five to 
elucidate the origin of binding energy generated from each part of the inhibitors59. A 
surface plasmon resonance based assay was developed to study fragment binding to IL-2. 
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CHAPTER 2. ENGINEERING A STABILIZED FORM OF NF-κB ESSENTIAL 
MODULATOR (NEMO) N-TERMINUS AS A DRUGGABLE PPI TARGET 
 
Notice: This chapter is published in Biochemistry 2014 53 (50), 7929-7944. Some 
contents of this chapter are taken verbatim from the above source. Reprinted (adapted) 
with permission from (Zhou, L.; Yeo, A. T.; Ballarano, C.; Weber, U.; Allen, K. N.; 
Gilmore, T. D.; Whitty, A., Disulfide-mediated stabilization of the IkappaB kinase 
binding domain of NF-kappaB essential modulator (NEMO). Biochemistry 2014, 53 (50), 
7929-44.). Copyright (2014) American Chemical Society.  
 
2.1. Background 
 NF-κB Essential Modulator (NEMO), also known as IKKγ, is an interesting yet 
challenging protein target for drug discovery60. Together with the catalytic subunits 
IKKα/β, NEMO forms into the active IκB kinase (IKK) complex, which plays an 
essential role in the NF-κB signaling pathway54. IKK phosphorylates IκB, which leads to 
its proteolytic degradation. Without the inhibitory association of IκB, the transcription 
factor NF-κB translocates into the nucleus, triggering regulation of biological effector 
gene transcription and expression61. The NF-κB signaling pathway is a major pathway for 
regulating essential cellular functions such as cell survival and apoptosis. Dysfunction of 
this pathway leads to diseases including inflammation, neurodegenerative diseases and 
cancers4, 55-56. Because NEMO constitutes a central regulatory element in NF-κB 
signaling pathway, it has drawn our interest in developing a small molecule inhibitor. 
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 Human NEMO is a 419 amino acid protein that contains five main domains: helix 
1 (HLX1, sometimes called “coiled-coil 1”), helix 2 (HLX2), a coiled-coil domain (CC), 
a leucine zipper domain (LZ), and a C-terminal zinc finger (ZF), as illustrated in Figure 
2.1. Some of these domains have been cocrystallized with their ligands giving atomic 
detail on the interactions5, 58. For example, Rush et al. has shown that the NEMO binding 
domain of IKKβ (residues 701−745) interacts with a region of NEMO within the helix 1 
domain (residue 44-111)5. The structure shows that, with a 44-mer peptide derived from 
IKKβ bound, NEMO44−111 exists as an α- helical coiled coil that binds two molecules of 
IKKβ, one on each face of the symmetric NEMO dimer. Rush et al. has also found that 
this NEMO fragment is disordered in the absence of IKKβ peptide and thus is not a good 
candidate for crystallization. In contrast, we have recently reported evidence suggesting 
that residues 44−111 of NEMO are not disordered in the context of the full-length 
protein6. Nevertheless, in the absence of a means to crystallize full-length NEMO, the 
disorder of NEMO44-111 presents an obstacle to obtain a crystal structure of IKKβ binding 
domain in an unbound state, or to cocrystallizing NEMO with small-molecule ligands to 
obtain information on their binding modes.  
In this chapter, we test whether NEMO44-111 is disordered as a dimer, which is 
likely the oligomerization state of full-length NEMO6.  Also presented in this chapter are 
efforts to engineer a disulfide-bond stabilized NEMO N-terminus fragment for 
crystallography study. 
		
16 
 
Figure 2.1. Domain structures of NEMO. (A) Schematic representation of the structure of 
human NEMO, showing the named domains and the locations of NEMO’s 11 cysteine residues, 
and also of Leu107 which we mutated to cysteine in some NEMO constructs. The binding site 
locations for selected NEMO ligands are indicated by colored bars under the cartoon. (B) Regions 
of NEMO that have been characterized crystallographically: NEMO44-111 in complex with IKKβ 
peptide (PDB: 3BRT) 5; NEMO150-272 in complex with vFlip (PDB: 3CL3) 62; NEMO252-336 in 
complex with di-ubiquitin (PDB: 2ZVN) 63; and NEMO397-417 (PDB: 2JVX) 64.  Regions for which 
no structure has been reported are shown as a string of dots (one dot per ~5 amino acids). Below 
is shown a close-up view of the 2:2 complex of NEMO44-111 (green) with IKKβ701-745 (orange) 
from reference 5, with the locations of Cys54, C7s76 and Cys95 highlighted in red, and Leu107 
shown in blue. 
 
2.2. Results 
2.2.1. Design, Expression and Purification of NEMO Variants 
 The NEMO 44-111 region has been reported as intrinsically disordered in the 
absence of its ligand IKKβ peptide in a reducing buffer5. However, we have obtained 
A 
B 
HLX1 CC1 HLX2 CC2 LZ ZF 
IKKβ cFlip di-Ubiquitin IκBα 
11 54 76 95 131 167 347 
396,397 
400,417 
L107 
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evidence suggesting that this region in full-length NEMO is not disordered, probably due 
to the stabilization provided by dimerization6. To test this hypothesis, and to make a 
stabilized variant for inhibitor discovery, we implemented two strategies in dimerizing 
NEMO N-terminal fragments. One approach was to make longer NEMO fragments. 
Compared with NEMO44-111, NEMO1-120 has extra 52 amino-acid residues, which may be 
important in making necessary contacts to maintain an elongated α-helical dimer 
structure. The other approach was to dimerize NEMO by enforcing disulfide bond 
formation between two NEMO fragment monomers. Among residues 1-120, there are 
four endogenous cysteines (11, 54, 76 and 95), as shown in Figure 2.2. It is estimated that 
a 3-6 Å distance between β carbons is required for endogenous disulfide bond 
formation65. A close examination of the NEMO44-111 crystal structure reveals that only 
Cys 54 is at a position capable of making a native interchain disulfide bond. It has been 
shown that none of these cysteines is required for IKKβ binding6. Therefore, Cys 11, 76 
and 95 were mutated to alanine to eliminate protein aggregates. Cys 54 was left in the 
constructs to allow interchain disulfide bond formation. The most important NEMO 
region for IKK peptide binding is from residues 89 to 10427. We posited that a disulfide 
bond at the other end of NEMO N-terminus could help lock it into a rigid coiled-coil 
helix dimer. In the NEMO44-111 structure, the distance between β carbons of Leu107 is 3.9 
Å, compared to a 4.3 Å distance between the β carbons at residue 54. We therefore 
created a NEMO variant containing Leu107Cys mutation. This mutation in full-length 
NEMO was tested in TNFα-induced cell death assay and was found to have no difference 
in activity when compared to wild type66. 
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Summarized in Figure 2.2, a total of four variants of NEMO 1-120 were created. 
They comprise des4C, with no cysteine; des3C/C54 and des3C/L107C, with one cysteine 
at either residue 54 or 107; des2C/C54/L107C, with two cysteines at 54 and 107. In 
parallel, we created a panel of corresponding NEMO44-111 variants to evaluate the impact 
of the extra 52 amino acids that are present in NEMO1-120 variants.  
 
Figure 2.2. Design of disulfide-stabilized NEMO constructs. (A) NEMO44-111 from the 
structure by Rushe et al. 5, with IKKβ peptide removed. The locations of the cysteine residues at 
positions 54, 76 and 95 are highlighted in red; Leu107 is shown in blue. (B) Close up of the 
region around Cys54, showing that these cysteines are well positioned to form an inter-chain 
disulfide bond. (C) Close-up of region around Leu107, showing that the β-carbons are positioned 
such that cysteine residues introduced through Leu107Cys mutation would be suitably positioned 
to form an inter-chain disulfide bond 67. (D) Schematic representation of the eight NEMO 
constructs made in the current work. The TEV cleavage site is indicated by a red triangle. The 
identities of the residues present at positions 54, 76, 95 and 107 (and at position 11 for the 
NEMO1-120 proteins) are indicated for each construct using the single letter code for the amino 
acid. 
 
 The variants described above were expressed in bacteria and contained a 
cleavable 9×His-SUMO tag at their N-terminus. The SUMO tag is used to increase 
NEMO expression and also its molecular bulk, which facilitates fluorescence anisotropy 
analysis. The tagged proteins were purified from inclusion bodies and the His-SUMO tag 
4.3 Å 3.9 Å 
A 
B C 
D 
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was removed by tobacco etch virus (TEV) protease. The cleaved products bear only three 
non-native amino acids (Gly-Ser-Gly) at their N-terminus after TEV cleavage.  
 SDS-PAGE analysis of the tagged NEMO variants showed that, with the 
exception of NEMO1-120(des4C) and NEMO44-111(des3C), all other variants that contain 
either one or two cysteins were purified as covalently linked dimers and could be reduced 
to monomers by being boiled in a SDS-PAGE loading buffer containing 100 mM DTT 
for 5 min (Figure 2.3A). The cleaved His-SUMO tag was removed by purification over a 
nickel affinity column, as described in Experimental Procedures. Notably, cysteine 54 
was extremely resistant to reduction under non-denaturing conditions. For example, even 
after a 3 week-long treatment with 25 mM DTT at 4 °C, the cleaved 
NEMO1−120(des3C/C54) achieved only around 50% reduction, and 
NEMO1−120(des3C/C54/L107C) showed even less reduction under similar conditions 
(Figure 2.3B). Either boiling or denaturant (urea) was required in addition to DTT to 
completely reduce the dimer (Figure 2.3C). Even under denaturing conditions, 25 mM 
DTT or TCEP was required to reduce Cys54-containing constructs within 1 h (Figure 
2.3D). In contrast, NEMO1−120(L107C) was readily reduced by DTT even in the absence 
of urea (Figure 2.3B).  
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Figure 2.3. Analysis of NEMO constructs by SDS-PAGE. (A) SDS- PAGE analysis showing 
that NEMO1−120 (des4C) and NEMO44−111 (des3C) purified as monomers, while the other cysteine 
containing NEMO1−120 and NEMO44−111constructs as isolated were predominantly covalent dimers 
that could be reduced to monomers by boiling under reducing, denaturing conditions. (B) 
Susceptibility of the NEMO1−120 proteins to reduction with 25 mM DTT after removal of the 
9xHis-SUMO fusion partner using TEV protease. The cleaved products were treated with 25 mM 
DTT in water at 4 °C for various times, and then analyzed by SDS-PAGE without boiling. The 
C54 containing constructs were highly resistant to reduction under nondenaturing conditions, 
whereas the construct containing only a single disulfide at position 107 was readily reduced. The 
result shown was representative of two independent experiments. (C) SDS-PAGE analysis 
showing that TEV-cleaved NEMO1−120 (des3C/C54) could be reduced by 25 mM DTT or TCEP 
(1 h at room temperature) under denaturing conditions. (D) SDS-PAGE analysis (without boiling) 
of TEV-cleaved NEMO1−120 (des3C/C54) incubated with various concentrations of DTT, 
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decreasing from 25 mM in 2-fold dilutions, in 6 M urea for 1 h at room temperature, showing that 
25 mM DTT was required to reduce NEMO1−120 (des3C/C54) even under denaturing conditions. 
 
2.2.2. Introduction Of Interchain Disulfides Induces Increased 
 α-Helical Structure In NEMO 
To test whether a longer NEMO fragment (NEMO1-120) or a cysteine-mediated 
dimer is largely structured, we used circular dichroism (CD) spectrometry. We 
characterized the structure content of the eight NEMO constructs shown in Figure 2.2D, 
after removal of the 9×His-SUMO tag with TEV protease (Figure 2.4C, 2.4D). The 
NEMO N-terminus has been proposed to have an elongated α-helical coiled coil 
structure5. To the best of our knowledge, there is no algorithm that predicts well of the 
secondary structures of a protein that is mostly alpha helical coiled coil like NEMO. 
Therefore we quantified α-helical content by comparing the CD spectra obtained in 
phosphate buffer and in 97% 2,2,2-trifluoroethanol (TFE), a solvent which favors α-helix 
formation68 (Eq. 2.2, Figure 2.4 B, 2.4E). 
The CD results suggested that the extra 52 amino acids in NEMO1-120 variants 
were insufficient to stabilize NEMO fragments’ secondary structure. The helical content 
of NEMO1−120(des4C), which contained no cysteine, was similar to that of the monomeric 
construct NEMO44−111(des3C) (37% versus 32%) (Table 2.1). Results also suggested that 
monomeric NEMO variants, either with no cysteine or fully reduced, had less α-helical 
structure than dimeric ones did. For example, fully reduced NEMO1−120(des3C/C54) gave 
a CD spectrum of only 37% α-helical structure while the same variant in its oxidized 
form gave 60% α-helical structure. NEMO1−120 containing an engineered interchain 
disulfide at position 107 (NEMO1−120(des4C/L107C)) or containing disulfides at both 
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positions 54 and 107 (NEMO1−120(des3C/ C54/L107C)) similarly showed 60−70% α-
helical content (Table 2.1). In the shorter NEMO44−111 constructs, the presence of 
disulfide bonds at positions 54 and/or 107 increased α-helical content to an even greater 
degree, with values ranging from 75 to 88% α-helix depending on the construct (Figure 
2.4E, Table 2.1). 
The observed α-helix content in CD experiments, for the three disulfide-stabilized 
NEMO44−111 constructs in the absence of IKK peptide, shown in Table 2.1, is consistent 
with the nearly complete adoption of the active conformation of the protein seen 
crystallographically5. In the published X-ray crystal structure of NEMO44−111 with 
IKKβ701−745, only amino acids 49-110 are visible as coiled coil5. The unobserved amino 
acids 44−48 and 111 are likely to be substantially disordered or mobile. In addition, the 
residual GSG sequence left at the N termini of our constructs after TEV cleavage 
presumably also is likely disordered. Thus, for our NEMO44−111 constructs to adopt the 
active conformation seen in the crystal structure, 62 residues out of 71 residues (87%) 
should be α-helix. Table 2.1 shows that the observed α-helix for three NEMO44-111 
variants is between 75-88%. For the longer NEMO1−120 constructs, adoption of a fully α-
helical structure between residues 49 and 110, with the remainder of the protein being 
disordered, corresponds to a α-helix content of 50% (62 out of 123 residues). The α-helix 
content observed (60-70%) for the disulfide-stabilized forms of NEMO1−120 thus indicates 
that an additional dozen or so of the 60 residues outside the immediate IKKβ binding 
region are also α-helical in these constructs. This interpretation is consistent with the 
observation that a fraction of NEMO1−120(des4C) spontaneously adopts an α-helical 
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structure even as a monomer. Taken together, the above results show that enforcing 
covalent dimerization via an interchain disulfide bond at position 54 and/or position 107 
stabilizes the NEMO IKKβ binding region extending roughly from residues 49−110.The 
disulfide-stabilized NEMO 49-110 region is largely α-helical even in the absence of its 
ligand. But the sequence outside of this region remains largely unstructured especially in 
the longer, NEMO1−120 constructs. 
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Figure 2.4. Effect of inter-chain disulfide bonds on NEMO secondary structure. (A) Overlaid 
CD spectra in 20 mM phosphate, pH 7.4, showing that fully reduced, monomeric TEV-cleaved 
NEMO1-120(des3C/C54) possesses only modest α-helix content (dotted line), whereas the oxidized 
form of the same construct, containing an inter-chain disulfide bond at position 54, possesses a 
substantially α-helical structure (solid line). Spectra shown are representative of two independent 
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experiments. (B) CD spectra showing that NEMO1-120(des4C), which in aqueous buffer is largely 
disordered (solid line), adopts an α–helical structure in 97% TFE (dotted line). Spectra shown are 
representative of two independent experiments. Spectra for all eight constructs are shown in (E). 
(C) Overlaid CD spectra (20 mM phosphate, pH 7.4) showing the relative α-helical content of the 
four TEV-cleaved NEMO1-120 constructs shown in Figure 2.2D. NEMO1-120(des3C/C54) (blue), 
NEMO1-120(des4C/L107C) (green) and NEMO1-120(des3C/C54/L107C) (red) are present in their 
oxidized, covalently dimeric forms. The spectrum of the monomeric NEMO1-120(des4C) is shown 
in black. Spectra shown are representative of three independent experiments. Corresponding data 
for the NEMO44-111 constructs are shown in Figure 2.4D. 
 
2.2.3. Disulfide-Stabilized NEMO Constructs Show Increased Binding Affinity for Ikkβ 
 To determine whether the increased α-helix content observed by CD stabilizes the 
active NEMO conformation, we tested each NEMO variant for binding to FITC-labeled 
IKKβ701-745. This IKK peptide has previously been shown to bind to full-length NEMO 
and to a truncated NEMO N-terminus fragment5-6, 27. We used a fluorescence anisotropy 
(FA) assay to test the NEMO/IKKβ701-745 peptide binding. In this assay, 15 nM FITC-
IKKβ701−745 is incubated with various concentrations of NEMO protein. Binding affinity 
is determined by plotting total anisotropy versus NEMO concentration and fitting to the 
appropriate quadratic or hyperbolic binding equation. The dynamic range of the signal 
depends on the fold change of molecular bulk between the unbound and bound state 
(Figure 2.5D). To give a bigger signal, we initially used His-SUMO tagged NEMO 
proteins for analysis.  
To assess the stabilization conferred by dimerization, we tested disulfide-
mediated dimeric NEMO variants as well as those without any cysteine residue. Also 
tested were NEMO1-120(des3C/C54) in both oxidized dimeric state and reduced 
monomeric state, to evaluate the impact of one single disulfide bond in stabilizing the 
NEMO active conformation. The results showed that in each group with the same amino-
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acid length, monomeric NEMO variants had only micromolar binding affinity, but the 
dimeric ones showed 6-30 fold-stronger binding (Table 2.1). To ensure the His-SUMO 
tag didn’t influence NEMO’s binding affinity, cleaved NEMO 1-120 variants were also 
tested in FA (Figure 2.5B). The results are in good agreement with those for the tagged 
proteins (Figure 2.5A). Taken together, these results indicated that the disulfide-stabilized 
forms of NEMO are active, and that covalent dimerization preorganizes the polypeptide 
in a conformation that confers relatively high affinity binding with IKKβ.  
 
Figure 2.5. NEMO binding affinity for IKKβ. (A) Binding affinity of the 9xHis-SUMO-tagged 
NEMO1-120(des4C) (black circles), -(des3C/C54) (blue squares), -(des4C/L107C) (green 
triangles), and -(des3C/C54/L107C) (red lozanges) for FITC-IKKβ701-745, measured by 
fluorescence anisotropy. The solid lines represent the best fit to a quadratic binding equation, as 
described in Experimental Procedures. Results show the averages of duplicate measurements, 
with the error bars showing the spread between the duplicate values. The corresponding data for 
the TEV-cleaved NEMO1-120 constructs  are shown in (B), and the tagged NEMO44-111 constructs 
are shown in (C). (D) Illustrates the principle of fluorescence anisotropy. The size of curved 
arrow represents the tumbling rate. 
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2.2.4. Interchain Disulfide Bonds Increase The Resistance Of NEMO  
To Chemical And Thermal Denaturation 
To assess the stability of disulfide-linked NEMO dimers as well as monomers, 
chemical and thermal denaturations were monitored at 222 nm in CD (222 nm is the 
signature wavelength for α-helix). A decrease of mean residue ellipticity at 222 nm 
(θMRE222) indicates a loss of α-helix69. To avoid any influence of His-SUMO tag, only 
cleaved NEMO variants were studied. In chemical denaturation experiments, each 
NEMO variant was incubated at different concentrations of urea for one hour and then 
analyzed by CD. The one-hour-long incubation time was shown to be sufficient for 
denaturation to reach equilibrium in preliminary studies. As shown in Figure 2.6A, all 
NEMO1-120 variants were completely denatured by 7 M urea at 25 °C. However, at lower 
concentrations of urea they showed different degrees of denaturation. 
NEMO1−120(des4C), which contains no cysteine and thus cannot form covalent dimers, 
was highly sensitive to denaturant. Indeed, the CD analysis showed that in the absence of 
urea, NEMO1−120(des4C) was <50% ordered. NEMO1−120(des3C/C54) and 
NEMO1−120(des4C/L107C) showed [urea]50 values of 1.5 − 2.0 M, indicating that 
formation of disulfide bond at either position 54 or 107 substantially stabilized NEMO. A 
second disulfide bond brought another degree of stabilization as demonstrated by the 
NEMO1-120(des2C/C54/L107C), which had a [urea]50 value at 4.3 ± 0.5 M. In comparing 
the denaturation curves for NEMO1−120(des3C/C54) and NEMO1−120(des4C/ L107C), it is 
notable that the construct containing the engineered Cys107 had a much steeper slope 
than that containing only the native Cys54.  
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To determine the free energy of NEMO unfolding with no denaturant, ΔGH2O, we 
analyzed the denaturation curve by nonlinear regression fit assuming a two state 
denaturation model (Eq. 2.3, Figure 2.6A, 2.6B)70. This analysis requires data to meet the 
assumption of reversibility. We tested this assumption by first incubating NEMO with 
high enough concentration of urea (4 M) to denature it, and then diluting it into CD 
sample buffer containing a final concentration of 0.4 M urea for protein refolding. The 
result as shown in Figure 2.6E showed no distinguishable difference between the 
denatured/refolded NEMO and the nondenatured NEMO, demonstrating that 
denaturation was fully reversible. The curve fitting results showed that NEMO1-
120(des4C) has ΔGH2O < 0 at 25 °C (Table 2.1), which meant this monomeric variant was 
largely disordered even in the absence of denaturant. The presence of a single interchain 
disulfide at position 54 stabilized the folded state to give ΔGH2O = 0.7 ± 0.2 kcal/mol, 
while the engineered disulfide at position 107 achieved a greater stabilization of 2.3 ± 0.2 
kcal/mol. The NEMO1−120 construct containing disulfides at both 54 and 107 was the 
most stable, with ΔGH2O = 3.0 ± 0.2 kcal/mol. The denaturation behavior of the 
NEMO44−111 variants was essentially identical to that of the longer NEMO variants, both 
qualitatively (Figure 2.6B, 2.6D) and quantitatively (Table 2.1). The denaturation data for 
the NEMO1−120 and NEMO44−111 were also plotted in a linearized form (Figure 2.6C, 
2.6D), and showed good linearity, further validating the use of a two-state unfolding 
model.  
We also characterized the stability of the NEMO variants in response to thermal 
denaturation. We monitored the structure of each protein by CD using ellipticity at 222 
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nm measured while slowly increasing the temperature of the sample from 5 to 90 °C. As 
shown in Figure 2.7A, the NEMO1−120 variants showed a range of melting temperatures. 
NEMO1−120(des4C) gave a melting temperature of Tm = 27 ± 2 °C, consistent with this 
monomeric construct being <50% structured at room temperature. The presence of a 
single disulfide at either position 54 or 107 substantially stabilized the proteins, resulting 
in Tm values of 33 and 45 °C, respectively. The construct containing two disulfides was 
highly stable to thermal denaturation, melting only at 67 ± 4 °C. The thermal stabilities of 
the NEMO44−111 constructs were also measured, and gave similar results to those seen 
with the longer NEMO1−120 proteins (Table 2.1 and Figure 2.7B).  
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Figure 2.6. Urea-induced denaturation study. (A) and (B) show urea denaturation curves for 
the TEV-cleaved NEMO1-120 constructs and NEMO44-111 constructs, respectively, as measured by 
CD (20 mM phosphate, pH 7.4). Symbols are as in Figure 2.5. The solid lines represent the best 
fit to a two-state denaturation equation, as described in Experimental Procedures. The curve fit 
for NEMO1-120(des4C/L107C) and NEMO44-111(des3C/L107C) contained an extra term to account 
for the effect of urea on the observed ellipticity of the fully denatured protein (see experimental 
procedures). Plotted are average values from three independent experiments; error bars are 
standard deviations. The [urea]50, slope (m) and ΔGu values obtained from the curve fits are 
collected in Table 2.1. (C) and (D) show linearized denaturation curves for the TEV-cleaved 
NEMO1-120 constructs and NEMO44-111 constructs, respectively. In panels A-D the cysteine-
containing constructs are present in their oxidized, covalently dimeric form. (E) CD analysis 
shows that chemical denaturation of NEMO constructs is truly reversible.  
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Table 2.1. Characterization of NEMO constructs 
 
1Percent α-helix content, determined by comparing CD spectra measured in aqueous buffer versus in 97% 
TFE. Values are the average ± S.D. from three independent experiments. 2Concentration of urea required to 
give 50% denaturation at 25 °C, and slope value (m) for the denaturation curve, determined through 
nonlinear regression analysis of urea denaturation curves measured in three independent experiments. 
Errors are Standard Errors from the fit of the averaged data. 3Free energy of unfolding extrapolated to 
[urea] = 0 M, determined through non-linear regression analysis of urea denaturation curves measured in 
three independent experiments. Errors are Standard Errors from the fit of the averaged data. 4Melting 
temperature, determined from CD melting curves. Values are the average Tm from two independent 
experiments ± half the difference. 5Affinity for binding to FITC-IKKβ701-745, measured by fluorescence 
anisotropy, for the 9xHis-SUMU-tagged constructs. Values are the best fit for a single experiment 
performed in duplicate; errors are the Standard Errors for the curve fit. 6Affinity for binding to FITC-
IKKβ701-745, measured by fluorescence anisotropy, for the untagged NEMO1-120 constructs generated by 
removal of the fusion partner using TEV protease. Values are the best fit for averaged data from three 
independent experiments; errors are the Standard Errors for the curve fit of the averaged data. 7Covalently 
dimeric due to inter-chain disulfide bond(s) at positions 54 and/or 107. 8Not done.  
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                                                                              Figure 2.7. Thermal denaturation of the TEV-
cleaved NEMO constructs. Secondary 
structural changes of NEMO1-120 constructs (A) 
and NEMO44-111 constructs (B) were monitored 
by the changes in θ222 measured by CD (in 20 
mM phosphate, pH 7.4). Colors are as in Figure 
2.5. Inset shows the first derivative of the 
melting curve to illustrate how Tm was 
determined. Data shown are representative of 
two independent experiments. (C) shows the 
thermal denaturation is fully reversible. Dotted 
line represents that NEMO refolds completely 
when cooled down from heating. 
 
 
2.3. Discussion 
In this chapter, we tested our hypothesis that the IKKβ binding region of NEMO 
is a stable coiled coil rather than intrinsically disordered in its dimeric state. Our results 
suggest that in the dimeric state, whether mediated by disulfide bond formed through 
native cysteine 54 or an engineered cysteine at position 107, NEMO possesses a 
preorganized, stable coiled coil that is the active conformation required for IKKβ binding. 
The conclusion is supported by our CD analysis, which shows that the dimeric NEMO is 
essentially 100% α-helix in the IKKβ binding region extending from residues 49-110. 
Another line of evidence supporting our conclusion is from FA results, which indicate the 
dimeric NEMO N-terminal variants have 6-30 fold higher binding affinity towards IKKβ 
B A 
C 
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than do the monomeric NEMO N-terminal variants. Previously, it has been reported that 
full-length NEMO exists in cells as dimers6. The full-length protein has single digit 
nanomolar binding affinity towards IKKβ701-745 in vitro, and none of the cysteines in 
NEMO N-terminus are required to achieve such strong binding6. Therefore, our current 
findings support the notion that dimerization of full-length NEMO, whether by disulfide 
enforcement at NEMO N-terminus or by some other mechanism such as noncovalent 
contacts from other regions of NEMO, induces a preorganized functional coiled coil at 
the IKKβ binding region.  
To design an inhibitor that binds at NEMO’s IKKβ binding region, it is critical to 
know the molecular details of this region. Studies presented in this chapter demonstrate 
that, in the absence of a full-length NEMO crystal structure, structural information about 
the IKKβ binding region in the context full-length NEMO can be deduced from 
combined biochemical studies of full-length NEMO and the NEMO N-terminal domain. 
One practical aspect of this study is to engineer a stabilized form of IKKβ binding region 
for determining the X-ray crystal structure of this region of the protein in unbound state, 
and for cocrystallization with small molecule inhibitors that bind to this region. Because 
of the lack of crystallographic conditions for both full-length NEMO and larger NEMO 
fragments that contain IKKβ binding region, the preferred approach will be to crystalize a 
smaller fragment of NEMO containing IKKβ binding region. However, the published 
IKKβ binding region, NEMO44-111, is disordered in the absence of IKKβ5. According to 
traditional wisdom in crystallography, it is difficult to crystalize a disordered protein. Our 
results show that the IKKβ binding region of NEMO can be induced to adopt a stable 
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coiled coil structure that is amenable for IKKβ binding. Also suggested in our results is 
that residues 1-48 in NEMO1-120 variants are disordered even in the dimeric state. 
Therefore, given the high correlation between structural order and the likelihood of 
obtaining crystals, we think the shorter fragments such as NEMO44−111(des2C/C54), 
NEMO44−111(des3C/ L107C) and NEMO44−111(des2C/C54/L107C), as disulfide bond 
stabilized dimers, are good candidates for crystallography. 
One interesting finding in our studies is that the disulfide bond formed at cysteine 
54, though more difficult to reduce, confers less stabilization on NEMO N-terminal 
variants than the one at cysteine 107. A close examination of the published crystal 
structure of NEMO44-111 in complex with IKKβ701-745 reveals that the disulfide bond at 
residue 54 is buried extensively in this interface, while a disulfide at residue 107 has 
minimal surrounding contact area (Figure 2.8). Our interpretation for the Cys 54 variant’s 
extraordinary DTT or TCEP resistance in a buffer without denaturant or boiling is that 
because the disulfide at this position is so extensively buried, it is difficult for DTT or 
TCEP to access the bond unless the protein is partly or fully denatured. In contrast, 
residue 107 is very solvent accessible, which renders it susceptible to reduction. This 
interpretation also accounts for the different slopes of the urea denaturation curves for the 
constructs with a single disulfide at position 107 versus position 54. According to the 
Transfer Model for protein denaturation71, the degree of cooperativity observed in 
chemical denaturation experiments, represented by the slope factor m in Eq. 2.3, reflects 
the extent to which the solvent exposed surface area of the protein increases upon 
denaturation72. Thus, the larger slope in constructs containing only 107 cysteine reflects 
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the fact that the denaturation is accompanied by large increase of solvent accessible area, 
as the contacts in the vicinity of (not disulfide bonded) residues are disrupted. 
Figure 2.8. Regions of contact at the NEMO-NEMO 
interface, from the published co-crystal structure of NEMO44-
111 in complex with IKKβ (PDB code 3BRV)5. Cys54 is 
largely buried at the center of an extensive and intimate 
contact interface between the two NEMO monomers, one of 
which is shown in surface representation, and the other as a 
wire-frame (Top panel). Much poorer contact is apparent in 
the vicinity L107 (middle panel).  
 
The difference in contacts at these two areas also 
explaines each NEMO N-terminal variants’ relative ease 
of denaturation. Denaturation of NEMO1-
120(des3C/L107C), which contains only one disulfide 
bond at residue 107, involves disrupting the extensive 
noncovalent interactions around residue 54. On the other hand, denaturation of NEMO1-
120(des3C/C54), which has only disulfide bond at residue 54, is more facile because the 
disulfide bond at residue 54 presumably locks the vicinity of residue 54 and only a 
minimal amount of disruption is needed around residue 107. The large denaturation 
energy seen in the construct containing disulfides at both of these positions likely has a 
different explanation, presumably reflecting the fact that the denatured state in a doubly 
cross-linked NEMO dimer is highly constrained and compact, and benefits from only a 
fraction of the entropy gain that accompanies denaturation of the singly cross-linked 
forms.  
CD studies and FA results provide us quantitative information of NEMO folding 
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and binding, as illustrated in Figure 2.9. The binding of monomeric NEMO44−111(des3C) 
to IKKβ can be considered to involve two steps: (1) association of two disordered 
monomers to form an ordered noncovalent coiled-coil dimer, with free energy ΔGDimeriz, 
and (2) binding of two IKKβ molecules to this noncovalent dimer to form the final 
complex. The first step can be further subdivided into three smaller steps. 1(a) 
Colocalization of the monomers into close proximity, with an energetic cost equal to the 
configurational entropy cost at 1M standard state (ΔSConfig). 1(b) Folding of each 
monomer separately, with an energy cost for each corresponding to the inverse of the free 
energy of unfolding, ΔGH2O. 1(c) Interaction of two folded monomers to form a 
noncovalent dimer, with the release of interaction energy ΔGInteract. If the hypothetical 
preorganized noncovalent NEMO44−111 dimer is assumed to bind IKKβ with a similar 
affinity to that observed for the disulfide-stabilized NEMO44−111 covalent dimers, then the 
20-fold difference in IKKβ binding affinity between dimer (step 2) and monomer (labeled 
as step 3 in Figure 2.9) implies that ΔGDimeriz is small (−RT ln20 = 1.8 kcal/mol). Given 
that ΔSConfig is known to be a large number (6−12 kcal/mol73) and ΔGH2O is negative, the 
noncovalent interaction energy between NEMO monomers, ΔGInteract, must be 
considerable. Specifically, to account for the 6−30-fold difference in IKKβ binding 
affinity, the NEMO monomers must interact sufficiently strongly that approximately 
(1/30) − (1/6) = 3 − 15% of the NEMO protein exists as dimer at the concentration of 
0.1−1 µM at which binding is seen in our assays. Thus, even the relatively small NEMO 
fragments we use here appear to show some tendency to preassociate. The interaction 
affinity is low, however, and therefore under the conditions of our experiments the 
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constructs lacking any interchain disulfide bonds are largely monomeric, consistent with 
the previously published NMR data for NEMO44−1115. The 35% α-helix content we 
observed with these constructs therefore presumably reflects mostly adventitious helix 
formation within a monomeric polypeptide. The observation that the shorter 
NEMO44−111(des3C) binds IKKβ approximately as strongly as the longer 
NEMO1−120(des4C) confirms that regions outside residues 44−111 do not significantly 
contribute to NEMO self-association or to IKKβ peptide binding. The energy diagram for 
the longer, NEMO1−120 constructs should therefore look essentially identical to that 
shown in Figure 2.9, as the additional residues present in these longer constructs do not 
contribute to IKKβ binding and remain largely disordered even in the bound state.  
 
Figure 2.9. Energetic relationship 
between NEMO-NEMO interaction and 
coiled-coil formation in NEMO44-111. The 
binding of monomeric NEMO44-111(des3C) 
to IKKβ can notionally be broken up into 
two hypothetical steps: (1) Association of 
two disordered monomers to form an 
ordered noncovalent coiled-coil dimer, 
with free energy ΔGDimeriz., and (2) binding 
of two IKKβ molecules to this 
noncovalent dimer to form the final 
complex. The self-association of NEMO 
monomers can be further subdivided into 
three notional steps: 1(a) co-localization 
of the monomers into close proximity 
(represented by a dashed red circle), 
where ΔSConfig. is the configurational 
entropy cost of co-localizing two 
molecules from a 1 M standard state such 
that their translational and overall 
rotational motions are coupled. 1(b) 
adoption of a fully α-helical structure separately by each monomer, with an energy cost for each 
corresponding to the inverse of the free energy of unfolding, ΔGH2O, for NEMO44-111(des3C). 1(c) 
interaction of the two α-helical monomers to form a noncovalent, coiled-coil dimer, with the 
release of interaction energy ΔGInteract.. If the hypothetical pre-organized noncovalent NEMO44-111 
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dimer is assumed to bind IKKβ with a similar affinity to that observed for the disulfide-stabilized 
NEMO44-111 covalent dimers, then the modest, 20-fold difference in IKKβ binding affinity 
between dimer (Step 2) and monomer (Step 3) implies that ΔGDimeriz. is small (-RTln20 = 1.8 
kcal/mol). Since ΔSConfig. is known to be a large number (6-12 kcal/mol, see text), and ΔGH2O is 
negative, the noncovalent interaction energy between NEMO44-111 monomers, ΔGInteract., must be 
considerable. The energy diagram for the longer, NEMO1-120 constructs would look essentially 
identical to that shown here, as the additional residues present in these longer constructs do not 
contribute to IKKβ binding and remain largely disordered even in the bound state. 
 
Compared to full-length NEMO, NEMO N-terminal variants, even in the dimeric 
state, bind 10-fold more weakly to IKKβ701-745. We consider several possible explanations 
here. First, we believe that the difference is not likely due to the Cys to Ala mutations at 
residue 76 and 95. Previously it has been shown in full-length NEMO that none of the 
four native cysteine residues in the IKKβ binding region are needed for high affinity 
IKKβ701-745 binding6, 74. Second, the enforced disulfide bond at residue 54 and/or 107 is 
unlikely to weaken binding. Previously it has been shown in full-length NEMO that 
oxidization of cysteine 54 does not change NEMO binding affinity to IKKβ701-7456. 
Moreover, if the enforced disulfide bonds do play a major role in influencing the binding 
affinity, it is hard to believe that two disulfides at distinct locations would produce the 
same magnitude of attenuation of binding affinity. However, even though we cannot rule 
out the above two explanations, we think a third explanation is more likely. The full-
length NEMO has stronger binding affinity than the NEMO N-terminal fragments in this 
study because other domains of NEMO are required to achieve the fullest binding 
interaction with IKKβ. 
Future studies can be focused on evaluating the aforementioned third explanation 
for the discrepancy in binding affinity between full-length NEMO and NEMO1-120 and 
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NEMO44-111 variants. Specifically, experiments can be designed to map the smallest 
domain of NEMO yielding the strongest IKKβ binding. In addition, the identified NEMO 
variants should be studied to elucidate their biophysical properties such as folding and 
unfolding stability as well as its secondary structure in CD to help us learn more about 
this important protein. This NEMO variant will also allow us to probe important 
biological questions related to NEMO/IKKβ interaction. Stabilized dimeric NEMO44-111 
variants can be used as good candidates for crystallography, which should provide 
important information for drug discovery. 
 
2.4. Experimental Procedures 
2.4.1. Construction Of Bacterial And Retroviral Expression Vectors 
Bacterial expression of the NEMO1-120 and NEMO44-111 constructs used the 
backbone vector pDEST™-His-SUMO containing an N-terminal 9xHis-SUMO tag 
(Invitrogen, Carlsbad, CA). The human NEMO1-120 or NEMO44-111 sequence together 
with an N-terminal Tobacco Etch Virus (TEV) cleavage site was cloned into this vector 
through two rounds of PCR and the standard Gateway cloning protocol. In the first round 
of PCR, the TEV cleavage site was added to the N-terminus of NEMO 1-120 or 44-111 
using primers containing both the TEV cleavage site and a partial NEMO sequence. A 
clone of full-length human NEMO containing cysteine to alanine mutations at positions 
11, 76, 95, 131 and 167 was used as a template74. In the second round, attB sites were 
added to both ends of the first round PCR product using primers encoding attB/attP sites. 
Primer sequences are provided in the Supporting Information. All PCRs were performed 
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on an MJ Mini Personal Thermal Cycler (Bio-Rad) using the following conditions: 95 °C 
for 1 min, then 30 cycles of 95 °C for 30 s, 58 °C for 30 s, and 72 °C for 30 s, followed 
by 72 °C for 10 min at the completion of the cycles, and then 4 °C until the run was 
stopped. A total volume of 50 µL was used for PCRs, and reactions consisted of 37 µL 
water, 5 µL DeepVent® thermal buffer, 1 µL DeepVent® polymerase (2.5 U/µL) (New 
England Biolabs), 1 µL dNTP (10 µM), 1 µL template (50 ng/µL), 2.5 µL forward primer 
(10 µM), and 2.5 µL reverse primer (10 µM). PCR products were purified using the 
QIAquick PCR Purification Kit (Qiagen). The BP reaction was performed in a total 
volume of 5 µL, which included 0.4 µL pDONR™221 (375 ng/µL), 3.6 µL PCR product 
(70 ng/µL), and 1 µL Gateway® BP Clonase® II Enzyme mix. Samples were incubated at 
25 °C for 1 h, and reactions were then quenched by adding 0.5 µL proteinase K and 
incubating at 37 °C for 10 min. Products were transformed into DH5α competent cells 
and colonies were isolated on LB plates containing kanamycin (50 µg/mL). Plasmids 
were purified from kanamycin-resistant colonies using QIAprep Spin Miniprep Kit 
(Qiagen), and were sequenced to verify that the DNA sequences were inserted 
successfully into pDONR™221. The LR reaction was then performed in a total volume 
of 5 µL, containing 1 µL pDEST™-His-SUMO (100 ng/µL), 2 µL pDONR™221-target 
DNA (125 ng/µL), 1 µL Gateway® LR Clonase® II Enzyme mix, and 1 µL water. 
Samples were incubated at 25 °C for 1 h and reactions were quenched by adding 0.5 µL 
proteinase K and incubating at 37 °C for 10 min. Products were transformed into DH5α 
competent cells and transformed colonies were selected on LB plates containing 
ampicillin (100 µg/mL). As above, plasmids were purified by using QIAprep Spin 
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Miniprep Kit (Qiagen) and sequenced to verify their integrity. 
2.4.2. Site-Directed Mutagenesis 
All mutations in bacterial expression vectors for NEMO were created using the 
following procedures: PCR was performed under the following conditions: 95 °C for 1 
min, then 15 cycles of 95 °C for 30 s, 55 °C for 1 min, and 68 °C for 7 min, followed by 
68 °C for 10 min at the completion of the cycles, and then 4 °C until the run was stopped. 
Components were as described above. After PCR, 1 µL DpnI was added and the samples 
were incubated at 37 °C for 3 h. Then 5 µL of the reaction was transformed into DH5α 
competent cells. Plasmids with mutations were selected and sequenced as described 
above.  
2.4.3. Protein Expression And Purification 
For protein expression, plasmids were transformed into T7 express competent E. 
coli BL21 (DE3) cells (New England Biolabs) according to the manufacturer’s 
instructions, and transformants were selected on LB plates containing ampicillin (100 
µg/mL). A single colony was used to inoculate 50 mL of LB with ampicillin and the 
culture was incubated at 37 °C overnight with shaking. For large-scale expression, 1 L of 
LB with ampicillin was inoculated with 10 mL of the overnight culture. Cells were grown 
at 37 °C to an OD600 of 0.4-0.6. To induce protein expression, IPTG was added to a final 
concentration of 1 mM and cells were grown for an additional 2 h. 2.5 g of cells were 
isolated by centrifugation and were lysed by microfluidizer® in 50 mL of lysis buffer 
containing 1 mM benzamidine, 1 mM PMSF, 0.1 mM EDTA, and 1 tablet of Roche 
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inhibitor cocktail. The cell lysate was centrifuged at 18,000 × g for 15 min. The 
supernatant was discarded because the target protein was expressed in inclusion bodies. 
The pellet containing cell debris and inclusion bodies was washed and suspended using 
wash buffer (lysis buffer supplemented with 0.5% Triton X-100). The washed inclusion 
body pellet was centrifuged as described above, and the wash step was repeated with 
water to remove the Triton X-100. Inclusion bodies were solubilized with 8 M Urea, by 
pipetting repeatedly until the inclusion bodies were thoroughly dissolved. This 
solubilization step can take as long as overnight to maximize the inclusion body 
dissolution, and to give time for full oxidation of cysteine thiols into disulfides. The 
denatured target protein was refolded on a HisTrap™ HP 5 mL column and purified. The 
on-column refolding and purification were performed under the following conditions: 10 
mL dissolved inclusion bodies was loaded onto the column, the bound protein was 
refolded by washing the column with 20 column volumes of a linear gradient of 8 M urea 
with nickel column binding buffer (20 mM sodium phosphate pH 7.4, 500 mM NaCl, 40 
mM imidazole), and then the refolded protein was eluted from column with elution buffer 
(20 mM sodium phosphate pH 7.4, 500 mM NaCl, 500 mM imidazole). Elution of the 
protein was monitored by UV absorbance at 280 nm, and the fractions containing protein 
were combined and concentrated using an Amicon Ultra-15 Centrifugal Filter Unit 
according to the manufacturer’s instructions. Protein was quantified by absorbance at 280 
nm using a NanoDrop 2000 (Thermo Scientific), using extinction coefficients calculated 
by the ExPASy Proteomics Server75. 
The 9xHis-SUMO fusion partner was removed using TEV protease, as described 
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previously. Briefly, the tagged proteins were dialyzed into TEV reaction buffer (50 mM 
Tris-HCl pH 8.0, 0.5 mM EDTA and 1 mM DTT). TEV protease was added to the 9xHis-
SUMO-NEMO substrate at a ratio of 1:100, based on O.D.280, and the reaction mixture 
incubated overnight at 4 °C. The product mixture was loaded onto a HisTrap™ HP 5 mL 
column to separate the untagged NEMO from the cleaved 9xHis-SUMO fusion partner. 
The cleaved NEMO protein was concentrated and dialyzed into 50 mM HEPES buffer. 
The protein was flash frozen and stored at -80 °C. All variants were sent for mass 
spectrometry to confirm the exact mass. Samples were estimated to be > 95% pure as 
determined by SDS-PAGE. After removal of the fusion partner the NEMO44-111 
constructs contained no tryptophan or tyrosine, and therefore had negligible absorbance 
at 280 nm. For these proteins, the concentrations were measured at 205 nm in a 1 cm path 
length quartz cuvette, using an extinction coefficient that was calculated from the amino 
acid sequence as described. Quantifications were performed in triplicate. 
All constructs containing cysteines at either position 54 and/or 107 were found to 
exist as 100% covalent dimer after purification, as shown by non-reducing SDS-PAGE, 
provided that sufficient time was allowed during solubilization of the inclusion bodies to 
ensure oxidation of free cysteines. For the constructs containing a cysteine at both 54 and 
107, which would migrate as a dimer in non-reducing SDS-PAGE even if only one 
disulfide were present, full oxidation was demonstrated using the colorimetric thiol 
reagent 5,5’-dithio-bis(2-nitrobenzoic acid) (DTNB). To prepare 100% monomeric forms 
of the cysteine-containing constructs, the protein was incubated overnight at 4 °C with 25 
mM DTT in 6 M urea. The urea was removed by buffer exchange, using an Amicon 
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column, into a storage buffer for monomeric protein of 50 mM HEPES buffer containing 
25 mM DTT.  
2.4.4. DTT Reduction Tolerance Test 
100 µM of NEMO1-120 proteins were incubated in water containing 25 mM DTT 
at 4 °C for various periods of time, and then analyzed by SDS-PAGE without boiling to 
assess each construct’s tolerance to DTT. To determine whether the protein could be 
reduced under denaturing conditions, 100 µM of protein was incubated with 25 mM 
reducing agent (TCEP or DTT) with or without 6 M urea at room temperature for 1 h. 
Samples were then analyzed by SDS-PAGE together with a control sample treated by 
boiling in reducing buffer containing 100 mM DTT. To determine the DTT concentration 
required to reduce Cys54-containing NEMO dimers under denaturing conditions, 
NEMO1-120(des3C/C54) was incubated for 1 h at room temperature with 6 M urea plus 
various concentrations of DTT.    
2.4.5. Circular Dichroism Spectroscopy 
CD spectra were measured using an Applied Photophysics CS/2 Chirascan with a 
1 mm path length quartz cuvette at a scan speed of 0.5 s/nm. Unless otherwise indicated, 
spectra were measured at 10 µM NEMO protein (based on NEMO monomer) in sodium 
phosphate at pH 7.4 at 25 °C. The buffer background was subtracted. The measured 
ellipticity in millidegrees (𝜃) was converted to mean residue ellipticity ([θ]MRE) using the 
following equation: 
   [𝜃]!!" = 𝜃/(10 × 𝐶𝑛𝑙)     Eq. 2.1 
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where C is the molar concentration, n is the number of residues, and 𝑙 is the path length 
in cm. The CD spectra in water and phosphate buffer were found to be identical, and so 
the results were combined and treated as replicates. Three independent measurements 
were conducted for each NEMO sample. The percent α-helix content was determined by 
comparing the [θ]MRE at 222 nm measured after 2 h of incubation at room temperature in 
aqueous buffer (20 mM phosphate, pH 7.4) with that measured in 97% 
2,2,2-trifluoroethanol (TFE), using the equation below:  𝛼– ℎ𝑒𝑙𝑖𝑥 % = 𝜃222 𝑎𝑞𝑢𝑒𝑜𝑢𝑠𝜃222 𝑇𝐹𝐸 ×100 Eq. 2.2 
2.4.6. Urea-Induced Denaturation 
NEMO protein was incubated at 25 °C for at least 1 h with freshly prepared urea 
solution diluted to different concentrations, in 20 mM phosphate, pH 7.4, before CD 
measurement of mean residue ellipticity at 222 nm as described above. Preliminary 
measurements showed no difference in denaturation curves when the protein was 
incubated for 1 h or 24 h, indicating that an incubation time of 1 h was sufficient to reach 
equilibrium. To determine whether the denaturation was reversible, identical samples of 
100 µM NEMO1-120(des4C/L107C) were treated either with 4 M urea to ensure complete 
denaturation, or with water as a control. After 1 h at 25°C, each sample was diluted 10-
fold into water. After 30 min of refolding, CD spectra were taken. There was no 
difference between the urea treated group after refolding and water treated group (Figure 
2.6E), indicating denaturation was fully reversible.  
Denaturation data were fitted by non-linear least-square analysis to a two-state 
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model containing additional terms to capture the effect of urea on the measured ellipticity 
of the fully folded and fully unfolded protein, as described70. The equation used for fitting 
was: 
[𝜃!!!]!"# = (𝑦𝑓+𝑚𝑓 𝑢𝑟𝑒𝑎 )+(𝑦𝑢 +𝑚𝑢[𝑢𝑟𝑒𝑎] )𝑒− ∆𝐺𝐻2𝑂𝑅𝑇  − 𝑚[𝑢𝑟𝑒𝑎]𝑅𝑇1+𝑒− ∆𝐺𝐻2𝑂𝑅𝑇  − 𝑚[𝑢𝑟𝑒𝑎]𝑅𝑇   Eq. 2.3 
Where 𝑦! and 𝑚! are the intercept and slope of the urea dependence of [θ222]MRE for the 
fully folded protein, 𝑦! and 𝑚! are the corresponding intercept and slope of the fully 
unfolded protein, ∆𝐺!!! is the free energy of unfolding at zero urea, 𝑚 is the slope of 
transition region, 𝑅 is the molar gas constant, and 𝑇 is absolute temperature. This model 
was used because the urea denaturation curves for NEMO1-120(des4C/L107C) and for the 
corresponding NEMO44-111 construct showed a positive linear slope at urea 
concentrations above the level required for full denaturation of the protein, indicating that 
in these cases urea has a small but significant effect on the ellipticity of the fully 
denatured protein. Fitting the denaturation curves for these constructs to the above 
equation while allowing mu to have a small positive value clearly gave a better fit to the 
data. For the other disulfide-stabilized constructs, allowing mu to have a non-zero value 
had no significant effect on the curve fits or the values of the parameters ΔGH2O or m that 
were obtained from the fitting; for the monomeric constructs NEMO1-120(des4C) and 
NEMO44-111(des3C) a value for mu of ~0 was clearly preferred. In no case was a non-zero 
value for mf indicated, and so this parameter was fixed at zero for all data fits. Thus, only 
for NEMO1-120(des4C/L107C) and NEMO44-111(des3C/L107C) was a pre-transition or 
post-transition slope allowed, with a positive value for mu being allowed in these two 
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cases. For the monomeric constructs NEMO1-120(des4C) and NEMO44-111(des3C) the 
value of yf, the ellipticity corresponding to fully folded protein, was poorly defined by the 
experimental data because the protein was < 50% folded even at zero urea. Therefore, in 
fitting the data for these two constructs we fixed the yf at the mean value observed for the 
other three constructs in the series, based on the assumption that the fully folded state 
would have an α-helical content similar to that seen for the native states of the other 
constructs of the same length. For all denaturation experiments we found that 
measurements made at the lowest and highest urea concentrations (zero and 7.76 M urea) 
were variable and frequently anomalous, and therefore data for these extreme urea 
concentrations were excluded from fitting in all cases. 
To linearize the denaturation data, for the purpose of more clearly illustrating the 
extrapolation to zero urea, we calculated the free energy of unfolding, ΔG, at each urea 
concentration using the following equation: 
   𝛥𝐺 = −𝑅𝑇ln 𝑦𝑓 –[𝜃222]𝑀𝑅𝐸[𝜃222]𝑀𝑅𝐸–𝑦𝑢    Eq. 2.4 
where the minimum and maximum ellipticities, yf and yu, are the values determined for 
each construct from the nonlinear regression analysis using Equation 5. 𝛥𝐺 was then 
plotted against urea concentration to generate the linear plots. 
2.4.7. Thermal Denaturation 
Proteins, at a concentration of 10 µM in 20 mM phosphate, pH 7.4, were heated 
from 5 °C to 90 °C at a rate of 2.5 °C/min, using the internal temperature control function 
of the CD spectrometer. Spectra from 180-260 nm were taken at a scanning rate of 0.5 
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s/nm. No obvious difference in melting curves was seen when the slower ramping rate of 
1 °C/min was used, suggesting that the selected rate was appropriate. Thermal 
denaturation was completely reversible, as demonstrated by comparing the CD spectra 
NEMO1-120(des4C/L107C) before and after thermal denaturation and refolding (Figure 
2.7C). The melting temperature Tm for each protein was estimated from the maximum of 
a plot of the first derivative of 𝜃222 was against temperature. Each result represents the 
average of two independent experiments.  
2.4.8. Fluorescence Anisotropy Binding Assay 
All bacterially expressed NEMO variants were measured for binding affinities of 
IKKβ peptide (residues 701-745) in a direct binding format using Fluorescence 
Anisotropy (FA) as described previously6, 27. Assays were performed in 96-well non-
treated black polystyrene plates (Corning® Costar®), using a SpectraMax M5 microtiter 
plate reader (Molecular Devices, Sunnyvale, CA). For each experiment, 50 µL water, 50 
µL 4x TNT buffer (200 mM Tris, 800 mM NaCl, 0.04% Triton X-100, 4 mM DTT, pH 
7.5), 50 µL N-terminally FITC-labeled IKKβ peptide (60 nM), and 50 µL NEMO protein 
at varying concentrations was added to each well to give final concentrations of 15 nM 
FITC-IKKβ in 50 mM Tris, 200 mM NaCl, 0.01% Triton X-100, 1 mM DTT, pH 7.5 in a 
total volume of 200 µL. The plates were incubated on a plate shaker (UltraCruz shaker 
for microplates, Santa Cruz Biothechnology) for 1 h at 250 rpm, and were then incubated 
at 25 °C for 5 min before fluorescence was measured. Samples were read by excitation at 
488 nm and emission at 520 nm in high sensitivity mode. Values were the averages of 
100 measurements for each well, and each experiment was done in duplicate. After 
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background subtraction the anisotropy values, A, were fitted by non-linear least-square 
regression to the modified quadratic binding equation shown below6: 
𝐴 = 𝐴! + (𝐴!"# − 𝐴!) [𝑅]𝑇+𝐾𝐷+[𝐿]𝑇− ([𝑅]𝑇+𝐾𝐷+[𝐿]𝑇)2−4[𝑅]𝑇[𝐿]𝑇2[𝐿]𝑇  Eq. 2.5 
Where A0 is the anisotropy observed for unbound FITC-IKKβ, Amax is the maximum 
anisotropy signal at saturating [NEMO],  [R]T and [L]T are the total concentrations of 
NEMO protein and FITC-IKKβ, and KD is the binding affinity. All results shown 
represent the average of at least three independent experiments. 
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CHAPTER 3. CHARACTERIZATION OF PEPTIDE-DERIVED SMALL 
MOLECULE INHIBITORS OF NEMO 
3.1. Chemotype evolution screening  
 Fragment based drug discovery (FBDD) has gained enormous popularity over 
recent years. Instead of screening small molecules (MW ~ 300-500 Da), FBDD is a 
method that is applied to search for hits from fragment libraries (MW < 300 Da)76. FBDD 
allows us to screen a much larger chemical space. Identified fragment hits are further 
elaborated to achieve high affinity binders. Through FBDD, numerous small molecule 
inhibitors, even for challenging targets such as PPI, have been discovered. ABT-263 
(navitoclax), a potent inhibitor (Ki ≤ 1 nM) of anti-apoptotic protein Bcl-xL31a, is a good 
example. Originally, fluoro-biary acid (KD = 300 ± 30 µM) and tetrahydronaphthalen-1-
ol (KD = 4300 ± 1600 µM) were identified to bind Bcl-xL by 15N-HSQC NMR77. The two 
fragments were linked by acylsulfonamide to give a molecule with double-digit 
nanomolar binding affinity77. Subsequent optimization of this molecule led to the 
discovery of ABT-26331b.  
 However, a technical challenge of FBDD is to measure weak binders reliably. 
Fragments, due to the limitation in size, generally don’t generate high binding energy. To 
achieve observable binding in a screening assay, it is usually necessary to test the 
fragments at very high concentrations, where the fragments can be insoluble. Carmot 
Therapeutics’ proprietary Chemotype Evolution is a FBDD based approach. It addresses 
the weak-binder challenge by linking a library of fragments to a “bait”, which is a 
fragment that is known to bind to the target. Fragments from identified hits are used as 
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new baits for building a second screening library. Through iteration, the original bait is 
completely replaced with novel fragments and the new hits are developed into molecules 
with high binding affinity (Figure 3.1).  
 
Figure 3.1. Chemotype Evolution by Carmot Therapeutics. Illustration is adapted from their 
website. (http://carmot-therapeutics.us/science/) 
 
 In pursuing small molecule inhibitors of NEMO, Carmot Therapeutics used a 
chemically modified partial IKKβ sequence (IKKβ737-745: LDWSWLQTE) as the bait. 
This 9-mer peptide contains the highest concentration of hot-spot residues that are 
important for NEMO binding27. Golden et al. have reported that the resides that 
contribute the most binding energy in the NEMO binding region of IKKβ are W739, 
W741, and L742 (ΔΔG = 4.3, 3.5, and 3.2 kcal/ mol, respectively)27. This 9-mer, 
therefore, provides sufficient binding to be used as the bait. To avoid charges not 
endogenously present in the 9-mer, and to increase its in vitro stability, a C-terminal 
bait fragments 1st round library target 1st round hit 
new bait 2nd round library 2nd round hit 
3rd round screening 
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amidation modification was added. The N-terminus of the 9-mer was modified with a 
bromoacetyl group for fragment attachment.  
Carmot constructed a fragment library (6600 fragments) by attaching a set of 
small molecule fragments to the 9-mer peptide bait through reaction with the bromoacetyl 
group. Carmot screened this fragment library against NEMO, using the FA inhibition 
assay6 (Figure 2.5 D), and identified several inhibitors that, due to the peptidic nature of 
the bait, are partially peptidic and partially organic. All those inhibitors have low 
micromolar IC50 values in the FA inhibition assay. To validate and characterize two of 
those hits (CT-7872 and CT-8086, Figure 3.2), I repeated FA inhibition assay and 
conducted SPR experiments. The results confirm the validity of these two hits, and also 
provide detailed information about binding affinity and kinetics. In addition, I developed 
an SPR assay using the NEMO N-terminal constructs I described in Chapter 2. This assay 
can be applied in future studies to measure 
high affinity inhibitors that bind NEMO N-
terminus. 
 
Figure 3.2 Structures of CT-7872 and CT-8086, 
two NEMO hits identified in FA inhibition assay 
by Carmot Therapeutics. Organic fragments of the 
two hits are attached to bromoacetyle peptide.  
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3.2. Results  
3.2.1. Identification and Characterization of CT-7872 and CT-8086 by FA 
Note: The FA assay used in this section was previously developed by our group6. Carmot 
Therapeutics did initial screening using full-length NEMO protein prepared by me. The 
binding characterization and data analysis presented in this section is my own work. 
 
The FA inhibition assay, previously developed in our lab6, was transferred to 
Carmot Therapeutics as their primary screening assay for identifying NEMO inhibitors. 
Through first round screening, Carmot Therapeutics identified several low micromolar 
hits, two of which were further characterized by me in this chapter.  
The IC50 values originally measured for CT-7872 and CT-8086 were 2.6 ± 0.6 µM 
and > 32.9 ± 26.2 µM respectively (Table 3.1), determined by fitting FA inhibition data 
obtained from Carmot Therapeutics with appropriate equations (Figure 3.3 A, Eq. 3.1 and 
3.2). In a repeated experiment done by me, CT-7872 inhibits 5×Ala NEMO, a full-length 
NEMO that was previously reported to bind IKKβ701-745 with single digit nanomolar 
affinity6, with an IC50 of 9.3 ± 1.1 µM (Table 3.1, Figure 3.3 B). Although the repeated 
assay wasn’t conducted under absolutely identical conditions to those used by Carmot, 
we believe the differences in assay condition (i.e. 96 well plate versus 384 well plate) 
were not likely to have any significant impact on binding. The difference in IC50 values 
(2.6 ± 0.6 versus 9.3 ± 1.1 µM) is due to sample loss during handling because an 
overestimation of inhibitor concentrations used in the replicate assays performed by me 
would result in underestimation of IC50. IKKβ701-745 C716S, with an IC50 at 0.2 ± 0.03 
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µM (Table 3.1), was used as a control for the activity of 5×Ala NEMO. This peptide was 
extensively characterized by me previously (data not shown). Shown in Figure 3.3, CT-
7872 reached complete NEMO inhibition over the course of roughly two log units, 
consistent with well-behaved, specific inhibition. If the interaction was a 1:1 binding and 
there was no nonspecific binding, data from a true inhibition event should fit to a 
hyperbolic binding equation, which mathematically requires that the concentrations of 
inhibitor needed to go from 10-90% inhibition spans roughly two log units. If the slope of 
inhibition curve was too steeper than this, it is very likely that there is assay artifact such 
as aggregation in the assay78. Taken together, these results suggested that CT-7872 was a 
true inhibitor of NEMO with low micromolar IC50.  
Carmot Therapeutics tested two batches of CT-8086, both of which showed 
similar IC50 values. Shown in Figure 3.3 A, neither batch reached full inhibition within 
the concentration range tested. Moreover, CT-8086 started to show an anomalous 
decrease in signal at concentrations above 100 µM (Figure 3.3 A). The decreasing 
inhibition at higher concentrations of CT-8086 (batch 2) suggested the occurrence of 
insolubility and nonspecific binding, because aggregates that bind nonspecifically to the 
fluorescently labeled IKKβ peptide will give an increased FA signal. To reflect the 
incomplete inhibition seen for CT-8086, only a lower limit for the IC50 was determined. 
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Figure 3.3. FA inhibition assay characterizing CT-7872 and CT-8086. (A) FA inhibition 
assay by Carmot Therapeutics shows CT-7872 and CT-8086 inhibit 5×Ala NEMO with low 
micromolar IC50s. IC50s of CT-7872 and CT-8086 are 2.6 ± 0.6 µM and > 33 ± 26 µM 
respectively. Plotted data are averages from duplicate measurements obtained by Carmot 
Therapeutics. Error bars are standard deviations. Both CT-7872 and CT-8086 (batch 1) are fitted 
using Eq. 3.1. CT-8086 (batch 2) is fitted using Eq. 3.2. 33 nM of 5×Ala NEMO and 20 nM 
FITC-IKKβ701-745 were used in the assay. (B) FA inhibition assay by me shows reproducible 
inhibition of 5×Ala NEMO by CT-7872. Inhibition by IKKβ701-745 C716S is used as a control for 
the FA inhibition assay. IC50s of CT-7872 and IKKβ701-745 C716S are 9.3 ± 1.1 µM and 0.2 ± 0.03 
µM respectively. Plotted data are averages from duplicate measurements obtained by me. Error 
bars are standard deviations. Both CT-7872 and IKKβ701-745 C716S are fitted using Eq. 3.1 with 
A0 being shared. 15 nM of 5×Ala NEMO and 15 nM FITC-IKKβ701-745 were used in the assay. 
 
3.2.2. Characterization Of CT-7872 And CT-8086 By SPR 	 Note: The SPR immobilization conditions used in this section was developed by 
Dan Petrescu. Binding experiments were conducted by both of us. The data analysis 
presented in this section is my own work. 
 
Binding affinity and kinetics are important pieces of information for almost any 
target-based drug discovery. A technology commonly employed to measure these 
properties is surface plasmon resonance (SPR). SPR is a biophysical method that 
monitors the refractive index change immediately above a chip surface, where binding 
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events are studied. Refractive index changes proportionally with the amount of analyte 
binding to ligand, which is immobilized to dextran chains on chip surface. In SPR 
terminology, “ligand” refers to molecules being immobilized on the chip surface while 
“analyte” refers to molecules injected onto chip surface to bind ligand. We conducted 
SPR studies on CT-7872 and CT-8086. In these studies, full-length 5×Ala NEMO was 
immobilized onto the chip surface using standard thiol coupling with 2-(2-pyridinyldithio) 
ethaneamine (PDEA). This reagent introduces a disulfide group to an N-
hydroxysuccinimide/1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (NHS/EDC) 
activated chip surface. The disulfide group is then utilized to exchange with a free thiol 
group in ligand. The binding of IKKβ701-745C716S was tested at the beginning of, in the 
middle of, and at the end of each binding experiment, to show that there was no loss of 
NEMO activity.  
 
Figure 3.4. Binding of IKKβ701-745C716S and 5×Ala full-length NEMO measured by SPR. (A) 
Fitted sensorgrams show IKKβ701-745C716S binds 5×Ala full-length NEMO. Solid lines are fitted 
curves based on Eq. 3.3 and Eq. 3.4. Dotted lines represent experimental data. Legend shows the 
concentrations of analyte in the unit of nM. Plotted here is one of three independent experiments. 
(B) Hyperbolic fit (Eq. 3.5) of equilibrium binding shows that IKKβ701-745C716S binds 5×Ala 
full-length NEMO with low micromolar binding affinity. Data plotted here are average of values 
from three independent experiments. Error bars are standard deviations.  
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In Figure 3.4 A, the SPR response is plotted against time. The experimentally 
measured sensorgram (represented by the dotted lines) was double referenced by 
subtracting the signals with blank buffer only and also with those measured for interlane 
detection spots on the chip that contains no immobilized NEMO. Analyte (IKKβ701-
745C716S) was injected onto the chip surface for 180 seconds. Association between 
analyte (IKKβ701-745C716S) and ligand (5×Ala full-length NEMO) happened quickly and 
reached equilibrium within the first 50 seconds. Data from the association phase was 
fitted using Eq. 3.4. Then injection was switched to running buffer, to measure the 
dissociation of bound IKKβ701-745C716S from 5×Ala full-length NEMO. Dissociation 
was fitted using Eq. 3.3. From the kinetic fitting, we obtained parameters such as kon, koff 
and KD (Table 3.1). To cross validate KD value obtained from kinetic fitting, we also 
conducted equilibrium binding fitting. Shown in Figure 3.4 B, responses from 
equilibrium binding (after the first 50 seconds and before 180 s in Figure 3.4 A) 
measured in three independent experiments were averaged and plotted with error bars 
representing standard deviations. The data were fitted using a hyperbolic equation (Eq. 
3.5). A KD value was obtained and is also listed in Table 3.1.  
The agreement in KD values between equilibrium (160 ± 20 nM) and kinetic (240 
± 100 nM) data analysis serves as a cross validation for our kinetic data fitting. In 
addition, the KD value measured by SPR is very similar to the IC50 (200 ± 40 nM) 
obtained by FA (Table 3.1). Agreement between these two orthogonal assays is 
additional evidence of accurate affinity determination. 
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SPR results for the binding of CT-7872 and CT-8086 to full-length NEMO are 
shown in Figure 3.5. The data were analyzed exactly as described above for IKKβ701-
745C716S, except for the equilibrium binding of CT-8086, which was fitted using Eq. 3.6 
to account for nonspecific binding at high concentrations. Results confirm that both of the 
Carmot inhibitors have low micromolar binding affinity for full-length NEMO (Table 
3.1). Compared with IKKβ701-745C716S, CT-8086 showed fast on and fast off kinetics 
(Figure 3.4 A and 3.5 C). Binding kinetics is useful to know if we were to rank hits for 
optimization. To achieve good efficacy, inhibitors are sometimes modified so that they 
dissociate from the target more slowly. Based on our result, we would rank CT-7872 
higher in priority for development. However, in practice, we chose to move forward with 
both inhibitors at the same time. The successful kinetic measurements by SPR 
demonstrated our capability of measuring the binding of small ligands to full-length 
NEMO. 
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Figure 3.5. CT-7872 and CT-8086 bind 5×Ala full-length NEMO measured by SPR. (A) SPR 
sensorgram of CT-7872 and 5×Ala full-length NEMO. Solid lines are fits based on Eq. 3.3 and 
Eq. 3.4. Dotted lines are SPR measurements. Legend shows the concentrations of analyte in units 
of nM. Plotted here is one single experiment of two independent experiments. Corresponding 
results for CT-8086 are shown in (C). (B) Equilibrium fit (Eq. 3.5) for binding between CT-7872 
and 5×Ala full-length NEMO. Plotted here are the average values of two independent 
experiments. Error bars show standard deviations. Corresponding results for CT-8086 are shown 
in (D), data fitted using Eq. 3.6. 
 
Table 3.1. Binding characterization of CT-7872, CT-8086 and IKKβ701-745 C716S by FA and 
SPR 
 FA SPR 
Analyte IC50 by Carmot 
Therapeutics 
(µM) 
IC50 by me 
(µM) 
KD from 
equilibrium 
(µM) 
KD from 
kinetics 
(µM) 
kon 
(M-1s-1) 
koff 
(s-1) 
CT-7872 2.6 ± 0.6 9.3 ± 1.1 2 ± 0.1 3.5 ± 0.5 12500 ± 500 0.042 ± 
0.004 
CT-8086 > 33 ± 26 n.d. 3 ± 0.4 10 ± 5 25500 ± 
13000 
0.205 ± 
0.049 
IKKβ701-
745 C716S 
n.d. 0.2 ± 0.03 0.16 ± 0.04 0.24 ± 0.1 160000 ± 
72000 
0.034 ± 
0.003 
n.d.: not determined. Mean values are averages of at least two independent experiments or duplicates. 
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3.2.3. Inhibitor fragments characterization by FA 
In order to quantify the energetic contributions of each fraction of the inhibitors, I 
tested the binding of the peptidic fragment (9-mer) alone using the FA inhibition assay. 
Less than 10% inhibition was detected at a concentration of up to 150 µM (Figure 3.6). 
The FA signal increased dramatically as 9-mer concentrations rose above 150 µM (to the 
right of short dashed line in Figure 3.6). This increase indicated occurrence of assay 
artifacts probably due to peptide insolubility. The IC50 should be roughly 10 times the 
inhibitor concentration where 10% inhibition was observed, for the reasons discussed in 
section 3.2.1. Therefore, the IC50 of the 9-mer was > 1.5 mM. Compared with CT-8086, 
the 9-mer was at least 50 times weaker in binding affinity, which corresponded to a loss 
of at least 2 kcal/mol in binding free energy (Eq. 3.7). The additional organic fragment of 
CT-8086 thus contributes > 2 kcal/mol binding free energy of CT-8086. Taken together, 
our results show that by linking the “bait” with fragments, we can identify potent 
inhibitors for challenging targets such as NEMO. 
 
Figure 3.6. FA inhibition assay of 9-mer. 9-mer (Acetyl-LDWSWQTE-NH2) shows no 
observable inhibition of 5×Ala NEMO. The dramatically increased signal at higher 
concentrations of 9-mer suggests the occurrence of insolubility and nonspecific binding. Plotted 
data are averages from duplicate measurements. Error bars are standard deviations. Dotted lines 
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indicate the signals observed for the high (no inhibitor) and low (no NEMO) controls. The dashed 
line indicates the critical concentration cutoff for 9-mer solubility in FA assay buffer. 15 nM of 
5×Ala NEMO and 15 nM FITC-IKKβ701-745 were used in the assay. 	
3.2.4. SPR Assay Development Using NEMO N-Terminal Constructs 	 Compared with full-length NEMO, N-terminal constructs that contain only the 
IKKβ binding region are much shorter and can be used to narrow down the location of 
the inhibitor binding region on NEMO. In addition, we found that NEMO N-terminal 
variants were less prone to aggregation in vitro than was full-length NEMO, and 
therefore might be more suitable to use in SPR in prolonged experiments.  
 To immobilize ligand (NEMO1-120des3C/C54 dimer) onto a BIAcore CM5 chip 
surface, two approaches can be used: direct covalent coupling, or indirect capture via an 
antibody or other affinity reagent coupled to the chip surface. NEMO1-120des3C/C54 
dimer was expressed in bacteria and purified through its N-terminal His-SUMO tag, as 
described in Chapter 2. Because we wanted to make a homogeneous chip surface, and 
there was already a His-SUMO tag on NEMO N-terminal constructs, we chose to try an 
indirect capture method first. For this method, His-SUMO tag was captured by anti-His 
antibody, which was immobilized onto the chip surface though amine coupling. NEMO 
was then injected onto the chip surface to be captured by the anti-His antibody (Figure 
3.7 left panel). If the anti-His antibody could bind NEMO strongly enough, we could use 
this prepared chip surface to study binding of small molecules (Figure 3.7 right panel). 
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Figure 3.7. SPR chip preparation by capturing His-SUMO-NEMO through anti-His 
antibodies. Left panel shows the setup for characterizing binding kinetics of anti-His and His-
SUMO tagged NEMO N-terminus. Right panel shows the setup for hit characterization. Anti-his 
antibody is first immobilized onto the chip surface through amine coupling. His-SUMO tagged 
NEMO N-terminus is captured by the anti-His antibody. Then the binding of small molecule 
analyte to NEMO is measured.  
 
Small molecule analytes give only small SPR signals, and to measure these small 
signals accurately requires that the binding properties of the surface remain constant 
during the measurement. Therefore, to measure small ligand binding reliably with a chip 
surface prepared by an indirect capture method, we need a high ligand density (> 5000 
Ru) chip surface to give the largest possible binding signal, and we need to make sure 
that the surface does not lose bound ligand due to dissociation from the capturing 
antibody. This requires an anti-His antibody to bound NEMO with an off-rate slow 
enough so that we won’t loose more than 5% of active surface during a 5 minute-long 
binding analysis. Loss of more than 5% active surface would make kinetics data hard to 
interpret.  
We tested two anti-His antibodies from Qiagen, Tetra and Penta (antibodies 
separately bind to 4×His and 5×His epitopes the most strongly), and conducted SPR 
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binding experiments to evaluate their binding kinetics for His-SUMO-NEMO1-
120des3C/C54 dimer. The fitted sensorgrams and residual plots are shown in Figure 3.8. 
As shown in Table 3.2, tagged NEMO1-120des3C/C54 dimer dissociated from Tetra and 
Penta at off-rates of 1.8×10-3 s-1 and 7.4×10-3 s-1 respectively. We calculated the lower 
limit of dissociation rate (1.7×10-4 s-1) needed for less than 5% loss of NEMO from 
surface in a 5 minute-long analysis. Neither of the two anti-His antibodies had a 
sufficiently slow off-rate to retain 95% of the bound NEMO for the duration of a 5 
minutes binding measurement. Therefore, we couldn’t move forward with this approach 
without suitable anti-His antibodies. 
 
Figure 3.8. NEMO1-120(des3C/C54) binding to the anti-His antibodies Tetra and Penta 
measured by SPR. Top left panel shows SPR sensorgrams for NEMO1-120(des3C/C54) binding 
to Tetra. Red lines are curve fits. Black lines are SPR measurements. Plotted here is one single 
experiment of three independent experiments. Top right panel is the residual plot data fitting of 
top left panel. Corresponding results for Penta are shown at the bottom two panels. 
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Table 3.2. Binding characterization of two anti-His antibodies used to capture NEMO1-
120(des3C/C54) 
Antibody ka (M-1s-1) kd (s-1) Rmax (RU) KD (nM) kd(s-1) 
GOAL 
Tetra 5.9×104 ± 2.7×104 1.8×10-3 ± 5.6×10-4 17 ± 2 35 ± 19 1.7×10-4 
Penta 2.1×105 ± 2.5×105 7.4×10-3 ± 1.1×10-2 7 ± 1 30 ± 16 1.7×10-4 
Values are average of three independent experiments. Values in parenthesis are average of the 
standard errors obtained from the three independent experiments. 
 
Direct coupling utilizes reactive groups on the ligand to covalently attach the 
ligand to the chip surface through either amine, thiol or aldehyde chemistry. Amine 
coupling is the most widely used method for ligand immobilization. However, this 
method links the ligand to the chip surface randomly, and may destroy ligand activity by 
linking the lysine residues in the active site to the chip surface and preventing analyte 
binding. Our previous results showed that was the case with NEMO immobilization (data 
not shown). We therefore devised a method to protect IKKβ binding site on NEMO. First, 
tagged NEMO1-120des3C/C54 dimer was incubated with IKKβ701-745 at a high 
concentration to form the bound complex. Then, the NEMO/IKKβ complex was injected 
onto an NHS/EDC activated SPR chip surface to be immobilized by amine coupling. The 
uncoupled IKKβ peptide was then dissociated from the covalently captured NEMO and 
washed away, leaving active unbound NEMO on the chip surface (Figure 3.9). Validation 
of the resulting surface showed that this method could prevent the active binding site on 
NEMO from being destroyed, because of the protection offered by IKKβ peptide during 
coupling. 
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Figure 3.9. Design of protective amine coupling. Top: EDC/NHS mediated amine chemistry for 
ligand immobilization. Bottom left panel: NEMO/IKKβ complex is injected onto the chip surface 
to be immobilized via amine chemistry. Bottom right panel: IKKβ dissociates from NEMO, 
leaving the active binding site ready for analyte binding. 
 
Shown in Figure 3.10, binding of IKKβ701-745C716S to tagged NEMO1-
120(des3C/C54) captured onto the chip with method described as above was measured to 
validate surface activity. The shape of the sensorgrams doesn’t show any sign of multiple 
binding sites, as the equilibrium response is completely flat (Figure 3.10 A). Figure 3.10 
B reveals that there is no nonspecific binding, as the response doesn’t continue to 
increase at high inhibitor concentration. Binding affinity was obtained from equilibrium 
binding (Figure 3.10 B). Data were analyzed by the same procedure described in section 
3.2.2. The KD measured by SPR (1.7 ± 0.1 µM) agrees with the value measured by FA 
(3.2 ± 0.6 µM, data not shown). Also, our results showed that 1753 RU of NEMO1-
NEMO 
IKKβ 
Analyte 
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120des3C/C54 dimer was captured on the biosensor surface (ligand density), giving a 
predicted maximum binding signal of 308 RU based on the fact that the IKKβC716S 
peptide has a molecular weight that is 5/28.5 of the molecular weight of His-SUMO- 
NEMO1-120des3C/C54 (RUmax(expected) = Ligand density × MW ratio of anlyte and ligand, 
RUmax(expected) = 1753 × 5/28.5 = 308). The maximum binding signal that was observed 
experimentally, from extrapolation of the curve fit in Figure 3.10 was 200 RU. This was 
65 % of the expected maximum signal, and therefore indicated that approximately 65 % 
of the NEMO captured on the biosensor surface retained activity. This finding showed 
that coupling the NEMO1-120des3C/C54 dimer in the presence of bound IKKβC716S 
effectively protected NEMO and gave a relatively active biosensor surface, but further 
refinement of the method is required to fully eliminate inactive NEMO from the surface. 
Taken together, these results show that the protected amine coupling method 
gives an active chip surface that shows no sign of nonspecific binding. We were not able 
to use this surface to characterize the binding of the Carmot inhibitors because the ligand 
(tagged NEMO1-120des3C/C54 dimer) didn’t have sufficiently strong binding affinity for 
the Carmot inhibitors. However, this method can be used for accurate binding 
measurements between tagged NEMO1-120des3C/C54 dimer and higher affinity small 
inhibitors in future. 
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Figure 3.10. IKKβ701-745C716S binds His-SUMO-NEMO1-120(des3C/C54) measured on a SPR 
chip prepared through protective amine coupling. Left panel: SPR sensorgrams. Plotted here 
is one single experiment of three independent experiments. Right panel: the hyperbolic fit of 
equilibrium binding based on Eq. 3.5. 
 
 3.3. Discussion  
In this chapter, two hits were identified by Chemotype Evolution and were further 
validated and characterized with an FA assay and by SPR. The binding affinity and 
kinetics of these two hits are summarized in Table 3.1. Based on our results, both CT-
8086 and CT-7872 are true NEMO inhibitors with low micromolar affinity. Previously, 
an 11-mer, which contains NEMO binding domain (NBD), has been shown to disrupt 
NEMO/IKKβ interactions in vitro at hundreds of micromolar concentration57b.  However, 
to our best knowledge, CT-8086 and CT-7872 are the first two NEMO inhibitors that are 
not completely peptidic and have low micromolar IC50 values for inhibiting NEMO in 
vitro. These two inhibitors may not themselves be useful leads for drugs, but they are 
good candidates for the next round of Chemotype Evolution. In addition, these two hits 
can be utilized as small molecule probes to study biological functions in vitro. Without 
considering synthetic ease, CT-7872 is probably a more promising hit to be carried to the 
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next step because of its good solubility, higher binding affinity and slower dissociation 
rate. 
FA inhibition results (Figure 3.3 and 3.6) show that CT-8086 binds NEMO ~50 
times more strongly than 9-mer does, which suggests that the organic fragment of CT-
8086 contributes >2 kcal/mol binding free energy to the binding of the compound. 
Examination of the NEMO44-111 crystal structure5 shows that, assuming the peptidic 
portion is aligned with the natural ligand IKK701-745, the organic fragment (represented in 
Fig. 3.11. as a green oval) likely interacts in the site on NEMO normally that is occupied 
by Phe 734 in the complex with IKKβ (Figure 3.11). Previously Phe734 of IKKβ was 
identified as a moderate hot spot, and a Phe734Ala IKKβ mutant lost 1.5 kcal/mol 
binding energy27. The organic fragments of the inhibitors likely bind at the same site that 
is occupied by Phe 734 of IKKβ. Taken together, our results validate CT-8086 as a 
NEMO inhibitor and suggest that it interacts with two adjacent binding hot spots on 
NEMO. 
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Figure 3.11. Possible binding pose for CT-8086 bound to NEMO shows that the organic 
fragment (represented as a green oval) of the inhibitor mimics Phe 734, a moderate hot spot on 
IKKβ, and interacts with L 93 (colored in pink) on NEMO. The peptidic fragment interacts with 
another hot spots on NEMO. Hot spots of NEMO44-111 identified by FTMap27 are shown as 
residues where fragment clusters are. The peptidic fragment of the inhibitor is aligned with 
corresponding IKKβ residues (LDWSWLQ). 
 
Compared to CT-7872, CT-8086 is 10 times weaker as a NEMO inhibitor. It has 
been shown that alpha carbon methylation on the serine residue of the peptidic fragment 
contributes to a two fold increase in binding affinity (personal communication: Galen 
Loving, Carmot Therapeutics). The difference in the organic fragments of these two 
inhibitors therefore likely corresponds to a difference in binding affinities.  
As described earlier, one great challenge of FBDD is to measure weak binders 
reliably. Our FA inhibition assay, we demonstrate this problem. Nonspecific binding was 
observed at concentrations above 150 µM of 9-mer.  To obtain an accurate measurement 
Phe 734 
L 
W 
D 
Organic fragment 
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of IC50 by FA inhibition assay, we need to put in at least 1.5 mM concentration of 9-mer. 
At such high concentration, most fragments become insoluble, which makes the readout 
unreliable. Chemotype Evolution circumvents the problem by starting with a known 
binder such as the 9-mer and linking the known binder with other fragments to make 
more potent molecules.  
Tested in SPR, IKKβ701-745C716S binds 5×Ala full-length NEMO at a KD of 0.16 
± 0.04 µM and binds tagged NEMO1-120(des3C/C54) at a KD of 1.7 ± 0.1 µM. The 10-
fold difference in binding affinities reflects the fact that different NEMO constructs were 
used in SPR. We have previously reported that shorter NEMO constructs (e.g. NEMO1-
120(des3C/C54)) bind IKKβ 10 times more weakly than full-length NEMO in the FA 
assay6, 66. The difference in binding affinity between NEMO constructs suggest that there 
may be another domain of NEMO that is not present in our NEMO N-terminal constructs 
and is important to IKKβ binding. Future research on NEMO/IKKβ can be directed to 
identify this domain of NEMO. 
In addition to NEMO inhibitor characterizations, I developed an SPR assay using 
N-terminal NEMO instead of full-length protein. By protective amine coupling, the 
active binding site on NEMO was shielded from amine chemistry. This coupling method 
offers an efficient way of protecting active binding sites on ligands and has not 
previously been reported in any other SPR applications, to our best knowledge. 
Admittedly, the primary amine group and two lysine residues of IKKβ701-745 can 
presumably also react with activated SPR chip surface and be immobilized on the dextran 
chains that coats the biosensor surface. This may potentially be a problem if the 
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immobilized IKKβ701-745 is in close proximity to immobilized NEMO. When in close 
proximity, IKKβ701-745 can bind NEMO and therefore reduce the available active binding 
sites on the chip surface. Fortunately, we were able to immobilize enough active binding 
sites on the chip surface to study binding of IKKβ701-745C716S. Based on the magnitude 
of SPR signal observed (Figure 3.10), the chip should also provide enough active ligand 
to study a molecule that is 10 times smaller than IKKβ701-745C716S is. The small 
molecule will give roughly a maximal signal that is 10 times smaller (~20 RU) based on 
RUmax(expected) = Ligand density × MW ratio of analyte and ligand. Future experiments to 
improve this innovative SPR coupling method might be to use a potent IKKβ peptide that 
is rid of primary amine group and lysine residues such as Lys 703 and Lys 704, neither of 
which seems to make direct contact with NEMO in crystal structure5 nor was identified 
as a hot spot27. The new IKKβ peptide should provide the same protection and won’t be 
immobilized by amine coupling. 
Penta and Tetra anti-His antibodies were shown to dissociate 9×His-SUMO 
tagged NEMO too quickly (Table 3.2). This is probably because the 9×His epitope is not 
good for these two anti-His antibodies. Qiagen reported that Penta has a binding affinity 
of 1-50 nM for 5×His epitope and Tetra has a binding affinity of 10-50 nM for 4×His 
epitope (QIAexpress Detection and Assay Handbook 10/2002). Assuming the on rates are 
consistent across experiments for different epitopes, neither of these two antibodies 
would have a sufficiently slow dissociation rate with their designed epitope targets. If a 
capturing method is needed for SPR in the future, a different pair of epitope and antibody 
that have stronger interactions will be needed. 
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 3.4. Experimental Procedures  
3.4.1. FA inhibition assay 
Assays were performed in 96-well non-treated black polystyrene plates (Corning® 
Costar®), using a SpectraMax M5 microtiter plate reader (Molecular Devices, Sunnyvale, 
CA). For each experiment, 50 µL 5×Ala full-length NEMO (60 nM) , 50 µL 4×TNT 
buffer (200 mM Tris, 800 mM NaCl, 0.04% Triton X-100, 4 mM DTT, pH 7.5), 50 µL 
N-terminally FITC-labeled IKKβ peptide (60 nM), and 50 µL compound at varying 
concentrations were added to each well. Each well contains 5% DMSO co-solvent to 
solubilize compounds. The plates were incubated on a plate shaker (UltraCruz shaker for 
microplates, Santa Cruz Biotechnology) for 1 h at 250 rpm, and were then incubated at 
25 °C for 5 min before fluorescence was measured. Samples were read by excitation at 
488 nm and emission at 520 nm in high sensitivity mode. Values were the averages of 
100 measurements for each well, and each experiment was done in duplicate. After 
background subtraction the anisotropy values, A, were fitted by non-linear least-square 
regression to four-parameter equation shown below6: 
 𝐴 = 𝐴! + (!!"#!!!)!!(!"!"! )!    Eq. 3.1 
    𝐴 = 𝐴! + (!!"#!!!)!!(!"!"! )! + 𝑎×[𝐿]   Eq. 3.2 
 
Where A0 is the anisotropy observed for complete inhibition, Amax is the maximum 
anisotropy signal at zero concentration of compound, 𝐿  is the concentration of 
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compound, 𝐻 is the Hill slope and a is the coefficient for nonspecific binding. All results 
shown represent the average of at least duplicate measurements. ΔΔG was calculated 
using equation below: 
    ΔΔG = −𝑅×𝑇×ln (!"!"!!"!"!)    Eq. 3.7 
Where ΔΔG is the change of Gibbs free energy, 𝑅 is the ideal gas constant, and 𝑇 is the 
temperature. 
3.4.2. SPR 
 ProteOn (Bio-Rad) XPR 36 system and GLH chip were used for inhibitor studies. 
The running buffer was 10 mM PBS with 0.01% tween 20 and 1% DMSO. Flow rate was 
set at 50 µL/min for kinetic runs. 
NHS/EDC (0.05/0.2 M) was injected for 5 min at 20 µL/min to activate the chip 
surface. PDEA (80 mM in 50 mM borate buffer pH 8.5) was then injected for 5 min at 20 
µL/min. 7x Ala full-length NEMO (1uM) in acetate pH 4.5 was injected for 5 min at 20 
µL/min. The unreacted chip surface was capped with L-cysteine (50 mM in 0.1 M 
sodium acetate buffer and 1 M NaCl pH 4) for 5min at 20 µL/min. Reference subtraction 
was done by using inter-lane spots. Data were collected in ProteOn and processed in 
Prism (Graphpad). The equation used for kinetics and equilibrium curve fits are listed 
below: 
   𝑌 = 𝑌! − 𝑁! ×𝑒 !!!×! + 𝑁!   Eq. 3.3 
 𝑌 = 𝐵!"#× !!!!!×(1− 𝑒(!(!!×!!!!)×!))+ 𝑁!   Eq. 3.4 
   𝑌 = 𝐵!"#× !!!!!     Eq. 3.5 
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  𝑌 = 𝐵!"#× !!!!! + 𝑁×𝐿 + 𝑁!    Eq. 3.6 
BIAcore 3000 and CM5 chips (GE Healthcare) were used to develop an SPR 
assay using the N-terminal NEMO constructs. Tagged NEMO1-120(des3C/C54) and 
IKKβ701-745C716S were incubated at 1:1 ratio at 10 µM to form bounded complex. 
Preformed complex was then injected onto an NHS/EDC activated CM5 chip surface. 
The chip surface was washed with running buffer for 5 mins at 100 µL/min to dissociate 
the IKKβ701-745C716S from the NEMO. The amount of immobilized ligand was 
calculated by subtracting the chip response after immobilization with response before 
immobilization. 
 Prism (Graphpad) was used for data analysis. The response at a time point after 
equilibrium was reached was plotted against the analyte concentrations tested. The 
binding data were fitted using a hyperbolic equation (Eq. 3.5).	 
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CHAPTER 4. PASSIVE MEMBRANE PERMEABILITY STUDY OF 
SYNTHETIC MACROCYCLES 
4.1. Macrocycles are a Promising Chemotype For Targeting PPI 
Over the years, companies have acquired large collections of druglike 
compounds2 for drug screening. Certain molecular scaffolds have emerged as being 
particularly good starting points for drug discovery against conventional targets. For 
example, purine is structure that shows up in drugs, such as Abacavir (target: viral 
reverse transcriptase) and Pentoxifyline (target: phosphodiesterase)79. However, these 
common scaffolds may not be suitable for PPI inhibition. As described in chapter 1, the 
open and extended PPI interface makes it difficult for small molecules to bind with high 
affinity. Current successful PPI small molecule inhibitors are relatively larger and have 
physicochemical properties that violate traditional concepts of druglikeness7a, 33b, 43, 53g. 
For example, according to Lipinski’s rule of five2a, a druglike small molecule ought to be 
smaller than 500 Da. Small molecule inhibitors of PPI, however, have an average size of 
547 Da33b.  
Natural product-inspired macrocycles are molecules with a macrocyclic ring that 
consists of at least 12 atoms80. They also contain functional groups and have a high 
structural and stereochemical complexity comparable to what is commonly seen in 
macrocylic natural products. Macrocycles have been proposed to be advantageous for 
targeting PPI7b. The reasons are as follows: The binding free energy generated from 
ligand binding can be expressed in the equation 4.1:  𝛥𝐺!"#$ = 𝛥𝐻 − 𝑇(𝛥𝑆!"#$%&!!"#$%! − 𝛥𝑆!"#$%&')  Eq. 4.1 
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   𝛥𝑆!"#$%&!!"#$%! = 𝛥𝑆!"#$%& + 𝛥𝑆!"# + 𝛥𝑆!"#$ 
Where 𝛥𝐺!"#$  is the overall binding free energy, 𝛥𝐻 is the enthalpy gained through 
favorable contacts such as electrostatic, hydrophobic and van der Waals interactions, 𝛥𝑆!"#$%&' is the entropy gain through release of structural water and the hydrophobic 
effect, 𝛥𝑆!"#$%&!!"#$%!  is the entropy change between bound and unbound states, 𝛥𝑆!"#$%&is the entropy change associated with bringing the ligand and receptor into the 
appropriate mutual orientation for binding, 𝛥𝑆!"# is the entropy change due to loss of 
ligand bond rotations upon binding, and 𝛥𝑆!"#$ is the entropy change due to adoption by 
the receptor of the appropriate conformation for ligand binding. Macrocycles provide a 
relatively large scaffold that connects substituents, which may tap into more delocalized 
binding energy hot spots on PPI7a. By interacting with multiple hot spots, macrocycles 
can generate a high amount of binding enthalpy (𝛥𝐻). Macrocyclization additionally 
limits ligand conformations to those that are preferable for binding. This reduction in 
conformational entropy (𝛥𝑆!"#), compared to an analogous acyclic ligand, leads to a 
higher binding affinity7b, 44a, 81.  
Macrocyclization has also been proposed to lead to improved solubility and 
membrane permeability7b, 44a, 45, 81-82, two properties that are critical for good oral 
absorption of drugs83. Compared with druglike compounds, macrocycles may form 
compact conformations that shield polar groups when passing through a hydrophobic 
membrane. In aqueous environments, macrocycles may adopt different conformations 
with polar substituents exposed. This chameleonic capability84 is proposed to help 
macrocycles achieve good membrane permeability and solubility45. Literature shows that 
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macrocyclic peptides achieve high permeability by adopting membrane permeable 
conformations that are stabilized by intramolecular hydrogen bonds45, 85.  	 A number of methods can be used to measure compound permeability. The 
parallel artificial membrane permeability assay (PAMPA) measures compound’s passive 
membrane permeability through an artificial membrane comprising phospholipids (Figure 
4.1 A). Passive permeability is mostly determined by compound’s physicochemical 
properties. Because there are no active transporters on the artificial membrane, PAMPA 
cannot be applied to study other modes of drug transport that can occur in cells.  Caco-2 
are heterogeneous human epithelial colorectal adenocarcinoma cells, which develop 
active transporter proteins and enzymes that are involved in compound permeation and 
absorption. A Caco-2 assay is used to study permeability by measuring the concentrations 
of compound being transported from donor well to acceptor well (Figure 4.1 B). It can 
also measure the opposite direction of compound transport. If the ratio of permeabilities 
obtained from both directions does not equal one, active transport is involved for this 
compound. The permeation rate of drugs through a monolayer of Caco-2 cells has been 
shown to correlate with human intestinal permeability86. Both PAMPA and Caco-2 
methods have been widely applied to assess drug permeability in vitro. Passive 
permeability measured by PAMPA and by Caco-2 correlate with each other quite well87. 
PAMPA is an economical method to measure passive membrane permeability that 
directly reflects a compound’s physicochemical properties, while Caco-2 is a method that 
can be applied to study active transport in addition to passive membrane permeability. 
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Figure 4.1. Working principles of PAMPA assay (A) and Caco-2 assay (B). In the Caco-2 
assay, permeability can be measured from both directions separately. The ratio of permeability 
from both directions, if it doesn’t equal one, reveals that an active transport mechanism is 
involved in permeation of the compound. 
 
There are several studies aimed at finding physicochemical properties that are 
important to macrocycles’ good permeability. Giordanetto et al. compiled a list of 34 
bioavailable macrocyclic drugs and clinical candidates. They found that, compared with 
traditional druglike molecules2, macrocyclic drugs have higher values for properties such 
as hydrogen bond donor (HBD), polar surface area (PSA), molecular weight (MW) and 
calculated partition coefficient (cLogP). Villar et al. reported similar conclusion, except 
for cLogP7a. They compiled 18 orally bioavailable macrocyclic drugs and proposed a set 
of rules for designing large (MW > 600 Da) bioavailable macrocycles based on their 
observation7a. 
The quantitative structure activity relationship (QSAR) approach is a quantitative 
artificial membrane 
compound 
acceptor well 
donor well A PAMPA 
Caco-2 monolayer 
compound 
acceptor well 
donor well B 
or 
Caco-2 
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approach that has been frequently used to study relations between permeability and 
compound physicochemical properties in nonmacrocycle chemical space87-88. However, 
there have been few systematic and quantitative studies of macrocycles’ structure and 
permeability, and our understanding of which structural features of macrocycles help or 
hinder permeability remains poor. The goal of this project is to establish which structural 
and physicochemical properties are important for the passive permeability of 
macrocycles, and to compare these properties with those that are important for 
nonmacrocycle druglike molecules. In this study, we implement PAMPA to measure the 
passive membrane permeability of macrocycles and correlate it with physicochemical 
properties through multiple linear regression (MLR) analysis. The study thereby provides 
quantitative insights for designing bioavailable macrocycles. 
 
4.2. Results 
4.2.1. Description of compound sets and calculation of physicochemical properties 
We tested a total of 57 macrocycles synthesized by CMLD-Boston University, 
which we randomly divided into two groups. One group (47 macrocycles) was used as a 
training set for model development, while the remaining 10 macrocycles were held aside 
for use as a test set for model validation. In addition, we analyzed data for 61 
conventionally druglike compounds from the literature87-88, to compare with our new data 
for the macrocycles. Figure 4.2 shows some representative molecules from each set. A 
complete list of molecules and their structures are in Appendix 4.1.  
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Figure 4.2. Several representative molecules from each data set.  
 
We calculated some permeability related properties for each molecule. The choice 
of what properties to consider was based on the literature2, 7a, 43, 89 and on our hypotheses. 
For example, according to Lipinski’s rule of five, an orally bioavailable drug tends to 
have a molecular weight < 500 Da, logP < 5, HBD < 5 and a hydrogen bond acceptor 
(HBA) count of < 102a. Lobell’s traffic light system defines a druglike molecule as 
having cLogP ≤ 3, a corrected molecular weight ≤ 400 Da, a polar surface area ≤ 120 Å2, 
and the number of rotatable bonds ≤ 72b. The count of aromatic rings (Ar ring) has been 
proposed to be important to solubility89 and therefore potentially has an impact on 
bioavailability. We also evaluated the degree of unsaturation of macrocyclic ring (DOS), 
as a surrogate for ring rigidity, because we posited that macrocycle’s restricted 
Trainings set Test set Excluded 
Verma set Fujikawa set 
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conformational flexibility was likely to be important. The average values of these 
properties for the macrocycles in the training set and the test set, and for the druglike 
molecules from Verma et al. and Fujikawa et al. 87-88are shown in Table 4.1.  
 
Table 4.1. Summary of properties for compounds used in statistical analyses 
 Training set (n = 47) Test set (n = 10) Druglike set (n = 61) 
 Mean Std Dev Mean Std Dev Mean Std Dev 
MW 485.36 67.10 518.76 83.03 379.53 84.79 
cLogP 2.75 0.77 3.21 0.89 1.96 1.46 
HBA 4.43 1.32 4.90 1.66 5.02 1.96 
HBD 2.38 0.82 1.90 0.88 2.44 1.49 
RB 3.32 1.86 3.80 1.99 7.34 4.72 
TPSA 101.05 18.11 101.71 20.47 96.50 37.57 
Radius 7.85 0.59 8.10 0.57 6.82 1.31 
Ar ring 1.57 0.77 1.90 0.88 1.56 0.79 
DOS 3.53 0.62 3.60 0.70 0.00 0.00 
Permeability 9.5E-061 6.8E-06 1.4E-051 1.1E-05 5.9E-062 6.5E-06 
Except for Ar ring, DOS and Permeability, all other molecular descriptors were calculated in Chembiodraw 
Ultra 14.0. Ar ring and DOS were counted by hand. Permeability is measured in PAMPA described below. 
1 this study. 2 from Verma et al. and Fujikawa et al. 
 
4.2.2. Label free quantification of macrocycles by mass spectrometry 
Compound permeability, using the PAMPA assay, was obtained by using Eq. 4.2 
in experimental procedures. Final concentrations of compound in both donor well and 
acceptor well were needed for this permeability calculation. The method therefore 
requires an ability to measure accurate and precise compound concentrations. Because 
most of our compounds didn’t have suitable UV absorbance for detection, we used mass 
spectrometry for small molecule label free quantification. As described in experimental 
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procedures, we implemented several steps to make sure the PAMPA assay and MS 
quantification were done properly. For example, to quantify the variability in the PAMPA 
results, each compound was tested in triplicate wells. To enable determination of absolute 
compound concentrations, an MS standard curve was created for each compound, as 
described below. Each standard curve was measured three times, twice before and once 
after the compound’s PAMPA sample was run. To monitor PAMPA assay plate-to-plate 
variation, we included 6 standard compounds in each PAMPA plate. 
The MS quantitation method was developed as follows: as shown in Figure 4.3 A, 
the parent ion for the compound in question was extracted from the MS spectrum for 
quantification. We compared quantifications using either the parent ion or daughter ions 
and found that, although daughter ion quantification generally gave slightly better signal 
to noise ratio and thus was a more sensitive method, the linearity wasn’t as good as for 
parent ion quantification. In almost all cases, we found sensitivity was not the challenge, 
but rather linearity, especially at high compound concentrations. Most compounds 
quantified using the parent ion showed good linearity from 625 nM to 20 µM, with a 
lower limit of quantification around 156 nM (represented in Figure 4.3B, left panel). For 
those compounds that did not have good linearity across the concentrations tested, we 
fitted the standard curve using a quadratic equation (Figure 4.3B, right panel). A 
complete list of compounds with quantification information is provided in Appendix 4.2.  
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Figure 4.3. Quantification by MS. (A) MS spectrum of Rifabutin The two panels are Rifabutin 
extracted ion chromatogram (all massà847.6) and MS spectrum. (B) Standard curve of Rifabutin 
and CMLD008564 by MS. Data plotted are measurements from one experiment in triplicate. 
Error bars are standard deviations. The regression equation used to fit Rifabutin data is 𝒚 = 𝒃𝒙 + 𝒚𝟎,𝒃 = 1.6×105± 1.5×103, 𝒚𝟎 = -4×107± 1.2×107, p < 0.0001, R2 = 0.9994. The 
regression equation used to fit CMLD008564 data is 𝒚 = 𝒃𝒙𝟐 + 𝒂𝒙 + 𝒚𝟎,𝒃 = -0.165± 0.0095; 𝒂 
= 9.4×103± 210, 𝒚𝟎 = -9×106± 7.5×105, p < 0.0001, R2 = 0.9998. 
 
We did not include internal standards for compound quantification in our study, 
because we found the instrument to be robust and reproducible with respect to sample 
transfer and injection, compound ionization, and parent ion detection. According to J. 
Wieling, “In particular for LC-MS-MS bioanalysis, internal standards should not be 
forced to fit in an application, since results may be impaired instead of improved”90. 
Internal standards were not only unnecessary in our case, but also greatly increase the 
complexity of the method and impaired ionization of certain compounds. 
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4.2.3. PAMPA results 
To validate and calibrate the PAMPA method, six standard macrocyclic drugs 
were tested. Three of them are known to be highly permeable while the other three have 
low permeability. We reached the same conclusion in our PAMPA assay. Rifabutin, 
Rifampicin and Rifapentine were more permeable than Desmopressin (Gln), Nystatin and 
Temsirolimus (Figure 4.4). To our best knowledge, there is no single numeric standard 
for classifying compound’s permeability. We therefore chose 5×10-6 cm/s to be the 
numeric cutoff for categorizing compounds as high versus low permeability in our 
PAMPA assay BD Biosciences, who supplies the PAMPA assay plates, recommends 
4×10-6 cm/s to be the cutoff.  	
Figure 4.4. Permeability of 6 standard 
macrocyclic drugs measured in our 
PAMPA assay and quantified by 
LC/MS. The test shows that the highly 
permeable group is significantly 
different from poorly permeable group, 
n = 3, p = 0.027. Columns plotted show 
the average results from the four 
independent experiments. Error bars are 
standard deviations. The dashed line 
indicates the chosen numeric cutoff 
(5×𝟏𝟎!𝟔 cm/s) for distinguishing high 
from low permeability. 
 
Figure 4.5 shows our measured 
PAMPA permeability for all 
macrocycles included in this study. We found that both the training set and the test set 
showed a good distribution of both highly permeable and poorly permeable compounds. 
Most macrocycles (50 out of 75 or 67%) tested were highly permeable. 
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Figure 4.5. Permeability of 75 CMLD macrocycles measured in our PAMPA assay and 
quantified by LC/MS. The results show that the permeability of this collection of compounds 
spans approximately two log units, with the lowest being 1.0×𝟏𝟎!𝟕 cm/s and the highest being 
3.8×𝟏𝟎!𝟓 cm/s. The results also show that there are a good number of compounds in each 
permeability class. The data plotted here are averages from triplicate PAMPA measurements, and 
are colored according to the legend. Error bars are standard deviations. The dashed line indicates 
the chosen numeric cutoff (5×𝟏𝟎!𝟔 cm/s) for distinguishing high and low permeability. 
 
4.2.4. Statistical analysis 
We first studied the simple relations between the individual molecular descriptors 
and the observed macrocycle permeability. A total of 9 permeability-related 
physicochemical properties were calculated. Studies have reported that some of these 
properties are important for permeability. For example, MW, HBD/HBA, and LogP, are 
described in Lipinski’s rule of five2a. TPSA is also important to permeability2b because it 
is a measure of molecular polarity. Molecular radius is relevant because it is a measure of 
the shape and size of a molecule, which affects molecular diffusion rates. We additionally 
hypothesized that Ar ring count and ring DOS were relevant to permeability because they 
respectively relate to solubility and molecular rigidity. Aromatic ring count is proposed to 
be detrimental to human bioavailability91. The balance of rigidity and flexibility of 
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macrocyclic ring, as measured by DOS, determines the possible conformations that a 
macrocycle can adopt, and therefore should also be important for permeability. We 
evaluated the statistical significance of the dependence of permeability on each individual 
molecular descriptor using Spearman rank correlation, which is a nonparametric measure 
of dependence between two variables. Compared with the commonly used Pearson 
correlation, Spearman rank correlation is less sensitive to outliers. For the compounds in 
the training set, statistically significant correlations were found between permeability and 
four of descriptors, HBA, HBD, TPSA, and Ar ring count (Figure 4.6). The correlation 
coefficient (rs) and p value for each pair are -0.329 and 0.0242 for HBA, -0.658 and 
<0.001 for HBD, -0.549 and <0.001 for TPSA, -0.344 and 0.018 for Ar ring count. HBA 
and Ar ring count showed weak negative correlations with permeability, TPSA showed a 
moderate negative correlation, while HBD showed a strong negative correlation with 
permeability. No other descriptors showed a statistically significant correlation with 
permeability in our single 
pair correlation analysis. 
Figure 4.6.  Spearman rank 
correlations show 
statistically significant 
negative correlation 
between four descriptors 
and permeability. The 
correlation coefficient (rs) 
and p value for each pair are 
-0.329 and 0.0242 for HBA, 
-0.658 and <0.001 for HBD, 
-0.549 and <0.001 for TPSA, 
-0.344 and 0.018 for Ar ring. 
Data plotted are from 
training set (n = 47). 
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To establish a quantitative model for describing the relationship between 
permeability and molecular descriptors, we applied multiple linear regression analysis to 
the training set permeability data and then validated this model with the data from the test 
set. Before applying this parametric statistical method, we checked its assumptions. All 
descriptors used in model derivation were considered to be relevant to permeability 
according to the literature2, 89 and our additional hypotheses, as described above. To make 
sure the training set was normally distributed, we tested it in the Shapiro-Wilk test92. The 
Shapiro-Wilk test utilizes a statistic computed from sample variables to determine 
whether the sample is normally distributed. The null hypothesis for this test is that the 
sample is normally distributed. A calculated p value that is less than the denoted α value 
(0.05) means we can reject the null hypothesis at a confidence of that p value. This test 
gave a p value of 0.569, indicating that we can’t reject the null hypothesis, which states 
the sample is normally distributed. We can’t draw any meaningful conclusion based on 
the MLR model if homoscedasticity is not obtained, or in other words, if there is a clear 
residual pattern along independent variables. A data set is said to be homoscedastic if the 
variation of residuals remains constant along all independent variables. We checked our 
data for homoscedasticity by looking at the correlation between the absolute values of the 
residuals and the observed value of the independent variables, and found the correlation 
between residuals and independent variables not to be significant (p = 0.136). Auto-
correlation or serial correlation, another assumption needed to meet for MLR analysis, is 
used to measure whether adjacent observations are correlated with each other. Violating 
this assumption will result in an overestimation of goodness of fit because each variable 
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is not completely independent from the others. To check it, we found Durbin-Watson 
statistic to be 2.1, which indicates that there is no auto-correlation (a Durbin-Watson 
statistic close to 2 means no auto-correlation). Multicollinearity measures the correlations 
of independent variables. High multicollinearity indicates a model has redundant 
variables. We checked multicollinearity by examining the correlations between 
descriptors. Before doing the multiple linear regression analysis (described below) we 
showed that none of the descriptors used in the MLR model had correlations above 0.7 
(Table 4.2). However, we saw strong correlations between cLogP and MW (rs = 0.74, p < 
0.001), HBA and TPSA (rs = 0.9, p < 0.001), HBD and TPSA (rs = 0.76, p < 0.001), Ar 
ring and MW (rs = 0.76, p < 0.001). The correlation between cLogP and MW suggest that 
as the molecules get bigger, they get more hydrophobic. The correlations of HBA with 
TPSA and HBD with TPSA are not surprising because these are all measurements of 
polarity. The correlation between Ar ring and MW suggest that molecules with more 
aromatic rings tend to be larger.  
Table 4.2. Spearman rank correlations of descriptors to check multicollinearity 
 MW cLogP HBA HBD RB TPSA Radius Ar ring DOS 
Permeability -0.17 0.22 -0.33 -0.66 -0.28 -0.55 -0.19 -0.34 0.26 
 0.24 0.14 0.02 0.00 0.06 0.00 0.21 0.02 0.07 
MW  0.74 0.67 0.43 0.51 0.61 0.49 0.76 -0.08 
  0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.60 
cLogP   0.29 0.03 0.31 0.16 0.47 0.53 0.05 
   0.05 0.83 0.03 0.29 0.00 0.00 0.74 
HBA    0.56 0.55 0.90 0.26 0.40 -0.04 
    0.00 0.00 0.00 0.08 0.01 0.79 
HBD     0.58 0.76 0.16 0.48 -0.44 
     0.00 0.00 0.29 0.00 0.00 
RB      0.62 0.30 0.49 -0.67 
      0.00 0.04 0.00 0.00 
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TPSA       0.28 0.48 -0.21 
       0.05 0.00 0.15 
Radius        0.60 -0.14 
        0.00 0.36 
Ar ring         -0.17 
         0.26 
DOS          
Values in gray rows are Spearman correlation coefficients. Values in white rows are p values for the 
coefficients. Those listed in bold are independent variables included in our MLR model. 
 
Multiple linear regression (MLR) is a method for correlating multiple independent 
variables with a single dependent variable in a linear fashion. We analyzed the 
permeability data for the training set of compounds, in relation to the molecular 
descriptors (MW, cLogP, HBA, HBD, RB, TPSA, Radius, Ar ring count, ring DOS) 
using Sigmaplot, (see experimental procedure for details). Only three descriptors 
contributed significantly to the variation in permeabilities among the compounds in the 
training set. These were cLogP, HBD, and Ar ring count. The resulting model is given 
below:  𝑝𝑒𝑟𝑚𝑒𝑎𝑏𝑖𝑙𝑖𝑡𝑦 = 𝑏! + 𝑏!×𝑐𝑙𝑜𝑔𝑃 + 𝑏!×𝐻𝐵𝐷 + 𝑏!×𝐴𝑟 𝑟𝑖𝑛𝑔  Eq. 4.3 
 
where 𝑏! = 1.2×10!!, 𝑏! = 4.6×10!!, 𝑏! = −3.8×10!!, 𝑏! = −3.7×10!! , standard 
error of estimate = 4.6×10!!, n = 47, R2 = 0.58, p < 0.001.  
 
According to this model, cLogP shows a positive correlation with permeability. HBD and 
Ar ring count are negatively correlated with permeability. Each of the three properties 
incorporated in this model were tested to be statistically significant, with p values less 
than 0.05.  
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To validate the model, we used Eq. 4.3 to calculate the permeabilities of the test 
set of compounds, which were not included in the development of the model, and plotted 
these calculated values against the experimentally observed permeabilities (Figure 4.7). A 
strong correlation was observed between the predicted and observed permeability values 
(R2 = 0.48, p = 0.026), demonstrating that the model can be applied to an independent set 
of macrocycles for permeability prediction. The dashed lines in Figure 4.7 show the 
permeability cutoff that discriminates high permeability from low permeability 
compounds, chosen based on the permeability observed for the six macrocyclic drugs 
standards as described above (Figure 4.4). Most compounds (57 out of 75, or 76%) were 
correctly categorized by our MLR model in Eq. 4.1 as possessing high or low 
permeability (corresponding to the upper right or bottom left area of Figure 4.7).  
		
Figure 4.7. Correlation of predicted and observed permeability. R2 value and p value are 
0.48, 0.026. Data are colored according to the following: training set (n = 47), black; test set (n = 
10), red; below detection set (n = 18), yellow. The red line is the trend line correlation of the test 
set. The dashed lines indicate the chosen numeric cut off for discriminating high versus low 
permeability (5×𝟏𝟎!𝟔 cm/s). Each data point is the average of triplicate PAMPA measurements.  
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To evaluate the difference in factors that are important to permeability between 
macrocycles and traditionally druglike molecules, we tested our MLR model against two 
sets of druglike compounds from the literature (Verma set and Fujikawa set)87-88. Shown 
in Figure 4.8, our model didn’t predict permeability for these druglike molecules well (R2 
= 0.09, p = 0.026 for Verma set; R2 = 0.27, p < 0.001 for Fujikawa set). Verma et al. 
developed a model to predict the passive permeability of conventionally druglike 
compounds 𝑙𝑜𝑔𝑃!"" = 0.51 ±0.11 𝐶𝑙𝑜𝑔𝑃 − 0.66 ±0.14 𝛽×10!"#$% + 1 −1.4 ±0.37 𝐼! − 0.03(±0.19), where 𝑙𝑜𝑔 𝛽 = −2.487, 𝐼!  is indicator variable, which 
acquires a value of one in the presence of –SO2NH2 group, 𝑛 = 55, 𝑟! = 0.743). Their 
model showed strong correlation of predicted and measured permeabilities for druglike 
molecules. 
	
 
Figure 4.8. Our MLR model, developed for macrocyclic compounds, does not accurately 
predict the permeabilities of compounds from two non-macrocycle druglike sets. The R2 
value and p value for the Verma set (n = 55) are 0.09, 0.026 and for Fujikawa set (n = 57) are 
0.27, <0.001. The black line is the correlation for the Verma set. The dashed line is the 
correlation of Fujikawa set. 
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 To demonstrate our MLR model is a better one to be applied to macrocycles, we 
compared our model with Verma’s with respect to how well they predict the permeability 
of our macrocycles. The result shows that the Varma model fails badly when applied to 
our compounds and data, showing that our MLR model is much better at predicting 
permeability of the macrocycles from this study (Figure 4.9). 
 
	
Figure 4.9. Comparison of the ability of the Varma permeability model87 versus our MLR 
model to predict the permeability of our macrocyclic compounds.. The Verma model, derived 
from a non-macrocycle, druglike compound set, fails to predict the permeability of the 
macrocycycle sets. The black line is the correlation of predicted permeability by our model and 
observed permeability. Verma model: 𝒍𝒐𝒈𝑷𝒂𝒑𝒑 = 𝟎.𝟓𝟏 ±𝟎.𝟏𝟏 𝑪𝒍𝒐𝒈𝑷 − 𝟎.𝟔𝟔 ±𝟎.𝟏𝟒 𝜷×𝟏𝟎𝑪𝒍𝒐𝒈𝑷 + 𝟏 − 𝟏.𝟒 ±𝟎.𝟑𝟕 𝑰𝟐 − 𝟎.𝟎𝟑(±𝟎.𝟏𝟗)Where 𝒍𝒐𝒈 𝜷 = −𝟐.𝟒𝟖𝟕, 𝑰𝟐 is indicator 
variable, which acquire a value of one in the presence of –SO2NH2 group, 𝒏 = 𝟓𝟓, 𝒓𝟐 = 𝟎.𝟕𝟒𝟑.  
 
In an attempt to more directly assess the effect of macrocyclization on compound 
permeability, we compared the permeability of one macrocycle from our set 
(CMLD010117) with a linear counterpart of otherwise similar structure (CMLD010119) 
that was a synthetic precursor of the macrocyclic compound (Figure 4.10 A). As shown 
in Figure 4.10 B, the macrocycle is highly permeable, and is substantially more 
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permeable than its acyclic counterpart. However, compared to its linear counterpart, 
CMLD010117 has one fewer hydrogen bond donor. Other studies have supported the 
notion that HBD correlates negatively with permeability2a, and so the permeability 
difference between these two compounds could be wholly or partly due to this difference 
in HBD. To address this question fully we would need to examine many more 
macrocyclic/acyclic pairs. Unfortunately, CMLD010119 and CMLD010117 were the 
only such pair available to us for study. 
 
Figure 4.10. Structure and permeability comparison of a macrocycle and its linear 
counterpart. (A) Structures of a macrocycle (CMLD010117) and its acyclic counterpart 
(CMLD010119). (B) Permeability comparison shows that CMLD010117 is more permeable and 
is above the threshold (5×10-6 cm/s) that distinguishes the high and low permeability classes. 
Data plotted are average values from triplicate PAMPA measurements. Error bars are standard 
deviations. The dashed line indicates the chosen numeric cutoff (5×𝟏𝟎!𝟔 cm/s) for 
distinguishing high and low permeability. Double asterisks indicate the p value is less than 0.01. 
A 
B 
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4.2.5. Caco-2 assay 
 Caco-2 cells were first seeded in a transwell plate and were grown into confluent 
monolayer. The formation of monolayers and cell differentiation were monitored using a 
microscope, and by trans-epithelial electrical resistance (TEER) measurements 
respectively. Through observation under microscope, we found that the monolayer 
formed completely on day 11 of culture. TEER was measured by a pair of electrodes that 
each sit in one the two chambers of the transwell apparatus (Figure 4.1 B). Electrical 
resistance across the membrane is measured to establish that there are no gaps in the 
monolayer, which would lead to a low resistance due to the resulting free flow of ions 
between the wells. The TEER measurements supported the conclusion drawn from 
microscopy that the monolayer was completely formed by day 11 (Figure 4.11). 
However, in order to ensure complete cell differentiation, as required for a valid assay93, 
we continued growing the cells for a total of 21 days. Immediately before performing the 
permeability assays the TEER measurement was repeated, and gave a resistance of >450 
Ω/cm2 which was indicative of an intact monolayer with good cell differentiation94.  
 
Figure 4.11. TEER measurement of Caco-2 monolayer seeded at different initial cell 
numbers shows the monolayer reaches complete confluency on day 11.  
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 Several standard compounds were assayed, with the concentrations passing 
through the Caco-2 cell layer analyzed by either UV-vis spectrophotometry or by HPLC. 
The standard compounds fell into two permeability categories (Figure 4.12). The 
classification of each standard compound in our assay agreed with the reported 
classification. A numeric cutoff (1×10-5 cm/s) was used for future compound 
permeability classification in our assay. 
 
Figure 4.12. Permeability of standard drugs by Caco-2 assay. The numeric cutoff (1×10-5 
cm/s) between high and low permeability is marked by the dashed line. The results show a similar 
permeability classification as that reported for the same compounds by two references 95. Papp AB 
is permeability in the direction of donor compartment to acceptor apartment, while Papp BA is 
permeability in the opposite direction.  
 
4.3. Discussion 
In this chapter, we measured passive membrane permeability of 75 macrocycles 
by PAMPA. Our results show that most of them are highly permeable (Figure 4.5). The 
results demonstrate that synthetic macrocycles of the types represented in our test set can 
achieve good permeability, consistent with the literature on macrocycle permeability7a, 43. 
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In one case we were able to compare the permeability or a pair of compounds comprising 
a macrocyle and its linear counterpart, the results showing that the macrocycle was 
significantly more permeable (Figure 4.10 B). However, due to the limited number of 
paired macrocycles and their acyclic counterparts available to us, we cannot draw any 
direct conclusion on the extent to which macrocycyclization itself imparts good 
permeability in this study. Future study of this question will require more data for 
analysis.  
We evaluated which molecular properties are responsible for the variation in 
permeability among the macrocycles in our set using two different approaches. Using a 
simple correlation analysis, we found that polarity related properties such as HBA, HBD 
and TPSA were negatively correlated with permeability. This finding is not surprising, 
considering that numerous reports have already drawn similar conclusions in 
nonmacrocycle chemical space2. Ar ring count was also found to be negatively associated 
with permeability, which has not previously been reported. We did not find any 
meaningful correlation between permeability and ring DOS, when tested as a simple 
correlation. We then went on to develop a more complex model in which combinations of 
properties were tested for their impact on permeability, using multiple linear regression 
analysis. Our best MLR model identified three molecular descriptors as being most 
important for passive permeability among our compounds: HBD and Ar ring count were 
negatively associated with permeability, while cLogP was positively associated. Each of 
these three descriptors captures a unique aspect of macrocycle structure. cLogP or 
lipophilicity is known to be correlated positively with bioavailability in other chemical 
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space88a, 96. HBD measures the polarity of a molecule and is considered to be detrimental 
to permeability2a.  The reason for the dependence on Ar ring count is less clear. One 
plausible explanation for this finding is that aromatic ring hurts permeability by being 
detrimental to solubility91, though it is also possible that Ar ring count is not itself 
important but is a surrogate for some other property that affects permeability and co-
varies strongly with Ar ring count. We were at first surprised that ring DOS did not 
emerge as an important property for macrocycle permeability. However, an examination 
of our compound set reveals that the range of DOS is very narrow, and is therefore 
probably too limited to draw any conclusion. Future study aiming at testing the 
importance of DOS needs to include molecules with a wider range of DOS. 
When comparing the identified properties between the high/low permeability 
macrocycles (Table 4.3), we find no single descriptor is sufficient to differentiate 
macrocycles from each class. To guide the design of future synthetic macrocycles, we 
should therefore take into account all these three properties incorporated in our MLR 
model. 
Table 4.3. Comparison of average property values for high  
versus low permeability macrocycles 
 cLogP HBD Ar ring count 
Highly permeable macrocycles 2.85 ± 0.79 2.0 ± 0.8 1.5 ± 0.8 
Poorly permeable macrocycles 2.78 ± 0.85 3 ± 0 1.9 ± 0.7 
 
 Compared with traditional oral drugs, the permeability of the macrocycles tested 
in this study depends on similar molecular properties such as MW, HBA, HBD and 
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cLogP. For example, cLogP and HBD are important to permeability for both classes of 
molecules87-88. However, Ar ring count is a property that is revealed in our study to be 
important to macrocycle’s permeability. This conclusion is supported by both simple 
correlation analysis and by MLR in this study.  
Although the kinds of molecular properties that affect permeability in 
macrocycles are similar to those that are important for acyclic, druglike compounds, it is 
also important to know whether there are quantitative differences between macrocyclic 
and acyclic compounds in the relative weight of properties that are important for 
permeability prediction. We tried answering this question by comparing the ability of our 
MLR model to predict permeability for published data sets of acyclic compounds, and by 
testing the ability of a published model developed for conventional drugs to predict the 
permeabilities of our macrocycles. Our MLR model was clearly better for predicting the 
permeability of the macrocycles in our set, giving a correlation coefficient of 0.76 
compared to the Verma model that did not produce any meaningful prediction (Figure 
4.9). Our models differ in properties being incorporated in the model and also differ in 
the coefficient used for cLogP87. For example, cLogP, HBD and Ar ring count are found 
to be important in predicting macrocycles’ permeability according to our model, while in 
Verma’s, cLogP and –SO2NH2 group are important to druglike molecules. Our results 
show that, traditional rules and studies for predicting druglikeness of conventional acyclic 
drugs may not necessarily apply to macrocycles. Presumably, for the same reasons, our 
MLR model performed relatively poorly when applied to acyclic compounds. Only 
moderate correlations between predicted permeability and observed ones were observed 
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(Figure 4.8). In contrast, the reported models for each corresponding data set produce 
good predictions of permeability87-88.  
Although macrocycle such as cyclosporine A can be up to 1000 Da, the mean 
molecular weight of training set, along with other properties, is within the range of 
traditionally druglike chemical space. Our training set has an average molecular weight at 
485 Da, above Lobell’s upper limit for optimally druglike compounds2b but within the 
range defined by Lipinski2a. Other descriptors are all within the range of druglikeness. 
Although a more diverse training set with larger range of properties would provide more 
information on large macrocycles (MW > 600 Da), no such compounds were available to 
us. Compared with the set of druglike compounds, the macrocycles included in our study 
have higher MW, cLogP, radius and DOS, but fewer rotatable bonds (Table 4.1 and 
Figure 4.13). Literature also suggests that macrocycles have higher MW and cLogP, and 
lower rotable bonds than nonmacrocycles do7a. Our results are likely most relevant for 
understanding the permeability of small macrocycles (MW < 600 Da)7a. 
 
Figure 4.13. Physicochemical property comparison between macrocycle training set and 
druglike set shows that MW, cLogP, number of rotable bonds, radius and degree of 
unsaturation are significantly different. Asterisk indicates p < 0.05 using a two-tailed t test. 61 
druglike compounds and 47 macrocycles were used in this analysis.  
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In summary, we measured the passive membrane permeability of a collection of 
small macrocycles and studied a range of permeability-related molecular descriptors. 
Hydrophobicity, polarity and aromatic ring count were found to be important for 
permeability in a Spearman rank correlation study. cLogP, HBD and aromatic ring count 
were identified as key parameters in our multivariate model for predicting small 
macrocycle permeability. The model is robust as it was validated using an independent 
set of macrocycles that were not included in the training set, and showed a strong 
correlation between predicted and observed permeability. Compared to other reported 
MLR models, our model showed a better correlation for macrocycles but poorer 
predictions for acyclic druglike molecules. The model is likely the most relevant one to 
assess macrocycle’s passive membrane permeability based on physicochemical 
properties.  We propose that for high permeability, synthetic macrocycles should contain 
limited HBD and few aromatic rings and avoid low cLogP. Other proposed guidance7a 
for designing high permeability macrocycles is based on studies empirically searching for 
the optimal range of each individual property. Our proposition is based on a quantitative 
model that takes multiple properties at once into consideration. One advantage offered by 
our approach is that we effectively eliminated redundant information that might be 
incorporated into design guidance for high permeable macrocycles. In addition, we also 
implemented a Caco-2 assay and validated it with several standard drugs. Future studies 
on macrocycle’s advantageous properties should test more macrocycles with greater 
values in size, polarity, hydrophobicity and rigidity.  	
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4.4. Experimental Procedures 
4.4.1. PAMPA To Measure Permeability 
Assays used BD GENTEST™ pre-coated PAMPA plate system, following the 
instruction provided97. Specifically, the PAMPA plate system is a 96-well plate 
containing an artificial membrane pre-coated filter plate. At the beginning of each 
experiment, the plate was taken out of -20 ºC to be equilibrated to room temperature. 300 
µL donor solution containing 60 µM compound and 5% DMSO in PBS, pH 7.4 was 
added to each donor well. 200 µL of 5% DMSO in PBS, pH 7.4 was added to the receiver 
plate. Then the receiver plate was gently put onto the donor plate, avoiding any air 
bubbles.  The plate was covered and incubated at 25 ºC for 5 hours. After incubation, 
only 100 µL of sample solution was taken out from each well on each plate to avoid 
touching the membrane of the filter plate. Each compound was tested in three wells.  
Each plate included six standard macrocyclic drugs. Permeability was calculated using 
the equations below: 
𝑃 = !!" [!! !!!!"#$%$&'$#(]!×( !!!! !!!)×!     Eq. 4.2 𝐶!"#$%$&'$#( = 𝐶!×𝑉! − 𝐶!×𝑉!𝑉! − 𝑉!  
Where, 𝑉! is the donor volume (0.3 mL), 𝑉! is the acceptor volume (0.2 mL), 𝑆 is the 
membrane area (0.3 cm2), 𝑡 is the incubation time (18000 s), 𝐶!  is the final donor 
concentration and 𝐶! is the final acceptor concentration. 
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The equation has already accounted for mass retention by assuming the compounds 
bound to the surfaces do not contribute to permeation. The effective initial compound 
amount is calculated to be the sum of final amounts in the donor and acceptor wells.   
4.4.2. LC-MS (ESI, Ion trap) To Quantify Small Molecules 
The samples were diluted to 300 µL of 5% DMSO in PBS, pH 7.4 solution in 96 
well plates. In the same plate, a serial dilution of the same compound in the same buffer 
was prepared using compound stocks. A standard curve was built using these known 
concentrations. The plate containing both standards and samples were stored at –20 ºC if 
not analyzed immediately.   
Upon MS measurement, the plate was first equilibrated to room temperature. The 
standards and the samples were measured on a same day to avoid instrument inter-day 
shifts. To avoid shifts within the same day measurements, the standard curve was 
measured twice before and once after the sample measurements. Each standard 
concentration was done three times.  
Liquid chromatography was done on an Agilent 1100 HPLC equipped with a 96 
well plate auto sampler (model G1367A WPALS). The instrument was operated on 
ChemStation for LC 3D system. 25 µL of sample was injected the auto-sampler. No 
column was used as it proved unnecessary in our experiments. However, a short gradient 
of acetonitrile and water was still required for compound elution, possibly because the 
hydrophobic compounds tended to stick to the tubing that connected the HPLC and MS. 
The two mobile phases used were water with 0.1% formic acid and acetonitrile with 0.1% 
formic acid. The gradient used was for the first three minutes, acetonitrile increased from 
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5% to 100%; then, 100% acetonitrile for one minute; Finally, acetonitrile decreased from 
100 % back to 5% in one minute. The flow rate was 1 mL/min. To reduce carry over 
between different samples, pure water was injected before a new compound was tested.  
MS data was collected on an Agilent 6340 Ion Trap mass spectrometer (model 
G2446A). The Instrument was operated on 6300 Series TrapControl Version 6.2. The MS 
was calibrated by ESI-T tuning mix (lot No: A985264). For all experiments, ultra scan 
(range 50-2200 m/z, speed 26,000 m/z/sec) and positive mode was selected for auto 
MS(n) experiment. The capillary voltage was set at -3500 V. The end plate offset was at  
-500 V. The nebulizer was at 55 psi. The nitrogen drying gas was set to 12 L/min, at 350 
Celsius. Ion optics and trap parameters were as follows: skimmer: 40 V, capillary exit: 
113.5 V, octopole RF amplitude: 187.1 Vpp, oct 1 DC: 8 V, oct 2 DC: 1.7 V, trap drive: 
63.2. Ion charge control was with a smart target at 200000, maximum accumulation time 
of 200 ms and 5 spectral averages per scan. Fragmentation was set to SmartFrag from 
30% to 200%. Cut-off selection was set to default.  
QuantAnalysis for 6300 Series Ion Trap LC/MS (version 2.0) and DataAnalysis 
for 6300 Series Ion Trap LC/MS (version 4.0) were used for data processing. Extracted 
ion chromatograms of parent ion were used for quantitation. The peak detection 
parameters were set to S/N threshold: 10, area threshold: relative 0.1, intensity threshold: 
relative 0.1, skim ratio: 0.1, smoothing width: 1, algorithm: 2.1. The actual width of the 
peak was used for calculation. Two kinds of standard curves were used to quantify 
samples. One was simple linear regression, which was used for most compounds tested. 
The other was a quadratic equation, where a simple linear regression couldn’t provide a 
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good fit at high concentrations. The standard curve contained a concentration range, 
which included the sample concentration. If the sample was below the MS detection limit 
or below the lowest calibration concentration, it was approximated to the lowest standard 
concentration. No internal standard was used.  
4.4.3. Calculation Of Molecular Descriptors 
A range of permeability related descriptors were selected to study their relations 
with permeability. These descriptors include molecular weight (MW), topological polar 
surface area (TPSA), calculated octanol-water partitioning coefficient (cLogP), number 
of hydrogen bond acceptor (HBA), hydrogen bond donor (HBD), number of ratable 
bonds (RB), number of aromatic rings (Ar ring), and radius. In addition, we thought the 
degree of unsaturation within the macrocyclic ring (DOS) was important to macrocycles, 
since the pi-bond or other features that rigidifies the ring will reduce the available 
conformations and decrease the molecular entropy, which might contribute to a high 
permeability. Ar ring and DOS were counted by hand. The remaining descriptors were 
calculated using Chembiodraw Ultra 14.0 (CambridgeSoft).  
4.4.4. Data Sets 
All statistical analysis was done in SigmaPlot, version 11.0 (Systat Software, 
Inc.). We tested a total of 105 CMLD macrocycles. 75 macrocycles’ standard curves 
were established.  Of the 75 macrocycles, 57 macrocycles showed detectable and 
quantifiable amount of compound in the PAMPA sample while the other 18 macrocyle 
samples were either below the lower limit of quantitation or below the lowest standard 
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concentration. So the 18 compounds were approximated to the concentration of the lower 
limit of quantitation and were named as the “below detection set”. Because of the 
inflation of permeability, we didn’t include these 18 macrocycles for linear regression 
modeling.  Among the 57 macrocycles included, we randomly chose 47 compounds as 
the training set and 10 compounds as the test set.  The regression was first built on the 
training set and then tested against the test set.  
4.4.5. Multiple Linear Regression 
Multiple linear regression assumes a linear relationship between dependent and 
independent variables as represented by the equation below. 𝑦 = 𝑏! + 𝑏!𝑥! + 𝑏!𝑥! +⋯+ 𝑏!𝑥!     Eq. 4.3 
where 𝑏!, 𝑏!, 𝑏!, 𝑏!  are coefficients, 𝑥!, 𝑥!, 𝑥!are independent variables. 
To determine which descriptors to use in predicting macrocycle permeability, forward 
step regression was applied to the training set. The multi-step method works by 
incorporating the independent variable that produces the best prediction of dependent 
variable into the model first. To do that, the F value for each independent variable was 
calculated and ranked according to equation below. The one with the highest F value was 
included first. Then the F values for the rest of independent variables were calculated 
again. The new highest variable was incorporated and so on. If there was no more 
independent variable that had F value above the set F-to-Enter value, the model stopped 
incorporating additional independent variable. After each variable entered, the F value of 
that variable was checked against the set F-to-Removal value. If the variable had an F 
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value below the set one, it was removed. The process was repeated until there was no 
more improvement of prediction.   𝐹 = !"#!"$$%&' !"#$"%$&' !"#$ !!! !"#"$!"$% !"#$"%&' !"#$!"#$%&'( !"#$"%$&' !"#$% !!! !"#!"$$%&' !"#$ = !"!"#!"!"#  Eq. 4.4 
𝑀𝑆!"# = 𝑠𝑢𝑚 𝑜𝑓 𝑠𝑞𝑢𝑎𝑟𝑒𝑠 𝑑𝑢𝑒 𝑡𝑜 𝑟𝑒𝑔𝑟𝑒𝑠𝑠𝑖𝑜𝑛𝑟𝑒𝑔𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝑜𝑓 𝑑𝑒𝑔𝑟𝑒𝑒𝑠 𝑜𝑓 𝑓𝑟𝑒𝑒𝑑𝑜𝑚 = 𝑆𝑆!"#𝑘 − 1 
𝑀𝑆!"# = 𝑟𝑒𝑠𝑖𝑑𝑢𝑎𝑙 𝑠𝑢𝑚 𝑜𝑓 𝑠𝑞𝑢𝑎𝑟𝑒𝑠 𝑟𝑒𝑠𝑖𝑑𝑢𝑎𝑙 𝑑𝑒𝑔𝑟𝑒𝑒𝑠 𝑜𝑓 𝑓𝑟𝑒𝑒𝑑𝑜𝑚 = 𝑆𝑆!"#𝑁 − 𝑘 
where N is the sample size, k is number of independent variables. 
Backward step regression was also applied to the training set. The procedure for 
this method was to start with all independent variables being included in the model. The 
F value of each variable was compared to the set F-to-Removal value. The one with F 
value that’s below the F-to-Removal was rejected from the model. The one with the next 
lowest F value was rejected and so on. After each rejection, the rejected variable was 
checked against F-to-Enter, and any variable with an F value higher than the F-to-Enter 
value was re-entered into the model. All statistical analysis was conducted in SigmaPlot, 
version 11.0 (Systat Software, Inc.) 
4.4.6. Caco-2 assay 	 Caoco-2 cells (ATCC) were seeded onto transwell plates (Corning) at different 
seeding densities and grown to mature differentiation for a total of 21 days. The integrity 
of cell monolayer was monitored by observation under a microscope as well as by TEER 
measurement (EVOM2 by WPI). Cell culture followed the manufacturer’s manual 
(http://www.atcc.org/products/all/HTB-37.aspx#culturemethod). Upon assaying, cells 
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were washed with assay buffer (HBSS, pH = 7.4, 1% DMSO).  
 The Caco-2 assay followed the published protocol93. Briefly, a fixed 
concentration of compound was put into the donor well at t = 0. The plate was shaken 
moderately on an orbital shaker in a cell incubator. At different time points, compound 
was sampled from acceptor well and the well was replenished with an equal volume of 
assay buffer. After the experiment, monolayer integrity was checked with Lucifer yellow 
and by TEER measurements. 
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CHAPTER 5. ANALYSIS OF INTERLEUKIN-2 (IL-2) INHIBITOR  
BINDING BY SURFACE PLASMON RESONANCE (SPR) 
5.1. Introduction to IL-2 and its inhibitors 
Interleukin-2 (IL-2) is a cytokine that, when binding to its receptor (IL-2R), 
induces T cell proliferation98. Mature human IL-2 has 133 residues and is packed as a 
compact globular protein, having mainly four α-helices adopting a down-down-up-up 
configuration. IL-2 binds its receptor chains sequentially with different affinities: α = 10 
nM, β = 100 nM, γ ~ 0.7 mM, β/γ ~ 1 nM, α/β/γ ~ 5 pM99. Hot spots at the IL-2/IL-Rα 
interface, identified through site-specific mutagenesis, are Phe 42 and Leu 72 on IL-2; 
Leu 42, Tyr 43 and Met 25 on IL-2Rα99-100. A crystal structure of IL-2 in complex with 
IL-2Rα/β/γ quaternary complex was solved (Figure 5.1)101.  
	
Figure 5.1. Crystal structure of IL-2 and IL-2 receptor101. IL-2 is colored in green. IL-2 
receptor α/β/γ chains are colored in red, orange and cyan. The interface of IL-2 and IL-2Rα spans 
1900 Å2. 
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Because of its role in stimulating the immune response, IL-2 has been 
recombinantly purified and used to treat renal cell carcinoma102. However, it is also 
associated with allergy and autoimmune diseases when overly upregulated99. Developing 
inhibitors to block the IL-2/IL-2R is thus useful to combat immunity-associated 
conditions99 such as organ transplant rejections.  
Both antibodies and small molecules have been discovered to inhibit IL-2/IL-2Rα. 
Therapeutic anti-IL-2Rα antibodies include daclizumab (Hoffmann La Roche) and 
basiliximab (Novartis), both directly blocking ligand-receptor interactions103. There are 
two interesting small molecule inhibitors discovered to bind IL-2. Originally designed to 
bind IL-2Rα, Ro26-4550 was later found to actually bind IL-2 instead. This competitive 
inhibitor has an IC50 of 3 µM8. SP4206, developed by Sunesis Pharmaceutical through 
fragment based disulfide tethering, was found to bind IL-2 with an IC50 of 60 nM59. 
Ro26-4550 consists of three parts: a hydrophobic biaryl fragment (colored in red in 
Figure 5.2, KD ~ 3 mM)99, a polar and soluble piperidinyl guanidine (colored in blue in 
Figure 5.2, no measurable binding), and a linker (colored in black in Figure 5.2, no 
measurable binding). Optimized from an analog of Ro26-4550, SP4206 also contains 
three similar groups. In addition, SP4206 contains an extended furoic acid group (colored 
in magenta in Figure 5.2), which is considered to improve SP4206 binding though 
additionally electrostatic interactions with IL-2104. However, no complete quantitative 
study has been done to elucidate the energetic role of SP4206 fragments. 
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Figure 5.2. Structures of IL-2 inhibitors and fragments tested in SPR. The polar and soluble 
guanidine groups on both Ro26-4550 and SP4206 are colored in blue. The hydrophobic groups 
are colored in red. The linkers are in black. The additional furoic acid group of SP4206 is colored 
in magenta. Below the two inhibitors are some representative fragments derived from them, 
which we tested by SPR. 
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Surface plasmon resonance is a biophysical method used to study real time 
binding interactions (the SPR working principle is described in Chapter 3). However, like 
most methods, SPR has its limitations in small fragment binding applications. The 
biggest challenge, as described in Chapter 3, is to measure fragment binding reliably. 
Because the SPR signal depends on the amount of ligand being immobilized on chip 
surface, which, in turn, depends on ligand density, binding stoichiometry and the 
molecular weight ratio of ligand and analyte, binding of a low molecular weight fragment 
won’t give a big signal if the ligand is much bigger (RUmax(expected) = Ligand density × 
MW ratio of anlyte and ligand). For example, assuming a 1:1 binding and the chip 
surface is fully active, binding of a 150 Da analyte to a 15 kDa ligand gives a 10 RU 
maximum signal at 1000 RU ligand density. In order to obtain a robust signal (i.e. 30 
RU), a large amount of active ligand is to be immobilized onto the chip surface 
homogeneously. A second challenge in small fragment applications of SPR is to 
distinguish true binders from false positive ones. At high concentrations, most fragments 
tend to aggregate and become insoluble. Aggregation on the chip surface significantly 
changes the refractive index, which changes the SPR signal dramatically. Unfortunately, 
it is usually necessary to measure fragments at high concentrations in order to obtain an 
accurate binding affinity. Therefore it is important to examine SPR data closely to 
exclude promiscuous binders from the true hits.  
The goal of this chapter is to obtain a deeper understanding of how fragments 
interact with IL-2 energetically, and to optimize an SPR assay that can be used to study 
fragment binding. We attempt to measure the binding of each fragment derived from 
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Ro26-4550 and SP4206 (Figure 5.3) by SPR. Presented in this chapter are studies mainly 
on SPR method development and some initial fragment binding measurements.  
 
5.2. Results 
5.2.1. IL-2 and Cys IL-2 mutant purification 
To study fragment binding by SPR, it is simpler to interpret results obtained when 
the protein of interest is coupled in a homogeneous fashion to the SPR chip. A protein 
that is heterogeneously immobilized onto the chip surface may interact with analyte 
nonspecifically or with compromised binding affinity, problems that are less likely to 
occur if the ligand was homogeneously immobilized. A directed coupling method such as 
thiol coupling, which utilizes sparsely existing free thiol groups on the ligand, is key to 
obtain a homogeneous SPR chip surface. We tried cysteine mediated thiol coupling to 
immobilize IL-2 in a directed orientation, first because there are only three endogenous 
cysteines (Cys 58, 105 and 145), in human IL-2, whereas there are 11 lysines that might 
react with succinimide ester on the chip surface if the commonly used amine coupling 
was applied. In addition, two of the endogenous cysteines (Cys 58 and Cys 105) are not 
reactive in thiol coupling since they already formed an intramolecular disulfide bond. We 
engineered three amino acids (Ser-Gly-Cys) at the C-termini of IL-2 and named this 
variant as “Cys IL-2”. The C-terminal cysteine was used for immobilization and the Ser-
Gly residues served as a small linker between Cys IL-2 and the chip. Endogenous Cys 
145 was additionally mutated to Ser to avoid unwanted thiol coupling at this residue. 
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The Ser-Gly-Cys triplet was cloned into human IL-2 by Quick Change 
mutagenesis. Cys IL-2 and IL-2 were expressed in bacteria (BL21 (DE3)) and purified 
from inclusion bodies by ion exchange chromatography. The mutant was verified by 
DNA sequencing and by mass spectrometry. Both Cys IL-2 and IL-2 were quantified by 
UV28075. IL-2 was purified as a monomer and Cys IL-2 was purified as a mixture of 
monomer and covalently linked dimer (Figure 5.3 A). The dimeric Cys IL-2 was 
probably due to disulfide bond formation involving the engineered cysteine. Under 
reducing condition (10 mM DTT at room temperature for one hour), dimeric Cys IL-2 
was reduced to monomer completely (Figure 5.3 B).  
 
Figure 5.3. SDS-PAGE gels show Cys IL-2 was purified mostly as dimers (panel A and B) 
and was completely reduced to monomer by 10 mM.DTT (panel B). 
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5.2.2. DTNB characterization of IL-2 Cys mutant 
We quantified the proportion of free thiols in Cys IL-2 by Ellman's reagent test 
(5,5'-dithiobis-(2-nitrobenzoic acid, or DTNB). Prior to this test, a desalting column was 
used to remove DTT from the protein sample. Free thiols react with DTNB to produce 
the TNB2- ions, which has a yellow color105. One molar of free thiols produce one molar 
of TNB2- ions, which can be quantified by its absorbance reading at 412 nm, using an 
extinction coefficient established through a standard curve (Figure 5.4). There were 102 
µM free thiols in 106 µM protein sample, which suggested that more than 95% ± 1% of 
Cys IL-2 were reduced under reducing condition. 
 
Figure 5.4. Standard curve of DTNB assay was used to quantify the amount of free thiols 
existing in reduced Cys IL-2. The standard curve was fitted in equation: 𝒚 = 𝟏𝟑.𝟐𝟒𝟗𝒙 −𝟎.𝟎𝟎𝟗𝟒,𝑹𝟐 = 𝟎.𝟗𝟗𝟗𝟗𝟓. The ratio of free thiols and total protein concentration suggested that 
more than 95% of reduced Cys IL-2 contained a free thiol. 	
5.2.3. CD characterization of IL-2 and Cys IL-2 
To make sure the engineered Ser-Gly-Cys triplet and the 10 mM DTT reducing 
condition didn’t cause any large structural alteration of Cys IL-2, we compared the 
secondary structures of Cys IL-2 with that of wild-type IL-2 by circular dichroism (CD) 
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spectrometry. Properly folded IL-2 mostly consists of α-helix with some random coil101. 
In a CD spectrum, α-helix has a signature negative signal at 208 nm and 222 nm69. Both 
Cys IL-2 and IL-2 had these signature minima at 208 nm and 222 nm to almost the same 
degree (Figure 5.5). The results suggested that both Cys IL-2 and IL-2 folded properly to 
almost the same degree. The small difference observed in Figure 5.5 can be attributed to 
a small difference in protein concentration.  
	
Figure 5.5. CD spectrum shows that there is no significant difference in secondary structure 
content between Cys IL-2 and wild-type IL-2. Both constructs show minima at 208 and 222 
nm, which suggest that both constructs contain mostly α-helix in their structures. 	
5.2.4. Enzyme-Linked Immunosorbent Assay (ELISA) 
Characterization of IL-2 and Cys IL-2 
We conducted ELISA measurements to compare the IL-2Rα binding activity of 
the two IL-2 variants. In our ELISA setup (Figure 5.6 A), recombinant IL-2Rα-Fc (R&D) 
was coated in a 96 well plate, followed by a blocking step. Different concentrations of 
IL-2 protein variants were added to each well for equilibrium binding. After the unbound 
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proteins were removed, anti-IL-2-biotin detection antibody was added into each well. 
After the washing, streptavindin-horseradish peroxidase (HRP) and its substrate, 
3,3’,5,5’-Tetramethylbenzidine (TMB), was added. Catalyzed by HRP, TMB is oxidized 
to 3,3',5,5'-tetramethylbenzidine diimine, which has an absorption at 652 nm. The 
absorbance was proportional to the amount of HRP, which was related to the amount of 
bound IL-2 variants. Both Cys IL-2 and IL-2 showed almost identical IL-2Rα-Fc binding 
activity (Figure 5.6 B and 5.6 C). In wells where all ELISA components were present, the 
signal increased with the concentration of IL-2 variants. In those wells where a single 
component was missing, only background signal was developed. Fitting the ELISA 
results with a four-parameter equation (Eq. 5.1), we found that EC50 of Cys IL-2 and IL-2 
were 0.26 ± 0.04 nM and 0.92 ± 0.46 nM respectively. Combining with CD analysis, we 
conclude that the engineered triplet in Cys IL-2 doesn’t have a negative impact on protein 
folding or binding activity. Cys IL-2 is therefore justified to replace IL-2 in SPR 
experiments. 
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Figure 5.6. ELISA of Cys IL-2/IL-2 and IL-2Rα-Fc shows that both constructs have 
comparable IL-2Rα-Fc binding activity. (A) Illustration of ELISA setup. See text for 
description. (B) ELISA Result shows both constructs have comparable IL-2Rα-Fc binding. (C) 
Four parameter fitting using data from (B) shows that both constructs have single digit nM EC50 
in ELISA.  
 
5.2.5. SPR based fragment binding assay development 
 In order to obtain a deeper understanding of how fragments interact with IL-2 
energetically, we developed an SPR assay. The SPR assay was set up as follows:	ligand 
(Cys IL-2) was first immobilized onto the chip surface though thiol coupling. Analytes 
such as an IL-2 inhibitor or its fragments were flowed over the chip surface in assay 
buffer. Upon binding, the refractive index of the flowing buffer that was just above the 
chip surface changed, which led to an angle change for the refractive light. This angle 
change was proportional to the mass bound to Cys IL-2. Because the signal was 
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monitored throughout binding process, SPR can be used to obtain information on both 
binding kinetics and equilibrium.  
We applied the setup described above and measured an IL-2 inhibitor discovered 
by Roche (Ro26-4550). In our SPR measurements, Ro26-4550 showed a dose dependent 
binding response from 0.43 µM to 100 µM (Figure 5.7). At higher concentrations, we 
observed nonspecific binding, indicated by the fact that the signal linearized with 
concentrations of compound (Figure 5.7 left panels). So we fitted the data using a 
hyperbolic equation with the addition of a linear term to account for the nonspecific 
binding (Eq. 5.3). The results from two independent experiments suggest that Ro26-4550 
binds Cys IL-2 with a binding affinity of 3 ± 1 µM (n = 2), which agrees with the 
reported value (3 µM)99. Measurements of this inhibitor validated our SPR assay, which 
was then applied to measure fragments binding. 
The proportion of active surface was calculated by the ratio of the expected 
maximum response and the experimentally measured maximal response. For example, 
binding between Cys IL-2 and Ro26-4550 ought to have an expected maximum response 
at 266 RU when the chip was immobilized at 7480 RU and was fully functional 
(calculation described in Chapter 3). The observed maximum response for specific 
binding was less than 100 RU, which indicated that less than 37% of immobilized ligand 
was active. As mentioned in the introduction, to obtain a robust response for fragment 
binding, a high density and/or a fully functional surface are required. If we had less than 
37% of active ligand on chip surface, we would need more than 14,960 RU of Cys IL-2 
to be immobilized. Because a chip surface with 7480 RU×37% active ligand gave a 
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maximal response ~ 25 RU (obtained through curve fitting in Figure 5.7) for specific 
binding, in order to maintain a maximal signal at 25 RU for fragments (Figure 5.2, 
usually one half the size of Ro26-4550), we need a chip surface immobilized with twice 
as much ligand.  However, we were not able to immobilize chip surface with that much 
Cys IL-2. 
 
Figure 5.7. Binding of Ro26-4550 and Cys IL-2 measured by SPR. Top left is Ro26-4550/Cys 
IL-2 binding sensorgrams obtained from a chip prepared via thiol coupling. Bottom left is a plot 
of equilibrium binding of Ro26-4550/Cys IL-2 obtained from the sensorgrams at top left. Data 
were fitted using Eq. 5.3. The right panels show data from a chip surface where maleimide 
chemistry was used. Data in bottom right panel were fitted with Eq. 5.2. Maleimide coupling 
showed no nonspecific binding at high concentrations where thiol coupling did.  
We tried a different coupling chemistry to increase active portion of chip surface 
and to reduce non-specific binding. Maleimide coupling was found to be a better 
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chemistry in our study because it eliminated nonspecific binding. Shown in Figure 5.7 
bottom right panel, the response doesn’t keep rising as concentrations of inhibitor 
increase. However, still only 60 % of the captured IL-2 was active by this chemistry 
(calculation not shown).  The outcome of not having active chip surface with high ligand 
density was that we were not able to conduct fragment-binding measurements reliably 
(reasons explained in Chapter 3). Shown in Figure 5.8 is one example of a fragment 
binding measurement. VIT001 is a fragment derived from SP4206. This fragment 
corresponds to the portion of SP4206 that binds to the hydrophobic hot spot on IL-299. It 
contains a furoic acid group, which was suggested to pick up extra electrostatic 
interactions within the Lys 32, Lys 35, Arg 38, and Lys43 region18. Nonspecific binding 
complicated data interpretation. SPR measurements of this fragment demonstrated the 
difficulty of eliminating nonspecific binding associated with fragments binding at high 
concentrations. 
 
Figure 5.8. Binding of VIT 001 by SPR demonstrates the challenge of measuring Cys IL-2 
specific binding at high compound concentrations. Left panel shows responses from each 
injection. The same concentration of compound was injected again at the 51st injection to show 
that the chip surface maintained the same level of activity during experiment. Right panel is a 
sensorgram showing the binding of VIT001/Cys IL-2. The increasing response during 
equilibrium binding phase indicates that at high concentrations, VIT001 becomes a promiscuous 
binder.  
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5.3. Discussion 
In this chapter, we designed and purified Cys IL-2, which contained the addition 
of a Ser-Gly-Cys triplet at C-termini plus a Cys 145 Ser mutation. Cys IL-2 was 
characterized and compared with wild type IL-2 by SDS-PAGE, CD and ELISA. The 
results suggested that the Ser-Gly-Cys triplets didn’t alter Cys IL-2’s structure or its IL-
2Rα binding activity. The C-terminal cysteine of Cys IL-2 provided a free thiol group for 
thiol coupling. Therefore, Cys IL-2 was immobilized onto an SPR chip surface to study 
fragments binding. 
However, because the immobilized surface was less than 37 % active, 
measurements of fragment binding at a ligand density of 7500 RU was almost 
impossible, especially when the binding was compounded with nonspecific binding. The 
reasons for such low active surface could be two fold. One possibility is that the 
recombinant Cys IL-2 was only partly active. This possibility was ruled out because in 
both CD and ELISA experiments, Cys IL-2 showed no meaningful difference from IL-2. 
The other reason why the SPR chip surface had low activity could be that Cys IL-2 
became partly inactive due to immobilization. For example, the Cys IL-2 was linked to 
the chip surface in a direction that was not optimal for receptor chain binding. By 
switching to maleimide chemistry, we were able to alleviate nonspecific binding. 
However, we still face challenges of not being able to immobilize enough active ligand 
onto the chip surface. Future efforts can be directed to engineer an IL-2 mutant with a 
longer linker in front of the C-terminal cysteine residue. The longer linker may be helpful 
in presenting the correct conformation of IL-2 to its binding partner. Other 
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immobilization strategies of SPR, such as antibody capture, may also provide a way to 
circumvent the low activity chip surface problem. 
In addition to SPR, other methods such as NMR and isothermal titration 
calorimetry (ITC) can be applied to study fragment binding quantitatively. Although each 
method has its own advantages and disadvantages, one shared problem among these 
methods is insolubility of fragments. When fragments bind weakly, high concentrations 
of fragments are needed for accurate determinations of binding affinity. Although 
cosolvent such as DMSO can solve the problem in some cases, many fragments remain 
insoluble under experimental conditions. A reliable way of distinguishing those insoluble 
fragments from soluble ones is therefore needed in the future to prioritize fragments. 
 
5.4. Experimental Procedures 
5.4.1. IL-2 and Cys IL-2 expression and purification 
Both IL-2 and Cys IL-2 were expressed and purified from NEB T7 express 
bacterial cells. The  human IL-2 DNA sequence was cloned into vector pET 11 for IPTG 
induced expression. A Ser-Gly-Cys mutation was engineered into the Cys IL-2 construct 
through site directed mutagenesis. The primers used are provided in the appendix. The 
mutagenesis protocol was described in 2.4.2. Site-Directed Mutagenesis. The expression 
protocol was described in 2.4.3. Protein Expression And Purification.  
IL-2 variants were lysed by microfluidizer® in 50 mL of lysis buffer containing 
100 mM Tris pH 8, 5 mM EDTA and 1mM PMSF. We used at least 50 mL of lysis 
buffer for 5 g of cells. The cell lysate was centrifuged at 18,000 ×g for 15 min. The 
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supernatant was discarded because the target protein was expressed in inclusion bodies. 
The pellet containing cell debris and inclusion bodies was washed and suspended using 
20 mL resuspension buffer (100 mM tris pH 8, 1 mM EDTA). The washed inclusion 
body pellet was centrifuged as described above, and the wash step was repeated with 
water. Inclusion bodies were solubilized in solubilizing buffer (100 mM Tris pH 8, 6 M 
guanidine hydrochloride), and pipetted repeatedly until the inclusion bodies were 
thoroughly dissolved. This solubilization step can take as long as overnight to maximize 
the inclusion body dissolution. We centrifuged the solution at 18,000 ×g for 15 min to 
remove the undissolved particles, and saved the supernatant. The denatured target protein 
was refolded in Slide-A-Lyzer Dialysis Cassettes (10K MWCO) overnight at 4 °C. The 
dialysis buffer used was 100 mM Tris pH 8, 6.5 mM cysteamine, 0.65 mM cystamine, 
1.1 M guanidine HCl. 40 mL of the refolding buffer was needed for 10 mL of protein. 
The final concentration of guanidine hydrochloride was 2 M. The next day, protein 
precipitate was removed by centrifuge at 39000 ×g for 10 minutes, and filtering the 
supernatant, with a 0.2 micron filter and syringe. 
. The refolded proteins were purified on ÄKTA using an ion exchange column 
(HiTrap SP HP 5 mL, GE Healthcare). The chromatography conditions used were: load 
the sample at 3 mL/min. Elute the protein in a linear gradient of two buffers over the 
course of 100 mL at a speed of 3 mL/min. The two buffers used were buffer A (25 mM 
ammonium acetate pH 6, 25 mM NaCl, pH 6.5) and buffer B (buffer A with 1 M NaCl, 
pH 6.5).  Protein elution was monitored by UV absorbance at 280 nm, and the fractions 
containing protein were combined and concentrated using an Amicon Ultra-15 
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Centrifugal Filter Unit according to the manufacturer’s instructions. Protein was 
quantified by absorbance at 280 nm using a NanoDrop 2000 (Thermo Scientific), using 
extinction coefficients calculated by the ExPASy Proteomics Server75. Cys IL-2 was 
stored in elution buffer B with the addition of 10 mM DTT.  
5.4.2. DTNB assay 
The number of cysteine residues that contain free thiol was analyzed by 5,5’-
dithio-bis(2-nitrobenzoic acid) or DTNB (Thermo Scientific). A cysteine standard curve 
was first established. Serial concentrations of Cysteine Hydrochloride Monohydrate 
solutions were prepared in reaction buffer (0.1M sodium phosphate, pH 8.0, containing 
1mM EDTA). To each test tube, 2.5 mL reaction buffer, 50 µL DTNB (4 mg/mL) and 
250 µL cysteine or protein were added. After 15 minutes incubation at room temperature, 
the absorbance at both UV280 and UV412 were measured on SpectraMax M5 microtiter 
plate reader (Molecular Devices, Sunnyvale, CA) in a quartz cuvette. The readout for 
UV412 was used to quantify the amount of free thiol while the one for UV280 was used for 
quantifying total protein concentration. The proportion of Cys IL-2 that contained a free 
thiol was calculated by the ratio of free thiol and total protein concentration. 
5.4.3. Circular Dichroism 
CD spectra were measured using an Applied Photophysics CS/2 Chirascan with a 
2 mm path length quartz cuvette at a scan speed of 0.5 s/nm. 200 µL 0.2 mg/mL of 
proteins were measured in sodium phosphate at pH 7.4 at 25 °C. The buffer background 
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was subtracted. Two spectra were measured for each sample and averaged. CD signal 
was measured from 200 nm to 260 nm. 
5.4.4. Enzyme-Linked ImmunoSorbent Assay 
 Each 96 well ELISA plate was first coated with IL-2Rα-FC (where) for 12 hours 
at 4 Celsius. To each well was added 100 µL of coating buffer (2 µg/mL IL-2Rα-FC, 1× 
PBS pH 7.4). The coated plate was washed with wash buffer (PBS pH 7.4 and 0.02% 
tween 20) twice. 200 µL was used for each well. After washing, the plate was blocked by 
blocking buffer (1% BSA in PBS pH 7.4). To each well was added 200 µL blocking 
buffer and the plate was incubated overnight at 4 Celsius. Upon analysis, the plate was 
taken out of the refrigerator to equilibrate to room temperature. The plate was first 
washed with PBST twice. Then 100 µL of IL-2 variants at different concentrations were 
added to the plate to allow binding. After two hours incubation at 25 Celsius, the 
unbound proteins were washed away by PBST. This wash step was repeated twice. 100 
µL of 1 µg/mL anti-IL-2-biotin detection antibody was added to the wells. The detection 
antibody was in PBS pH 7.4, containing 0.1% BSA. The plate was washed again after 
one-hour incubation at 25 Celsius. To each well, 100 µL of 0.3 µg/mL streptavidin-HRP 
was added. The plate was incubated for 30 minutes at 25 Celsius and washed three times. 
Finally, 50 µL TMB was added and incubated for 15-30 minutes at 25 Celsius. Signal 
was  measured at 652 nm or the reaction quenched with by 50 µL 2 M sulfuric acid and 
signal was measured at 450 nm. Data were fitted using equation 5.1: 
    𝑌 = (!!!)!!(!"!"/!)! + 𝐵     Eq. 5.1 
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where Y is the ELISA measurement, 𝑥 is concentration, 𝑇 is the maximum ELISA signal, 𝐵 is the minimal signal, 𝐻 is the Hill slope and 𝐸𝐶!" is the inflection point. 
5.4.5. Surface Plasmon Resonance  
 BIAcore 3000 (GE Healthcare) was used for SPR analysis with CM5 chips. Cys 
IL-2 was immobilized onto the chip surface through thiol or maleimide coupling. Unless 
otherwise indicated, every step of immobilization was done at a 5 µL/min flow rate. 0.2 
M 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) and 0.1 M N-
hydroxysuccinimide (NHS) was flowed over the chip for three minutes to activate the 
surface. 80 mM 2-(2-pyridinyldithio) ethaneamine hydrochloride (PDEA) or 50 mM N-ε-
maleimidocaproic acid hydrazide (EMCH) in 10 mM borate buffer (pH 8.5) was flowed 
for four minutes. 2 µM Cys IL-2 in 10 mM sodium acetate (pH 5.5) was flowed for 100 
minutes. Then the chip was capped with 50 mM cysteine in 1 M sodium chloride (pH 
4.3) for 10 minutes. Finally the chip was deactivated by 1 M ethanolamine for 2 minutes. 
In the control cell, all of the above steps, except for Cys IL-2 immobilization, were 
followed. The amount of immbolized ligand was calculated by subtracting the chip 
response after immobilization with response before immobilization.  
Binding analysis was conducted in a HBS-EP running buffer (0.01 M HEPES pH 
7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% v/v Surfactant P20), supplemented with 5% 
DMSO. The flow rate was set at 20 µL/min. Ro26-4550 and inhibitor fragments were 
weighted out on a fine balance and dissolved in DMSO. Upon analysis, the DMSO stock 
solution was diluted in running buffer at various concentrations. Each concentration 
contained a final 5% DMSO. Compound solution was injected over the chip surface, 
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which contained Cys IL-2, for 3 min to allow it to reach binding equilibrium at all 
concentrations analyzed. Then compound injection was stopped and the flowing channel 
was switched to running buffer for 2.5 min to allow dissociation. Finally, the chip surface 
was regenerated in running buffer for 10 min. Each compound was tested again after the 
entire range of compound concentrations was measured. The chip surface was monitored 
by measuring the response at the same concentration of compound at various time.  
 Prism (Graphpad) was used for data analysis. The response at a time point, after 
equilibrium was reached, was plotted against the compound concentrations tested. The 
binding data collected from thiol coupling chip was fitted to a hyperbolic equation with 
nonspecific binding (Eq. 5.3). Data from maleimide coupling chip was fitted by 
hyperbolic equation (Eq. 5.2). 
    𝑌 = 𝐵!"#× !!!!!     Eq. 5.2 
    𝑌 = 𝐵!"#× !!!!! + 𝑁!×𝐿 + 𝑁   Eq. 5.3 Where	𝐵!"# 	is	 the	 maximum	 response	 at	 steady	 state,	𝐿	is	 the	 concentration	 of	analyte,	𝐾! is	 binding	 affinity,	𝑁! is	 nonspecific	 binding	 coefficient,	 and	𝑁 	is	 the	background	response.		
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APPENDIX 
Appendix 4.1. Structures of macrocycles from BU-CMLD.  
Set Barcode SMILES/names and structure 
Trai
ning 
CMLD00
8561 
	
C[C@@H]1\C=C\CC(=O)OCCCC(=O)N[C@@H](CC=C)C(=O)N[C@@H]1C1=C
C(Br)=CC=C1 
	
Trai
ning 
CMLD00
8563 
	
[H][C@@]12COC(=O)C\C=C\[C@@H](C)[C@H](NC(=O)[C@H](CC=C)NC(=O)[
C@]1([H])OC(C)(C)O2)C1=CC(Br)=CC=C1 
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Trai
ning 
CMLD00
8564 
	
C[C@@H]1\C=C\CC(=O)OCCCCC(=O)N[C@@H](CC=C)C(=O)N[C@@H]1C1=
CC(Br)=CC=C1 
	
Trai
ning 
CMLD00
8569 
	
C[C@@H]1\C=C\CC(=O)OCCCCC(=O)N[C@@H](CC=C)C(=O)N[C@@H]1\C=C
\C1=CC=CC=C1 
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Trai
ning 
CMLD00
8572 
	
C[C@@H]1\C=C\CC(=O)OCCC(OC2=CC=CC=C2)C(=O)N[C@@H](CC=C)C(=O
)N[C@@H]1C1CC1 
	
Trai
ning 
CMLD00
8573 
	
[H][C@@]12COC(=O)C\C=C\[C@@H](C)[C@H](NC(=O)[C@H](CC=C)NC(=O)[
C@]1([H])OC(C)(C)O2)C1CC1 
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Trai
ning 
CMLD00
8574 
	
C[C@@H]1\C=C\CC(=O)OCCCCC(=O)N[C@@H](CC=C)C(=O)N[C@@H]1C1C
C1 
	
Trai
ning 
CMLD00
8578 
	
[H][C@@]12COC(=O)C\C=C\[C@@H](C)[C@H](NC(=O)[C@H](CC=C)NC(=O)[
C@]1([H])OC(C)(C)O2)C1=CC=CC=C1 
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Trai
ning 
CMLD00
8583 
	
[H][C@@]12COC(=O)C\C=C\[C@@H](C)[C@H](NC(=O)[C@@H]3CCCN3C(=O
)[C@]1([H])OC(C)(C)O2)\C=C\C1=CC=CC=C1 
	
Trai
ning 
CMLD00
8584 
	
C[C@@H]1\C=C\CC(=O)OCCCCC(=O)N2CCC[C@H]2C(=O)N[C@@H]1\C=C\C
1=CC=CC=C1 
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Trai
ning 
CMLD00
8585 
	
C[C@@H]1\C=C\CC(=O)OCC2=C(CC(=O)N3CCC[C@H]3C(=O)N[C@@H]1\C=
C\C1=CC=CC=C1)C=CC=C2 
	
Trai
ning 
CMLD00
8590 
	
[H][C@@]12COC(=O)C\C=C\[C@@H](C)[C@H](NC(=O)[C@H](CC3=CNC4=C3
C=CC=C4)NC(=O)[C@]1([H])OC(C)(C)O2)C1=CC(Br)=CC=C1 
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Trai
ning 
CMLD00
8596 
	
C[C@@H]1\C=C\CC(=O)OCCCC(=O)N2CCC[C@H]2C(=O)N[C@@H]1C1CC1 
	
Trai
ning 
CMLD00
8538 
	
C[C@@H]1\C=C\CC(=O)OCCCC(=O)N2CCC[C@H]2C(=O)N[C@@H]1c1ccccc1 
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Trai
ning 
CMLD00
8539 
	
C[C@@H]1\C=C\CC(=O)OCCCCC(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C
@@H]1c1ccccc1 
	
Trai
ning 
CMLD00
8540 
	
C[C@@H]1\C=C\CC(=O)OCCCC(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C
@@H]1C1CC1 
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Trai
ning 
CMLD00
8541 
	
C[C@@H]1\C=C\CC(=O)OCCC(Oc2ccccc2)C(=O)N2CCC[C@H]2C(=O)N[C@@
H]1c1cccc(Br)c1 
	
Trai
ning 
CMLD00
8542 
	
C[C@@H]1\C=C\CC(=O)OCCCC(=O)N2CCC[C@H]2C(=O)N[C@@H]1c1cccc(B
r)c1 
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Trai
ning 
CMLD00
8543 
	
C[C@@H]1\C=C\CC(=O)OCCCCC(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C
@@H]1\C=C\c1ccccc1 
	
Trai
ning 
CMLD00
8544 
	
C[C@@H]1\C=C\CC(=O)OCc2ccccc2CC(=O)N2CCC[C@H]2C(=O)N[C@@H]1c1
ccccc1 
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Trai
ning 
CMLD00
8546 
	
C[C@@H]1\C=C\CC(=O)OC[C@@]2([H])OC(C)(C)O[C@@]2([H])C(=O)N[C@@
H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H]1c1ccccc1 
	
Trai
ning 
CMLD00
8549 
	
C[C@@H]1\C=C\CC(=O)OCCCCC(=O)N2CCC[C@H]2C(=O)N[C@@H]1c1ccccc
1 
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Trai
ning 
CMLD00
8550 
	
C[C@@H]1\C=C\CC(=O)OC[C@@]2([H])OC(C)(C)O[C@@]2([H])C(=O)N[C@@
H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H]1C1CC1 
	
Trai
ning 
CMLD00
8551 
	
C[C@@H]1\C=C\CC(=O)OCCCCC(=O)N2CCC[C@H]2C(=O)N[C@@H]1c1cccc(
Br)c1 
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Trai
ning 
CMLD00
8552 
	
C[C@@H]1\C=C\CC(=O)OCCCC(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C
@@H]1\C=C\c1ccccc1 
	
Trai
ning 
CMLD00
8555 
	
C[C@@H]1\C=C\CC(=O)OCc2ccccc2CC(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=
O)N[C@@H]1C1CC1 
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Trai
ning 
CMLD00
8512 
	
C[C@@H]1\C=C\CC(=O)OCCCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]
1c1ccccc1 
	
Trai
ning 
CMLD00
8513 
	
C[C@@H]1\C=C\CC(=O)OCCC(Oc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O
)N[C@@H]1c1ccccc1 
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Trai
ning 
CMLD00
8514 
	
C[C@@H]1\C=C\CC(=O)OC[C@@]2([H])OC(C)(C)O[C@@]2([H])C(=O)N[C@@
H](Cc2ccc(O)cc2)C(=O)N[C@@H]1c1ccccc1 
	
Trai
ning 
CMLD00
8515 
	
C[C@@H]1\C=C\CC(=O)OCCCCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@
H]1c1ccccc1 
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Trai
ning 
CMLD00
8516 
	
C[C@@H]1\C=C\CC(=O)OCc2ccccc2CC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C
@@H]1c1ccccc1 
	
Trai
ning 
CMLD00
8517 
	
C[C@@H]1\C=C\CC(=O)OCCCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]
1C1CC1 
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Trai
ning 
CMLD00
8518 
	
C[C@@H]1\C=C\CC(=O)OCCC(Oc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O
)N[C@@H]1C1CC1 
	
Trai
ning 
CMLD00
8519 
	
C[C@@H]1\C=C\CC(=O)OC[C@@]2([H])OC(C)(C)O[C@@]2([H])C(=O)N[C@@
H](Cc2ccc(O)cc2)C(=O)N[C@@H]1C1CC1 
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Trai
ning 
CMLD00
8520 
	
C[C@@H]1\C=C\CC(=O)OCCCCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@
H]1C1CC1 
	
Trai
ning 
CMLD00
8521 
	
C[C@@H]1\C=C\CC(=O)OCc2ccccc2CC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C
@@H]1C1CC1 
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Trai
ning 
CMLD00
8525 
	
C[C@@H]1\C=C\CC(=O)OCCCCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@
H]1c1cccc(Br)c1 
	
Trai
ning 
CMLD00
8929 
	
C=CC[C@@H]1NC(=O)[C@]2([H])OC(C)(C)O[C@]2([H])COC(=O)C\C=C\[C@
@H](C)[C@H](NC1=O)c1ccc(O)cc1 
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Trai
ning 
CMLD00
8933 
	
C[C@@H]1\C=C\CC(=O)OCCCCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@
H]1\C=C\c1ccccc1 
	
Trai
ning 
CMLD00
8936 
	
C[C@H]1\C=C\CC(=O)OCC2OC(C)(C)OC2C(=O)N[C@@H](Cc2c[nH]c3ccccc23)
C(=O)N[C@H]1c1ccccc1 
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Trai
ning 
CMLD00
8941 
	
C[C@H]1\C=C\CC(=O)OCCCCC(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@
H]1c1ccccc1 
	
Trai
ning 
CMLD00
9177 
	
C[C@@H]1COC(=O)C\C=C\[C@H](C)[C@@H](NC(=O)[C@H](Cc2c[nH]c3ccccc
23)NC(=O)C1)c1ccccc1 
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Trai
ning 
CMLD00
8959 
	
C=CC[C@@H]1NC(=O)C(CCOC(=O)C\C=C\[C@@H](C)[C@H](NC1=O)c1ccc(O
)cc1)Oc1ccccc1 
	
Trai
ning 
CMLD00
8960 
	
C=CC[C@@H]1NC(=O)CCCCOC(=O)C\C=C\[C@@H](C)[C@H](NC1=O)c1ccc(
O)cc1 
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Trai
ning 
CMLD01
0112 
	
C[C@H]1\C=C\CC(=O)OCCC(OC2=CC3=C(OCO3)C=C2)C(=O)N[C@@H](COC
C2=CC=CC=C2)C(=O)N[C@H]1C1=CC(NC(C)=O)=CC=C1 
	
Trai
ning 
CMLD01
0113 
	
COC1=C(OC)C=C(OC2CCOC(=O)C\C=C\[C@H](C)[C@@H](NC(=O)[C@H](CO
CC3=CC=CC=C3)NC2=O)C2=CC(NC(C)=O)=CC=C2)C=C1 
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Trai
ning 
CMLD01
0115 
	
COC1=C(OC)C=C(OC2CCOC(=O)C\C=C\[C@H](C)[C@@H](NC(=O)[C@H](CC
3=CC=CC=C3)NC2=O)C2=CN=CC=C2)C=C1 
	
Test 
CMLD00
8579 
	
C[C@@H]1\C=C\CC(=O)OCCCCC(=O)N[C@@H](CC=C)C(=O)N[C@@H]1C1=
CC=CC=C1 
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Test 
CMLD00
8581 
	
C[C@@H]1\C=C\CC(=O)OCCCC(=O)N2CCC[C@H]2C(=O)N[C@@H]1\C=C\C1
=CC=CC=C1 
	
Test 
CMLD00
8582 
	
C[C@@H]1\C=C\CC(=O)OCCC(OC2=CC=CC=C2)C(=O)N2CCC[C@H]2C(=O)N[
C@@H]1\C=C\C1=CC=CC=C1 
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Test 
CMLD00
8556 
	
C[C@@H]1\C=C\CC(=O)OC[C@@]2([H])OC(C)(C)O[C@@]2([H])C(=O)N2CCC[
C@H]2C(=O)N[C@@H]1c1cccc(Br)c1 
	
Test 
CMLD00
8557 
	
C[C@@H]1\C=C\CC(=O)OCCC(Oc2ccccc2)C(=O)N2CCC[C@H]2C(=O)N[C@@
H]1c1ccccc1 
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Test 
CMLD00
8560 
	
C[C@@H]1\C=C\CC(=O)OCCCCC(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C
@@H]1C1CC1 
	
Test 
CMLD00
8523 
	
C[C@@H]1\C=C\CC(=O)OCCC(Oc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O
)N[C@@H]1c1cccc(Br)c1 
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Test 
CMLD00
8524 
	
C[C@@H]1\C=C\CC(=O)OC[C@@]2([H])OC(C)(C)O[C@@]2([H])C(=O)N[C@@
H](Cc2ccc(O)cc2)C(=O)N[C@@H]1c1cccc(Br)c1 
	
Test 
CMLD01
0116 
	
COC1=C(OC)C=C(OC2CCOC(=O)C\C=C\[C@H](C)[C@@H](NC(=O)[C@@H](C
C3=CC=CC=C3)NC2=O)C2=CC=CN=C2)C=C1 
	
		
156 
Test 
CMLD01
0117 
	
C[C@H]1\C=C\CC(=O)OCCC(OC2=CC3=C(OCO3)C=C2)C(=O)N[C@@H](COC
C2=CC=CC=C2)C(=O)N[C@H]1C1=CC=CN=C1 
	
BD 
CMLD00
9403 
	
C[C@H]1\C=C\CC(=O)OCCC(Oc2cccc3OCOc23)C(=O)N[C@@H](Cc2c[nH]c3ccc
cc23)C(=O)N[C@H]1c1ccccc1 
	
		
157 
BD 
CMLD00
8366 
	
C[C@H]1\C=C\CC(=O)OCCC(Oc2ccccc2)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C
(=O)N[C@H]1c1ccccc1 
	
BD 
CMLD00
8526 
	
C[C@@H]1\C=C\CC(=O)OCc2ccccc2CC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C
@@H]1c1cccc(Br)c1 
	
		
158 
BD 
CMLD00
8545 
	
C[C@@H]1\C=C\CC(=O)OCc2ccccc2CC(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=
O)N[C@@H]1c1ccccc1 
	
BD 
CMLD00
8554 
	
C[C@@H]1\C=C\CC(=O)OC[C@@]2([H])OC(C)(C)O[C@@]2([H])C(=O)N[C@@
H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H]1\C=C\c1ccccc1 
	
		
159 
BD 
CMLD00
8577 
	
C[C@@H]1\C=C\CC(=O)OCCC(OC2=CC=CC=C2)C(=O)N[C@@H](CC=C)C(=O
)N[C@@H]1C1=CC=CC=C1 
	
BD 
CMLD00
8586 
	
C[C@@H]1\C=C\CC(=O)OCCCC(=O)N[C@@H](CC2=CNC3=C2C=CC=C3)C(=
O)N[C@@H]1C1=CC(Br)=CC=C1 
	
		
160 
BD 
CMLD00
8587 
	
C[C@@H]1\C=C\CC(=O)OCCC(OC2=CC=CC=C2)C(=O)N[C@@H](CC2=CNC3
=C2C=CC=C3)C(=O)N[C@@H]1C1=CC(Br)=CC=C1 
	
BD 
CMLD00
8591 
	
C(=C)C[C@@H]1NC(=O)CCCOC(=O)C\C=C\[C@H](C)[C@@H](NC1=O)c1cccc
c1 
	
		
161 
BD 
CMLD00
8597 
	
C[C@H]1\C=C\CC(=O)OCCC(C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@
H]1c1ccccc1)c1ccccc1 
	
BD 
CMLD00
8931 
	
C[C@@H]1\C=C\CC(=O)OCCC(Oc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O
)N[C@@H]1\C=C\c1ccccc1 
	
		
162 
BD 
CMLD00
8932 
	
C[C@@H]1\C=C\CC(=O)OC[C@@]2([H])OC(C)(C)O[C@@]2([H])C(=O)N[C@@
H](Cc2ccc(O)cc2)C(=O)N[C@@H]1\C=C\c1ccccc1 
	
BD 
CMLD00
8944 
	
CC1CCCC(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@H]([C@@H](C)\C=C\
CC(=O)O1)c1ccccc1 
	
		
163 
BD 
CMLD00
8947 
	
C[C@H]1\C=C\CC(=O)OC[C@@H]2OC(C)(C)O[C@@H]2C(=O)N[C@@H](Cc2c
[nH]c3ccccc23)C(=O)N[C@H]1c1cccn1S(=O)(=O)c1ccc(C)cc1 
	
BD 
CMLD00
8950 
	
C[C@H]1\C=C\CC(=O)OC[C@@H](NC(=O)OCc2ccccc2)CC(=O)N[C@@H](Cc2c
[nH]c3ccccc23)C(=O)N[C@H]1c1cccn1S(=O)(=O)c1ccc(C)cc1 
	
		
164 
BD 
CMLD00
9175 
	
C[C@H]1\C=C\CC(=O)OCCC(C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@
H]1c1cccn1S(=O)(=O)c1ccc(C)cc1)c1ccccc1 
	
BD 
CMLD00
9404 
	
COc1cccc(OC2CCOC(=O)C\C=C\[C@H](C)[C@@H](NC(=O)[C@H](Cc3c[nH]c4
ccccc34)NC2=O)c2ccccc2)c1OC 
	
		
165 
Ver
ma 
Acebutol
ol 
	
(RS)-N-{3-acetyl-4-[2-hydroxy-3-(propan-2-
ylamino)propoxy]phenyl}butanamide 
	
Ver
ma 
Bumetani
de 
	
3-butylamino-4-phenoxy-5-sulfamoyl-benzoic 
acid 
	
		
166 
Ver
ma 
Chloram
phenicol 
	
Chloramphenicol 
	
Ver
ma 
Chlorpro
mazine 
	
Chlorpromazine 
	
		
167 
Ver
ma 
Clozapin
e 
	
8-Chloro-11-(4-methylpiperazin-1-yl)-5H-
dibenzo[b,e][1,4]diazepine 
	
Ver
ma 
Corticost
erone 
	
Corticosterone 
	
		
168 
Ver
ma Diltiazem 
	
Diltiazem 
	
Ver
ma 
Doxorubi
cin 
	
(7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-
methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-
hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-
tetracene-5,12-dione 
	
		
169 
Ver
ma 
Etoposid
e 
	
C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@@H]
3c4cc5c(cc4[C@H]([C@@H]6[C@@H]3COC6=O)c7cc(c(c(c7)OC)O)OC)OCO5)O
)O 
	
Ver
ma 
Flumazen
il 
	
Ethyl 8-fluoro-5-methyl-6-oxo-5,6-dihydro-4H-
benzo[f]imidazo[1,5-a][1,4]diazepine-3-
carboxylate 
	
		
170 
Ver
ma 
Fluoxetin
e 
	
Fluoxetine 
	
Ver
ma 
Furosemi
de 
	
Furosemide 
	
		
171 
Ver
ma 
Griseoful
vin 
	
O=C2c3c(O[C@@]21C(/OC)=C\C(=O)C[C@H]1C)c(Cl)c(OC)cc3OC 
	
Ver
ma 
Hydrocor
tisone 
	
Hydrocortisone 
	
		
172 
Ver
ma 
Indometh
acin 
	
Indomethacin 
	
Ver
ma Labetalol 
	
(RS)-2-hydroxy-5-{1-hydroxy-2-[(1-methyl-3-
phenylpropyl)amino]ethyl}benzamide 
	
		
173 
Ver
ma 
Methotre
xate 
	
(2S)-2-[(4-{[(2,4-Diaminopteridin-6-
yl)methyl](methyl)amino}benzoyl)amino]pentanedioic 
acid 
	
Ver
ma 
Methylpr
ednisolon
e 
	
Methylprednisolone 
	
		
174 
Ver
ma 
Norfloxaci
ne 
	
1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1H-
quinoline-3-carboxylic acid 
	
Ver
ma Piroxicam 
	
4-Hydroxy-2-methyl-N-(2-pyridinyl)-2H-1,2-
benzothiazine-3-carboxamide 1,1-dioxide 
	
		
175 
Ver
ma Prazosin 
	
2-[4-(2-Furoyl)piperazin-1-yl]-6,7-
dimethoxyquinazolin-4-amine 
	
Ver
ma 
Progestero
n 
	
Progesteron 
	
		
176 
Ver
ma Quinidine 
	
Quinidine 
	
Ver
ma Sulpiride 
	
O=S(=O)(N)c1cc(c(OC)cc1)C(=O)NCC2N(CC)CCC2 
	
		
177 
Ver
ma Terazosine 
	
Terazosine 
	
Ver
ma Timolol 
	
(S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-
1,2,5-thiadiazol-3-yl)oxy]propan-2-ol 
	
		
178 
Ver
ma 
Verapami
l 
	
Verapamil 
	
Ver
ma Warfarin 
	
Warfarin 
	
		
179 
Ver
ma 
Zopiclon
e 
	
(RS)-6-(5-chloropyridin-2-yl)-7-oxo-6,7-
dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-
methylpiperazine-1-carboxylate 
	
Fuji
kaw
a 
Boc-Trp 
	
Boc-Trp 
	
		
180 
Fuji
kaw
a 
Cbz-Trp 
	
Cbz-Trp 
	
Fuji
kaw
a 
Fmoc-
Trp 
	
Fmoc-Trp 
	
		
181 
Fuji
kaw
a 
Phe-Trp-
NH2 
	
Phe-Trp-NH2 
	
Fuji
kaw
a 
Trp-Ala-
Val-NH2 
	
Trp-Ala-Val-NH2 
	
		
182 
Fuji
kaw
a 
Ac-Trp-
Val-NH2 
	
Ac-Trp-Val-NH2 
	
Fuji
kaw
a 
Ac-D-
Trp-Val-
NH2 
	
Ac-D-Trp-Val-NH2 
	
		
183 
Fuji
kaw
a 
Ac-Tyr-
Leu-NH2 
	
Ac-Tyr-Leu-NH2 
	
Fuji
kaw
a 
Ac-Tyr-
Phe-NH2 
	
Ac-Tyr-Phe-NH2 
	
		
184 
Fuji
kaw
a 
cyclo(-
Trp-Gly) 
	
3-(1H-indol-3-ylmethyl)piperazine-2,5-dione 
	
Fuji
kaw
a 
cyclo(-
Trp-Tyr) 
	
c1ccc2c(c1)c(c[nH]2)C[C@H]3C(=O)N[C@H](C(=O)N3)Cc4ccc(cc4)O 
	
		
185 
Fuji
kaw
a 
cyclo(-
Trp-Trp) 
	
c1ccc2c(c1)c(c[nH]2)C[C@H]3C(=O)N[C@H](C(=O)N3)Cc4c[nH]c5c4cccc5 
	
Fuji
kaw
a 
Acebutol
ol 
	
(RS)-N-{3-acetyl-4-[2-hydroxy-3-(propan-2-
ylamino)propoxy]phenyl}butanamide 
	
		
186 
Fuji
kaw
a 
Chloram
phenicol 
	
Chloramphenicol 
	
Fuji
kaw
a 
Corticost
erone 
	
Corticosterone 
	
		
187 
Fuji
kaw
a 
Dilthiaze
m 
	
O=C2N(c3c(S[C@@H](c1ccc(OC)cc1)[C@H]2OC(=O)C)cccc3)CCN(C)C 
	
Fuji
kaw
a 
Furosemi
de 
	
Furosemide 
	
		
188 
Fuji
kaw
a 
Hydrocor
tisone 
	
Hydrocortisone 
	
Fuji
kaw
a 
Labetalol 
	
(RS)-2-hydroxy-5-{1-hydroxy-2-[(1-methyl-3-
phenylpropyl)amino]ethyl}benzamide 
	
		
189 
Fuji
kaw
a 
Nadolol 
	
OC(CNC(C)(C)C)COc1cccc2c1C[C@H](O)[C@H](O)C2 
	
Fuji
kaw
a 
Ranitidin
e 
	
Ranitidine 
	
		
190 
Fuji
kaw
a 
Verapami
l 
	
Verapamil 
	
Fuji
kaw
a 
Piroxica
m 
	
4-Hydroxy-2-methyl-N-(2-pyridinyl)-2H-1,2-
benzothiazine-3-carboxamide 1,1-dioxide 
	
		
191 
Fuji
kaw
a 
Pirenzepi
ne 
	
11-[(4-methylpiperazin-1-yl)acetyl]-5,11-
dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-
one 
	
CM
LD 
CMLD00
9178 
	
OCC(C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H]([C@@H](C)\C=C\C
C(=O)OC)c1ccccc1 
	
		
192 
CM
LD 
CMLD00
9179 
	
OCC(C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H]([C@@H](C)\C=C\C
C(=O)OC)c1cccn1S(=O)(=O)c1ccc(C)cc1 
	
CM
LD 
CMLD01
0107 
	
COC(=O)C\C=C\[C@H](C)[C@@H](NC(=O)[C@H](COCC1=CC=CC=C1)NC(=O
)OC(C)(C)C)C1=CC(=CC=C1)NC(=O)C 
	
		
193 
CM
LD 
CMLD01
0108 
	
COC(=O)C\C=C\[C@H](C)[C@@H](NC(=O)[C@H](CCC(=O)OCC1=CC=CC=C1
)NC(=O)OC(C)(C)C)C1=CN=CC=C1 
	
CM
LD 
CMLD01
0110 
	
COC(=O)C\C=C\[C@H](C)[C@@H](NC(=O)C1CCC(=O)N1)C1=CC(NC(C)=O)=
CC=C1 
	
		
194 
CM
LD 
CMLD01
0111 
	
COC(=O)C\C=C\[C@H](C)[C@@H](NC(=O)C1CCC(=O)N1)C1=CC(NC(C)=O)=
CC=C1 
	
CM
LD 
CMLD01
0118 
	
COC(=O)CC[C@H](NC(=O)OC(C)(C)C)C(=O)N[C@H]([C@@H](C)\C=C\CC(=O
)OC)C1=CC=CN=C1 
	
		
195 
CM
LD 
CMLD01
0119 
	
COC(=O)C\C=C\[C@H](C)[C@@H](NC(=O)[C@H](COCC1=CC=CC=C1)NC(=O
)C(CCO)OC1=CC2=C(OCO2)C=C1)C1=CC=CN=C1 
	
 	  
		
196 
Appendix 4.2. Permeability measurements and MS quantification of macrocycles from BU-
CMLD. 
Set Barcode Papp (cm/s)2 Stdev of Papp 
Standard curve 
(Linear/Quadratic) R 
LLOQ 
(nM) 
ULOQ 
(nM) 
Training CMLD008561 2.2E-05 1.2E-06 L 0.998 156 20000 
Training CMLD008563 1.2E-05 4.3E-06 L 0.996 1250 20000 
Training CMLD008564 2.0E-05 7.4E-06 Q 1 1250 20000 
Training CMLD008569 1.7E-05 4.8E-06 L 0.993 625 20000 
Training CMLD008572 1.9E-05 2.7E-06 L 0.997 156 20000 
Training CMLD008573 1.5E-05 3.5E-06 Q 0.998 625 20000 
Training CMLD008574 1.1E-05 1.1E-06 Q 0.998 313 20000 
Training CMLD008578 1.3E-05 1.6E-06 L 0.994 1250 20000 
Training CMLD008583 2.2E-05 4.2E-06 L 0.99 156 20000 
Training CMLD008584 2.0E-05 2.3E-06 L 0.99 313 20000 
Training CMLD008585 1.7E-05 1.7E-06 L 0.998 625 10000 
Training CMLD008590 2.5E-05 5.0E-06 L 0.997 5000 20000 
Training CMLD008596 5.8E-06 3.2E-07 L 0.991 313 20000 
Training CMLD008538 1.1E-05 9.4E-07 L 0.993 157 20000 
Training CMLD008539 3.1E-06 2.4E-06 L 0.995 157 20000 
Training CMLD008540 1.1E-05 1.9E-06 L 0.997 0 20000 
Training CMLD008541 7.3E-06 2.2E-06 L 0.998 0 20000 
Training CMLD008542 9.8E-06 1.5E-06 L 0.999 313 20000 
Training CMLD008543 3.2E-06 7.8E-07 L 0.997 157 20000 
Training CMLD008544 1.7E-05 4.5E-06 L 0.996 157 20000 
Training CMLD008546 7.6E-06 1.6E-06 Q 0.988 157 20000 
Training CMLD008549 1.9E-05 7.9E-07 L 0.999 0 20000 
Training CMLD008550 8.3E-06 1.4E-06 L 0.997 157 20000 
Training CMLD008551 2.0E-05 1.1E-06 L 0.998 157 10000 
Training CMLD008552 1.1E-05 1.8E-06 L 0.999 625 20000 
Training CMLD008555 2.8E-06 6.7E-07 Q 0.996 157 20000 
Training CMLD008512 2.1E-06 5.2E-07 L 0.998 157 20000 
Training CMLD008513 6.1E-06 7.6E-07 L 0.992 157 20000 
Training CMLD008514 2.8E-06 3.8E-07 L 0.995 625 20000 
Training CMLD008515 4.0E-06 3.7E-07 L 0.999 157 20000 
Training CMLD008516 7.4E-06 7.8E-07 L 0.996 157 20000 
Training CMLD008517 7.7E-07 3.6E-07 L 0.997 157 20000 
Training CMLD008518 1.1E-05 1.0E-06 L 1 157 20000 
Training CMLD008519 4.0E-06 2.9E-07 L 0.996 625 20000 
Training CMLD008520 2.5E-06 6.0E-07 L 0.998 157 20000 
Training CMLD008521 2.5E-06 6.1E-07 Q 0.972 625 20000 
Training CMLD008525 3.5E-06 7.4E-07 L 0.995 313 20000 
Training CMLD008929 3.1E-06 3.1E-07 L 0.997 1250 20000 
Training CMLD008933 4.3E-06 5.2E-07 L 0.998 625 20000 
Training CMLD008936 5.6E-06 1.0E-06 L 0.993 1250 20000 
Training CMLD008941 6.3E-06 1.0E-06 L 0.997 1250 20000 
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Training CMLD009177 8.5E-06 1.1E-06 Q 0.994 0 5000 
Training CMLD008959 7.6E-06 8.1E-07 L 0.999 157 20000 
Training CMLD008960 6.0E-07 2.9E-07 L 0.995 157 20000 
Training CMLD010112 1.9E-06 2.3E-07 Q 0.999 157 20000 
Training CMLD010113 4.7E-06 8.0E-07 Q 0.996 157 20000 
Training CMLD010115 7.7E-06 2.5E-06 L 0.987 313 20000 
Test CMLD008579 1.6E-05 3.3E-06 Q 0.991 1250 20000 
Test CMLD008581 1.4E-05 2.3E-06 L 0.997 156 20000 
Test CMLD008582 3.8E-05 2.9E-05 Q 0.998 156 20000 
Test CMLD008556 2.1E-05 1.3E-06 L 0.997 313 20000 
Test CMLD008557 1.5E-05 1.4E-06 L 0.998 157 20000 
Test CMLD008560 1.3E-05 1.2E-06 L 0.996 157 20000 
Test CMLD008523 9.4E-07 4.2E-07 L 0.995 157 20000 
Test CMLD008524 1.9E-06 1.1E-06 L 0.997 157 20000 
Test CMLD010116 6.6E-06 2.0E-06 L 1 313 20000 
Test CMLD010117 9.1E-06 1.9E-06 L 1 0 20000 
BD1 CMLD009403 0.0E+00 0.0E+00 Q 0.995 0 20000 
BD CMLD008366 8.5E-06 1.8E-06 L 0.994 2500 20000 
BD CMLD008526 5.8E-07 4.1E-08 L 0.998 157 20000 
BD CMLD008545 9.7E-07 4.1E-07 L 0.992 157 20000 
BD CMLD008554 1.1E-05 3.5E-06 L 0.999 625 20000 
BD CMLD008577 7.2E-06 7.8E-07 L 0.991 2500 20000 
BD CMLD008586 4.1E-06 1.3E-06 L 0.993 1250 20000 
BD CMLD008587 2.9E-06 4.5E-07 L 0.994 625 10000 
BD CMLD008591 7.4E-06 1.2E-06 L 0.997 2500 20000 
BD CMLD008597 8.7E-06 8.3E-07 Q 0.934 2500 20000 
BD CMLD008931 5.5E-06 1.3E-06 L 0.991 1250 20000 
BD CMLD008932 1.0E-05 4.5E-07 L 1 2500 20000 
BD CMLD008944 9.4E-06 1.5E-06 L 0.99 5000 20000 
BD CMLD008947 8.5E-07 8.4E-08 L 0.998 157 20000 
BD CMLD008950 5.3E-06 2.5E-07 L 0.992 625 20000 
BD CMLD009175 1.9E-06 3.3E-07 L 0.991 625 20000 
BD CMLD009404 9.2E-07 9.5E-08 Q 0.999 157 20000 
1. BD stands for below detection set. 2. Papp stands for average permeability measured by PAMPA. n = 3.  
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